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ABSTRACT
The work described in this thesis investigated the contribution of Zn2+ metalloprotein
enzymes to human and murine CD4+ T cell activation. The experiments described here
reveal that addition of a hydroxamic acid containing pseudopeptide, BB-3103, capable of
inhibiting a broad range of metalloproteinases, to selected T cell proliferation assays, could
reduce the T cell responses by up to 40% compared to controls at certain time points. B cell
proliferation was not affected suggesting the metalloproteinase activity on lymphocytes is
targeted specifically to CD4+ T cells. Phenotypic analysis of activated CD4+ T cells revealed
that two markers were differentially expressed in the presence of BB-3103, CD27 (a co-
stimulatory molecule of the TNFR family highly expressed on CD4+ T cells) and CD62L (L-
selectin, an adhesion molecule mediating interaction between CD4+ T cells and
endothelium). These two molecules were not shed from the surface of the cell upon
activation in the BB-3103 treated samples.
Enriched CD4+ T cells isolated from CD62L gene deficient mice were not inhibited by the
presence of BB-3103 and demonstrated deficient or delayed proliferation as compared to
wild type controls even in the absence of the inhibitor at certain time points. These data
suggested that expression of CD62L on the CD4+ T cells was necessary for complete
activation. Cross-linking CD62L with monoclonal antibodies in a proliferation assay
increased wild type CD4+ T cell responses and protected the CD4+ lymphocytes from BB-
3103 mediated inhibition of proliferation previously observed. CD4+ T cells secreted reduced
amounts of IL-2 in the presence of BB-3103, correlating to the results obtained from CD4+ T
cell proliferation assays.
Signalling pathways of activated CD4+ T cells were investigated. Tyrosine phosphorylation
of CD3<; ITAM sequences and ZAP-70, two key signalling molecules was found to be
downregulated in the presence of BB-3103 although the method used could not accurately
and quantitatively assess these downregulations. Calcium ion mobilisation, however, was
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upregulated in the presence of BB-3103 which suggested that CD62L shedding plays an
important role in regulating CD4+ T cell activation pathways.
The effect of BB-3103 was also investigated on Tfq and Th2 type CD4+ T cell proliferation.
The results of these experiments were unexpected in that, although, BB-3103 was still
capable of inhibiting proliferation of both these subsets when added at time Ohrs, later time
point addition of the inhibitor (24 or 48hrs), increased the Th-i type CD4+ T cell proliferation.
The expression of CD62L on activated CD4+ Thq and Th2 cells was subsequently
investigated and, contrary to previous studies, was found to be maintained on the Thi
population. This proposed a dual effect of CD62L on the surface of CD4+ T cells; since
inhibition of CD62L downregulation upon activation of CD4+ T cells could inhibit proliferation
whereas inhibition of CD62L shedding when CD4+ T cells were actively dividing had either
no effect or increased cell proliferation.
These studies suggest that CD62L expressed on CD4+ T cells should not exclusively be
studied as an adhesion molecule mediating interactions with endothelium, but also as a co-
stimulatory molecule capable of regulating CD4+ T cell activation.
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INTRODUCTION
1.1 AIMS OF THESIS
The aims of the research reported in this PhD thesis were to investigate, with the use of a
synthetic zinc metalloproteinase inhibitor, the potential role of metalioproteinase enzyme
activity in the process lymphocyte activation and any differential functions on Th-i and Th2
subsets of CD4+ Th cells. Identification of metalloproteinase substrates expressed on
lymphocytes and the function of these targets would advance our knowledge of the
pathways required for regulating immunological responses.
1.2 INTRODUCTION LAYOUT
The introduction first summarises the knowledge known to date on zinc metalloproteinase
members expressed on lymphocytes and then describes structures and function of natural
and synthetically manufactured metalloproteinase inhibitors.
The following section describes the role of major substrates for metalloproteinases
expressed by lymphocytes, which include TNF superfamily members.
Finally, the introduction ends with a summary of the activation requirements and signalling
mechanisms in T lymphocytes.
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1.3 ZINC METALLOPROTEINASES
Zinc metalloproteinases are a large family of zinc dependent peptidases (Figure 1.1)
(Hooper 1994). Ail enzymes in this family contain a single zinc ion (Zn2+) in their catalytic
site which is indispensable for their enzymatic function, and, chelating Zn2+ with chemicals
such as EDTA or o-phenanthroline, inactivates all current members of zinc dependent
metalloproteinases (Black and White 1998).
As shown in Figure 1.1, each sub-family of zinc metalloproteinases contains many members
and the nomenclature and categorisation of various enzymes within the zinc
metalloproteinase family is based on analysis of the catalytic site of the enzyme (Hooper
1994). The sequence immediately within the catalytic site responsible for binding the Zn2+
defines the first subset to which an enzyme will belong (Zincins: HEXXH, Inverzincins:
HXXEH, Carboxypeptidase: HXXE and DD-carboxypeptidase: HXH where the residues in
bold directly bind Zn2+). Subsequent categorisation is dependent on sites distal from the
catalytic site but which are also thought to be capable of binding Zn2+ (see Figure 1.1).
In this introduction, matrix metalloproteinases (MMP-matrixin family) and adamalysins
(ADAMS- a disintegrin and metalloprotease - closely related to reprolysin family) expressed
by lymphocytes will be discussed (shaded in Figure 1.1), since the main aim of this thesis
was to investigate the effect of zinc metalloproteinase inhibition in lymphocyte activation.
These include MMPs 1, 2, 3 and 9 and ADAMs 10 and 17.
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Zinr.ins Inverzinr.ins Carboxy- DD-Carboxy-
Gluzincins Astacin Serratia Adamalysin Matrixin
HE3XHX3GXW M
Metzincins
Figure 1. 1: Families of zinc metalloproteinases. The families of the zinc
metalloproteinases and their inter-relationships based on the sequence around the
zinc binding residues. Italicised bold letters represent positively identified zinc ligands.
Bold letters represent residues involved in catalysis. B stands for bulky, polar
residues. X stands for any residue. The number of amino acids(aa) represents the
distance between the ligands of the first histidine in the short zinc binding motif (i.e.
HEXXH). Met-turn = Methionine turn in protein tertiary structure. Adapted from
Hooper 1994.
-22-
Defective CD4* T Cell Activation in the Presence of a Metalloproteinase Inhibitor
1.3.1 MATRIXINS / MATRIX METALLOPROTEINASES (MMPs)
As the name suggests, MMPs degrade components of the extracellular matrix (ECM). The
controlled enzymatic degradation of ECM is essential in many physiological processes such
as development, growth and tissue repair (Streuli 1999). Dysregulated enzymatic
degradation of ECM can lead to several pathological conditions such as rheumatoid arthritis,
osteoarthritis and autoimmune skin blistering disorders (Kahari and Saarialho-Kere 1997;
Shapiro 1998).
There currently are 19 members in the MMP family which are capable of collectively
degrading all ECM components (Johnsen et al. 1998; Kahari and Saarialho-Kere 1997).
These have been classified into subgroups according to their substrate specificity and
structure. The subgroups are composed of collagenases, stromelysins, gelatinases, and
membrane type MMPs (MT-MMPs) (Table 1.1). Generally, all MMPs contain a signal
peptide, a propeptide, a catalytic domain and a haemopexin-like domain linked to the
catalytic site by a hinge region also known as the Methionine-turn region (Figure 1.2). The
MT-MMPs (or MMP14-17), however, have an additional carboxyl segment which anchors the
proteinase in the cellular membrane of the cell (Bode et al. 1999). Figure 1.2 shows
variations in structure and Table 1.1 summarises the known functions observed between
MMP members identified to date.
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SP Pro peptide Zn2+ Met-turn Haemopexin
Fibronectin type II COOH domain
domains
Figure 1. 2: Diagrammatic representation of MMPs 1, 2, 3 and 9 secreted by
T lymphocytes. All MMPs contain signal peptides (SP), pro-peptides, catalytic
sites (Zn2+-binding) and carboxy terminals (COOH). MMPs 2 and 9 contain
additional sequences with homology to fibronectin type II (circles). Adapted from
Hooper 1994.
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MMP-8 Collagens I, II, and III
aggrecan, link protein
Collagenase 3 MMP-13
Collagens I, II and III, XI, IV,
X, IX, gelatin, laminin,
tenascin, aggrecan,
fibronectin
Collagenase 4 (X. laevis) MMP-18 Collagen I
Gelatinases
gelatins, collagens I, IV, V,
VII, X and XI, fibronectin,
Gelatinase A MMP-2 laminin, aggrecan, elastin,
large tenascin C, vitronectin,
proMMP-9
Gelatinase B MMP-9












collagens III, IV, IX
Stromelysin 2 MMP-10 Aggrecan, fibronectin,collagen IV, nidogen
Membrane type MMPs
Collagens I, II, III, fibronectin,
laminin-1, vitronectin,
MT1-MMP MMP-14 dermatan sulphate
proteoglycan, proMMP-2 and
proMMP-13
MT2-MMP MMP-15 Not known
MT3-MMP MMP-16 Activates proMMP-2
MT4-MMP MMP-17 Not known
Others
Stromelysin 3 MMP-11




Unnamed MMP-19 Not known
Table 1. 1 :Summary of members of the MMP family and their substrate specificities.
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1.3.1.1 MMPs SECRETED BY LYMPHOCYTES
This section describes MMPs which are known to be secreted by lymphocytes, namely
MMP-2 and 9, although MMP-1 and 3 have also been also been identified to be secreted by
T lymphocytes. Secretion of these MMPs is upregulated following activation through a
variety of factors, namely cytokines and chemokines such as IL-1 (a and (3), IL-2, IL-4,
RANTES and MIP1a (Goetzl et at. 1996; Leppert et at. 1995b), but is more evident upon
VCAM-1 dependent adhesion of T lymphocytes to endothelial cells (Romanic and Madri
1994) and integrin dependent adhesion to fibronectin (Xia et at. 1996). Other factors which
upregulate MMP expression in T lymphocytes are eicosanoids such as prostaglandin E2
(PGE2) and vasoactive intestinal peptides (VIPs) (Xia et at. 1996; Leppert et at. 1995a). The
known main functions of T lymphocyte derived MMPs are to hydrolyse matrix components of
the basement membrane (BM)-mainly composed of collagens IV, V and fibronectin (Leppert
et at. 1995b) for subsequent cell migration into inflamed tissue or lymph node (Goetzl et at.
1996).
1.3.1.1.1 MMP-1 (COLLAGENASE-1)
MMP-1 is capable of degrading collagens type I, II, III, VII, VIII, X; aggrecan, serpins,
gelatins, entactin and a2-macroglobulin (Kahari and Saarialho-Kere 1997; Shapiro 1998).
MMP-1 is expressed by lymphocytes as well as a variety of other cells including fibroblasts,
keratinocytes, chondrocytes, monocytes and macrophages and hepatocytes.
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1.3.1.1.2 MMP-2 AND MMP-9 (GELATINASES A AND B)
Gelatinase-A (72kDa) or MMP-2 is expressed by a variety of normal and transformed cells
including T lymphocytes. Gelatinase-B (92kDa) or MMP-9 is also produced by T
lymphocytes as well as keratinocytes, monocytes, alveolar macrophages, neutrophils and a
large variety of malignant cells. In addition to their capacity to degrade gelatin, MMP-2 and
MMP-9 also have laminin and nidogen as substrates. MMP-2 is unique in that it is capable
of proteolytically activating MMP-9 and MMP-13 by cleaving the pro-peptide and thus
releasing mature enzyme (Basset et al. 1997) (See section on MMP regulation 1.3.1.2).
1.3.1.1.3 MMP-3 (STROMELYSIN-1)
MMP-3, although expressed at low levels by lymphocytes, is capable of degrading aggrecan,
gelatin, nidogen, fibronectin, laminin and collagens type III, IV and IX which are the major
components of the vascular BM (Airola et al. 1997; Goetzl et al. 1996).
From the brief description of MMPs secreted by lymphocytes above and the summary of
substrates in Table 1.1, it emerges that a wide range of ECM substrates can be cleaved by
very few MMPs due to the broad specificity of each enzyme. The enzymes' specificity for
the substrates was thought to rely on the presence of the haemopexin domain (Figure 1.2),
however, deletion of this domain in collagenases, although eliminating the capacity to cleave
triple helical collagen, did not affect the hydrolysis of gelatin, casein or synthetic substrates
(Murphy and Knauper 1997).
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1.3.1.2 REGULATION OF MMPs
Since MMPs are a vast family of enzymes which have the potential to cause severe damage
to ECM components, the regulation of MMP activity must be tightly regulated in vivo. There
are three main events regulating MMP activity-
(1) regulation of protein expression
(2) secretion as inactive zymogens
(3) inhibition by Tissue Inhibitors of MetalloProteinases (TIMPs).
1.3.1.2.1 REGULATION OF PROTEIN EXPRESSION
The transcription of MMP genes is very tightly regulated for the majority of MMPs, and is
induced in the presence of inflammatory cytokines such as IL-1 (a and P) IL-2, IL-4 and TNF-
a, and growth factors such as PDGF, TGF-a, EGF, basic FGF and NGF. TGF-Pi, however,
represses the transcription of all MMPs (Birkedal-Hansen et al. 1993). Individual sensitivity of
MMPs to these cytokines varies and is also cell specific. In general however, many factors
must be integrated to elicit the transcription of MMPs, since regulation has also been
induced with cell-matrix interactions and components of the ECM such as lymphocyte
VCAM-1 dependent adhesion to FIEV (Bonfil et al. 1992; Fridman et al. 1992; Romanic and
Madri 1994; Werb et al. 1989). Other stimuli which induce MMP transcription include
calcium flux (Unemori and Werb 1988), ultraviolet light (Angel et al. 1985) and cell shape
(Werb et al. 1986). Taken together, these observations indicate that MMP expression is
tightly controlled by various factors which synergise to elicit gene transcription.
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1.3.1.2.2 ZYMOGEN SECRETION
MMPs are secreted as inactive zymogens with the pro-peptide intact. A cysteine amino acid
contained within the pro-peptide binds to the Zn2+ within the catalytic site thus inactivating
the enzyme. The removal of the pro-peptide and subsequent activation of MMPs occurs in a
two step fashion, firstly, the pro-peptide is cleaved in a 'bait' region, upstream of the
cysteine, which induces a conformational change. This conformational change allows the
removal of the remaining cysteine containing region of the pro-peptide thus revealing the
catalytic site (Nagase 1997).
Table 1.2 below summarises the enzymes capable of activating MMPs by removal of pro¬
peptide.
Zymogen Initial step Final step
ProMMP-1 Trypsin, plasmin MMP-3, MMP-2, MMP-7,
MMP-10
ProMMP-2 MMP-1, MMP-14, MMP-16 MMP-3
ProMMP-3 Trypsin, chymotrypsin, N/A
plasmin, leukocyte elastase
ProMMP-9 MMP-1, MMP-2, MMP-3, MMP-1, MMP2, MMP-3,
MMP-7 MMP-7
Table 1. 2: Enzymes capable of two step activation of MMPs
1.3.1.2.3 INHIBITION BY TISSUE INHIBITORS OF METALLOPROTEINASES
(TIMPs)
Once MMPs are activated by complete removal of the pro-peptide, they are subject to further
regulation by TIMPs. The balance between activated MMPs and TIMPs determines net
MMP activity. There are three distinct TIMP molecules, TIMPs 1-3 which exhibit 41-52%
sequence homology (Douglas et al. 1997) and thus the TIMPs do not seem to differentiate
much between various MMPs (Murphy and Willenbrock 1995). Knowledge of expression
patterns of TIMPs is limited and has not been investigated in lymphocytes, although the
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current understanding is that MMP expressing cells always also express TIMPs (Shapiro
1998). The regulation of TIMP expression, on the other hand, is not fully understood.
TIMP-1 is a 28kDa glycoprotein that preferentially forms a 1:1 non-covalent complex with
activated MMP-1 and MMP-3. TIMP-1 is also capable of binding both latent and active
forms of MMP-9. Interaction with activated MMP-9 results in proteinase inhibition, whereas
interaction with pro-MMP-9, inhibits MMP-3 activation of MMP-9 (Bode et al. 1999) (Table
1.2).
TIMP-2 is a non-glycosylated 21kDa protein with high affinity for pro-MMP-2 that also binds
to the activated form of MMP-2. TIMP-2 has been reported to block the hydrolytic activity of
all activated MMPs (Ponton et al. 1991). TIMP-3 differs from other TIMPs as it is localised to
the ECM and preferentially binds to ECM components rather than latent or activated MMPs.
TIMPs are, therefore, either capable of inhibiting activation of latent gelatinases or inhibition
of active MMPs and form a final regulatory step in the control of MMP activation. Recent
reports, however, suggest that the function of TIMPs is not limited to inactivation of MMPs
but they may also act as growth factors and may have anti-angiogenic activity (Cawston
1998).
1.3.2 ADAMALYSINS
Adamalysins (ADAMs) form a large group of novel cell surface proteins that combine
features of both cell surface adhesion molecules and proteinases (Figure 1.1) (Yamamoto et
al. 1999). Like MMPs, ADAMs are zinc dependent and can be inhibited by chelating Zn2+
with EDTA or o-phenanthroline (Black and White 1998). All ADAMs display a common
domain organisation and, as a group, possess four functions; proteolysis, adhesion,
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signalling and fusion. Figure 1.3 below shows the common structure of ADAMs and the





















Figure 1. 3: Domain organisation and predicted function of
ADAMs. The thick black bar seen in the Cys rich domain
depicts a candidate fusion peptide seen only in a limited
number of ADAMs. The vertical lines delimiting the TM domain
represent the boundaries of the lipid bilayer. Adapted from
Black and White, 1998.
To date there are 23 full length ADAM sequences representing cDNAs cloned from
mammals, frogs, flies and worms. Among these, 10 are predicted to be active proteinases
(ADAMs 1, 8-10, 12, 13, 15, 17, 19 and 20), of which only ADAM10 and ADAM17 have been
extensively studied (Black and White 1998).
Since the initial discovery of ADAMs, it has become clear that the proteolytic substrate
specificity for the majority of these enzymes is directed against cell surface substrates
(Yamamoto et at. 1999). This is typified by the two enzymes, ADAM 10 and 17 which are
expressed by T lymphocytes.
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1.3.2.1 ADAMS SECRETED BY T LYMPHOCYTES
1.3.2.1.1 ADAM-10
ADAM 10, first identified in Drosophila melanogaster as 'Kuzbanian' and subsequently
identified in Caenorhabditis elegans as 'SUP-17' was found to be capable of cleaving the
Notch receptor from the cell surface and can, thus, modify the early development of the
peripheral and central nervous system of these organisms (Sotillos et at. 1997; Wen et at.
1997).
In mammals, ADAM 10 was identified in bovine brain and can cleave myelin basic protein as
well as collagen IV (Howard et at. 1996; Millichip et at. 1998). There are to date, however,
no reports that these two proteins are physiologic substrates for ADAM 10. Notch protein is a
substrate for ADAM 10 and since the Notch receptor is highly expressed on T cells (Hoyne
et at. 2000), ADAM-10 may be required for proper Notch signalling to occur.
1.3.2.1.2 ADAM-17
ADAM 17, highly expressed on T cells, is also known as tumour necrosis factor (TNF) a
converting enzyme (TACE) and was first identified as a proteinase which specifically cleaves
full length 26kDa TNFa from the cell surface to release the soluble 17kDa form (Black et at.
1997; Moss et at. 1997). T lymphocytes homozygous for a targeted mutation in the Zn2+
binding region of ADAM 17 released 80-90% less soluble TNFa as compared to wild type
cells (Black et at. 1997).
Various other studies have demonstrated that TNF receptor family members are the primary
cell surface molecules identified to be cleaved by ADAM proteinases (Arribas et at. 1996;
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Hooper et al. 1997). These include TNF receptors I and II (Crowe et at. 1995) IL-6 receptor
(IL-6R) (Mullberg et al. 1994), Fas ligand (FasL) (Tanaka et al. 1995) and CD30 (Hansen et
al. 1995). These TNF family members amongst others will be discussed later.
1.3.2.2 REGULATION OF ADAMS
The regulation of ADAMs members is less well understood than MMPs as there is very little
evidence for the transcriptional regulation of any of the ADAMs members. The homology
between ADAMs pro-domains and MMP pro-domains suggests that enzymes capable of
activating MMPs could theoretically also activate ADAMs, although there is no evidence for
this yet (Black and White 1998).
TIMP regulation of ADAM activity remains a controversial issue with reports that TIMP-3 is
capable of inhibiting TACE (Moss et al. 1997) and other reports stating TIMPs are incapable
of inhibiting any ADAM family members (Black and White 1998). Inactivating mutations in
TACE inhibits TNFa release by 80-90% (Black et al. 1997), and the remainder of the release
is probably mediated by MMPs although this has yet to be demonstrated.
1.3.3 DESIGN OF METALLOPROTEINASE INHIBITORS
The design of synthetic metalloproteinase inhibitors has focused on two aspects, the
cleavage site of the substrate (designing competitive peptides) and the presence of zinc ions
in the catalytic site of the enzyme (chelating the Zn2+). The initial guide for substrate design
of pseudopeptide drugs revolved around screening compound libraries based on the
Glycine-lsoleucine and Glycine-Leucine cleavage site in human collagen molecules which
are hydrolysed by collagenases (MMP-1, 8, 13). The key to obtaining potent enzyme
inhibition was to incorporate potent zinc binding groups (ZBG) within the pseudopeptides
(Figure 1.4, below).
-33-
Defective CD4* T Cell Activation in the Presence of a Metalloproteinase Inhibitor
Figure 1. 4: Design of metalloproteinase inhibitors is based around the
cleavage site of collagen molecules. Inclusion of a zinc binding group (ZBG)
within the pseudopeptide renders the inhibitors much more effective in
inactivating the enzyme. LHS= Left Hand Side, RHS= Right Hand Side.
Adapted from Moore and Spilburg 1986.
The generation of ZBG containing pseudopeptides also gave rise to three potential drug
designs. The inhibitor could mimic both NH2 and COOH terminals of collagen (combined
inhibitor) or either the left (LHS- NH2) or right hand sides (RHS- COOH) of the collagen
molecule (Pratt et al. 1998) (Figure 1.4). In 1986, studies showed that ZBG containing RHS
inhibitors were more efficient at inhibiting metalloproteinases than either LHS or combined
inhibitors (Moore and Spilburg 1986).
The study of potential ZBG which could be used in pseudopeptide molecules has revealed
that hydroxamic acid groups were more potent at chelating the Zn2+ in the catalytic site of
collagenase (MMP-1). The preference of chelating agents is as follows: hydroxamic acid»
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formylhydroxylamine> sulphydryl> phosphinate> aminocarboxylate> carboxylate (Pratt et al.
1998).
The PT group (Figure 1.5) is the major determinant of activity and selectivity of the drugs.
For example, small alkyl groups are preferred for the inactivation of neutrophil collagenase,
whereas longer alkyl groups or phenylalkyl chains preferentially inhibit stromelysin 1 and
gelatinase. The P2' (Figure 1.5) groups can include a wide variety of substituents without
affecting inhibitor performance, although aromatic substituents are preferred for activity in
vitro. The P3' (Figure 1.5) groups can also accommodate a wide variety of substituents, and
bulky or aromatic groups have been found to improve inactivation of stromelysin (Pratt et al.
1998).
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Figure 1.5 below shows the structure of the metalloproteinase inhibitor used in this project,
BB-3103, and the concentrations of inhibitor required to inhibit enzyme activity by 50% (IC50
values) against various MMPs tested at British Biotech pic.
1—i o ui o MMP1 MMP2 MMP9 MMP3 MMP7 TACE
(nM) 2 20 7 30 20 800
Figure 1. 5: Diagrammatic representation of BB-3103. IC50 values tested
on various MMPs show the broad range inhibition properties of BB-3103.
Adapted from British Biotech BB-3103 technical data information sheet
shipped with BB-3103.
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1.4 SUBSTRATE CANDIDATES FOR
METALLOPROTEINASES EXPRESSED BY
LYMPHOCYTES
There are increasing numbers of reports suggesting that membrane bound molecules are
shed from the surface of T cells upon activation. These markers include TNFa, TNF
receptors 1 and 2, FasL, IL-6 receptor a-chain, CD62-L, CD43 and CD30. Downregulation
of these molecules is thought to be orchestrated by zinc-dependent metalloproteinases
(Arribas et al. 1996; Hooper et al. 1997). This introduction gives a brief outline of knowledge
gained to date on each of the molecules mentioned above and the importance of molecular
shedding from the lymphocyte cell surface upon activation.
1.4.1 TNFa AND TNF RECEPTORS 1 AND 2
TNFa is constitutively expressed on naive T cells as a 26kDa transmembrane protein and is
shed within hours from the surface upon TCR activation as a soluble 17kDa molecule. This
process is mediated by TACE or ADAM 17 (Black et al. 1997; Moss et al. 1997). Shedding
of TNFa from the cell surface enhances the trimerisation of soluble TNFa, which
consequently becomes biologically active. The TNFa shedding process and subsequent
homo-trimerisation suggests that TNFa is capable of not only acting in a paracrine, but also
in an autocrine fashion. Soluble TNFa homo-trimers, however, are not as effective as the
membrane-bound homo-trimers in triggering a cell receptor-mediated response (Grell et al.
1995).
Soluble or membrane bound homo-trimers of TNFa are capable of binding two types of
receptors, TNFR1 (p55 or CD120a) and TNFRII (p75 or CD120b), although there are reports
showing that TNFRII has lower affinity for soluble TNFa (Grell et al. 1995).
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Both of these receptors are also capable of being shed, like their ligands, by zinc dependent
metalioproteinases (Mullberg et al. 1995) or by alternative splicing events (Tanaka et al.
1998). Unlike the ligands, however, the soluble forms of receptors are reported to inhibit
signalling by competing with membrane bound receptors for TNFa ligands (Wallach et al.
1998).
TNFR1 and TNFRII share homology in their extracellular domains but they differ structurally
in the cytoplasmic tail region. TNFR1 contains intracellular 'death domains' (DD), in the
cytoplasmic tail which, upon ligation with a homo-trimer ligand, are capable of recruiting and
activating two types of adapter proteins (Wallach et al. 1998) (Figure 1.6)
The first family of adapter proteins also contain DD and are thus capable of interacting with
each other as well as with the cytoplasmic tail of the receptor. TNFR1 binds four such
adapter proteins (TRADD, Mort1/FADD, RIP and RAIDD/CRADD) (Figure 1.6) (Wallach et
al. 1998). Once the adapter proteins interact with TNFR1, they can recruit and activate pro-
forms of cysteine proteases known as caspases, namely caspases 2, and 8 (Figure 1.6).
The activity of these enzymes are central to all known processes of programmed cell death
(Nicholson and Thornberry 1997; Wallach 1997).
The second group of adapter molecules which interact with TNFR1 are those which lack DD.
Daxx is such a molecule and is capable of activating a Jun-NH2 kinase (JNK) which leads to
cell death by as yet, unknown mechanisms (Yang et al. 1997).
TNFRII, on the other hand, does not contain intracellular DD and, upon ligation with TNFa
homo-trimer, associates with TNF receptor associated factors 1 and 2 (TRAF1 and 2)
(Figure 1.6). TRAFs are molecules which are capable of recruiting and activating A20, a
zinc finger containing adapter protein which can inhibit apoptosis by an unknown mechanism
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(Jaattela et al. 1996). TRAFs can also recruit the cellular inhibitor of apoptosis proteins 1
and 2 (clAP1 and 2). clAPs inhibits the activation of caspases and thus programmed cell
death (Rothe et al. 1995). In addition, TNFR associated factors (TRAFs) can activate NFkB
inducing kinases (NIKs), which through a series of phosphorylations, activate NFkB and
subsequent gene transcription leading to cell activation (Beg and Baltimore 1996; Gravestein
and Borst 1998) (Figure 1.6).
There are however, complications to this system since TRADD and RIP are reported to
recruit TRAF2 and clAP1/2 and thus can also inhibit the apoptotic cascade expected by
ligation of TNFR1 with TNFa homo-trimers (Shu et al. 1996; Wallach et al. 1998).
1.4.2 FasL (CD95L/AP01-L)
FasL is a type II membrane protein and member of the TNF family which binds Fas (CD95),
a member of TNFR family. FasL is inducibly expressed on T lymphocytes and constitutively
expressed on epithelial cells found in the eye and testes thus conferring antigen ignorance
(Moulian and Berrih-Aknin 1998).
Upon T lymphocyte activation, FasL is upregulated and subsequently released from the
membrane by metalloproteinases to generate a soluble form of FasL (Peter and Krammer
1998). Fas, however, is constitutively expressed on T lymphocytes and is also found in
soluble form, but, this isoform is generated through alternate splicing rather than proteolytic
activity (Moulian and Berrih-Aknin 1998) and acts as a soluble competitor to membrane
bound Fas.
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Fas contains cytoplasmic DD and, as in TNFR1 signalling, association of FADD/Mort1 and
pro-caspase-8 on the DD of Fas initiates the proteolytic release of active caspase-8 which
subsequently leads to the apoptotic caspase cascade (Zhang et al. 1998a). Fas/FasL
interactions, therefore, initiate cell-mediated cytotoxicity, activation induced cell death
(AICD) and confer antigen ignorance (Moulian and Berrih-Aknin 1998).
Mice with null mutations in Fas or FasL (Ipr and gld, respectively) develop systemic
autoimmune disease since Fas/FasL dependent deletion of auto-reactive thymic T cells is
impaired (Kishimoto and Sprent 1999; Kurasawa et al. 1999). These observations indicate
that AICD and thymic selection are highly dependent on Fas/FasL interaction (Brunner et al.
1995; Ju etal. 1995).
In contrast to the death-inducing signalling action of Fas/FasL interaction, some groups have
also found that FasL signalling can increase activation and thus proliferation of human T
lymphocytes in conjunction with TCR mediated signalling (Alderson et al. 1993). These
observations may be related to the possibility that Fas, like TNFR1, may recruit TRAF1/2
and thus induce gene transcription and cell survival through NFkB activation (Figure 1.6).
Like TNFa, proteolytically secreted soluble homo-trimers of FasL, can induce apoptosis in
Fas bearing cells but not as effectively as membrane bound FasL. The existence of soluble
FasL is, therefore, believed to enable cells to induce apoptosis in para- and autocrine
fashion (Kayagaki et al. 1995; Tanaka et al. 1995).
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Figure 1. 6:Structure and signalling from some TNFR family
members and their intracellular adapter proteins. Adapted
from Wallach at at. 1998.
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1.4.3 IL-6 RECEPTOR COMPLEX (IL-6R)
IL-6R complex is expressed on naive T lymphocytes and upon IL-6 ligation T lymphocytes
undergo enhanced proliferation and differentiation. The IL-6R complex consists of an 80kDa
IL-6 binding molecule termed IL-6Ra, and a signal transducer, gp130 (Hibi et at. 1990; Taga
et at. 1989). Many cytokine receptors share similar structures to IL-6Ra and constitute the
type I cytokine receptor super family (Bazan 1990). IL-6Ra is also shed from the surface of
T lymphocytes by metalloproteinase activity (Mullberg et at. 1995).
Contrary to TNFRs and Fas, the soluble form of IL-6Ra acts in an agonistic, rather than an
antagonistic manner. Indeed, a complex composed of IL-6 and soluble IL-6Ra can
associate with gp130 and may generate growth signals in cells which express gp130 but not
necessarily the IL-6R a-chain. This effect was demonstrated in double transgenic mice
which expressed human IL-6 and IL-6R. These mice displayed myocardial hypertrophy
(Hirota et at. 1995) indicating that the complex of IL-6 and the soluble form of IL-6Ra
affected heart muscle cells which expressed gp130, whereas IL-6 alone could not induce
such an effect.
Signal transducers JAK1, JAK2, and Tyk2 have been shown to associate constitutively with
gp130 and to be tyrosine-phosphorylated in response to IL-6, and thus, IL-6 has been shown
to activate STAT3 and STAT1 (Fujitani et at. 1997; Lai et at. 1995; Zhong et at. 1994).
Phosphorylated, dimerised STATs play pivotal roles in gp130-mediated signal transduction
inducing cell growth, differentiation, and survival (Durbin et at. 1996; Meraz et at. 1996;
Kaplan et at. 1996a; Thierfelder et at. 1996; Kaplan et at. 1996b).
In addition to the STAT signal-transduction pathway, the Ras-MAPK pathway may also be
activated through binding SFIP-2, an adapter protein which recruits downstream signalling
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mediators (Grb2 and Sos) (Fukada et al. 1996). These will be discussed in the T cell
activation section of the introduction.
1.4.4 L-SELECTIN (CD62L)
Figure 1. 7: Schematic representation of the CD62L
adhesion molecule.
L-selectin (Figure 1.7), also referred to as LAM-1, LECAM-1, Leu-8 MEL-14 (mouse), TQ-1
but more recently CD62L, is a 65kDa transmembrane adhesion molecule highly expressed
on lymphocytes, neutrophils and monocytes (Bevilacqua 1993). CD62L is capable of
binding heavily glycosylated, fucosylated, sulphated syalated glycoproteins including CD34,
Glycam-1 and MAdcam-1 which are expressed on endothelium (see web site:
http://www.ncbi.nim.nih.gov/PROW/cd/cd62l.htm). CD62L, therefore, mediates the
adhesion events between lymphocytes and high endothelium venules (FIEV) as well as
leukocyte rolling on activated endothelium at inflammatory sites (Spertini et al. 1991; Spertini
et al. 1992; Tedder et al. 1989).
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Lymphocytes from CD62L-deficient mice do not bind to peripheral lymph node HEV, thus
lymphocyte recirculation cannot occur, resulting in lymph node atrophy (Arbones et al. 1994;
Bennett et at. 1996). CD62L also plays a role in the attachment of lymphocytes to
myelinated tracts of the central nervous system (CNS) and may contribute to the
pathogenesis of some demyelinating disorders of the CNS (Huang et al. 1991; Kanda et al.
1995). In addition to its adhesive function, many studies have investigated CD62L as a
signalling molecule specifically in neutrophils. Antibody cross-linking of CD62L, for example,
was shown to (1) enhance neutrophil adhesive functions via Mac-1 integrin, (2) potentiate
the fMLP (chemo-attractant peptide) and TNF-induced oxidative burst, (3) induce down-
regulation of TNF receptors and (4) enhance tyrosine phosphorylation and activation of
mitogen activated protein kinase (Richter and Zetterberg 1994; Simon et al. 1995; Waddell
etal. 1994; Waddell et al. 1995).
Upon activation of lymphocytes and leukocytes, CD62L is rapidly shed from the surface of
the cell (Kishimoto et al. 1989) as a soluble molecule 5-12kDa smaller than membrane
bound CD62L (Jung and Dailey 1990). The CD62L shedding process can also be initiated
in T lymphocytes by activation with phorbol esters such as PMA (Jung and Dailey 1990).
Elevated levels of soluble CD62L have been reported in plasma of patients suffering from
sepsis, leukaemia and AIDS (Spertini et al. 1992) whilst the levels remain abnormally low in
patients suffering from acute respiratory distress syndrome (ARDS) (Donnelly et al. 1994).
The CD62L shedding event upon lymphocyte and neutrophil activation can be inhibited by
hydroxamate inhibitors indicating that this process is mediated by a metalloproteinase
(Bennett et al. 1996).
Extensive studies on CD62L shedding were performed in neutrophils and showed that
binding of CD62L to natural ligands (sulphatides and CD34) or monoclonal anti-CD62L
antibody results in CD62L shedding, independent of the state of activation of the cell
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(Palecanda et al. 1992). It also emerged from similar studies that ligand induced shedding
of CD62L, could initiate intracellular signalling cascades such as an increase in [Ca2+],
MAPK activation and signalling components such as Rac and Ras (Brenner et al. 1996;
Brenner et al. 1997; Laudanna et al. 1994; Waddell et al. 1995).
CD62L has been found to be associated with the Src tyrosine kinase p56lck in T lymphocytes
(Murakawa et al. 1992) although the significance of this association was not fully assessed.
In summary, studies performed on neutrophils show that CD62L can be shed under two
different conditions: (1) by activation of cells with either chemo-attractants or inflammatory
cytokines and (2) by binding of CD62L to ligands. Both of these shedding processes can be
inhibited by metalloproteinases. Further studies in neutrophils demonstrate that CD62L is
capable of activating several signalling pathways. Since CD62L is associated with signalling
components of T lymphocytes, it is possible that CD62L is capable of regulating activation
induced signalling pathways in these cells, although this has not been investigated.
1.4.5 CD43/LEUKOSIALIN
CD43 is a heavily glycosylated transmembrane protein expressed on all lymphocytes
(Walker and Green 1999) and extends from the surface of lymphocyte by -450A (Cyster et
al. 1991), compared to the TCR which measures ~70A (Garcia et al. 1996). CD43 is,
therefore, thought to be implicated in steric hindrance, inhibiting interactions of TCR/CD3
complex with either MHC:peptide or anti-CD3 antibodies (Sperling et al. 1995). Co-ligation
of TCR and CD43 with monoclonal antibodies results in increased CD28 independent
proliferation since CD28 gene deficient T lymphocytes also proliferate upon CD43 cross-
linking (Sperling et al. 1995). Unfortunately, no natural ligand for CD43 has yet been
identified.
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CD43 gene deficient animals show increased proliferative responses to anti-CD3 monoclonal
antibodies compared to their wild type counterparts (Thurman et al. 1998). Transfecting
CD43 deficient T lymphocytes with intact cytoplasmic tails of CD43 restores proliferation to
wild type levels (Walker and Green 1999). These results indicate that CD43 is capable of
not only regulating T lymphocyte activation by steric hindrance but also by inhibitory signals
through cytoplasmic interactions with adapter molecules such as Shc/Grb2 and Vav
(Pedraza-Alva et al. 1998), and subsequent MAPK activity.
CD43 has also been reported to be proteolytically cleaved from the surface of activated
lymphocytes (Bazil and Strominger 1993), especially when it is directly cross-linked with
monoclonal antibodies (Sperling et al. 1995). The process of CD43 proteolysis has been
reported to be mediated by metalloproteinases (Bazil and Strominger 1993) and is inhibited
by the metalloproteinase inhibitor 1,10-phenanthroline. The shedding, however, can also be
inhibited by serine protease inhibitors suggesting CD43 shedding can be performed by
metalloproteinases as well as serine proteases (Bazil and Strominger 1993; Weber et al.
1997).
1.4.6 CD30 AND CD27
CD30 is a type I glycosylated transmembrane receptor belonging to the TNFR superfamily,
which was originally described as an antigen expressed on Reed Sternberg cells in
Hodgkin's disease (Schwab et al. 1982). Subsequently, CD30 was shown to be induced
upon activation of T lymphocytes (Ellis et al. 1993). A soluble form of CD30 (sCD30) was
identified in serum, levels of which correlated with viral infection and Th2 type immune
responses (Caligaris-Cappio et al. 1995). CD30 has also been reported to be cleaved by
metalloproteinases (Hansen et al. 1995).
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Dual stimulation of CD4+ T cells by cross-linking CD30 and TCR induces varied responses
including increased proliferation, activation, differentiation and apoptosis depending on the
cell type, stage of differentiation and presence of other stimuli (Gruss et al. 1994).
Expression of CD30 on CD4+ T cells was originally thought to be restricted to Th2 subsets
(Del Prete et al. 1995), but later observations proved this to be incorrect and it is now
accepted that all CD4+ Th populations express CD30 (Hamann et al. 1996) The confusion
over Th2 and CD30 expression originated from the ability of IL-4 signalling to induce the
expression of CD30 on T cells. Increased expression of CD30 is also observed following
CD28 signalling and this occurs in an IL-4 independent fashion (Hamann et al. 1996).
Maintenance of Th2 cells in the presence of IL-4 would, therefore, be expected to increase
expression of CD30 on those clones.
The ligand for CD30 (CD30L) is expressed on a range of cell types including activated T
cells, neutrophils, eosinophils and resting B cells (Horie and Watanabe 1998). It is a
member of the TNF family and, although it shares homology with TNFa and FasL, it is not
cleaved by metalloproteinases.
CD30 ligation in conjunction with TCR stimulation increases levels of IL-2, TNFa and IFNy
and suggests that CD30, like CD28, is a potent co-stimulator of T cells. CD30 has been
shown to enhance proliferation of human and murine peripheral T cells stimulated with sub-
optimal levels of immobilised monoclonal anti-CD3 antibody (Gilfillan et al. 1998; Smith et al.
1993). CD30 ligation results in increased mobilisation of NFkB to the nucleus (McDonald et
al. 1995). The activation of NFkB is mediated by signalling through the cytoplasmic tail of
CD30 which, like TNFRII, associates with TRAF 1 and 2 (Aizawa et al. 1997) (Figure 1.6).
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CD27 is a 240 amino acid type I transmembrane member of the TNFR family which is highly
expressed on both resting and activated T lymphocytes (Hintzen et al. 1995; Lens et al.
1998; Watts and DeBenedette 1999). CD27 is believed to increase T cell proliferation upon
binding its ligand, CD70 which is, in contrast, is only transiently expressed on activated T
lymphocytes. The mechanism by which CD27 augments T cell proliferation is unknown
although some reports state that CD27 can modify ZAP-70 phosphorylation directly (Kobata
et al 1994). The outcome of activating T lymphocytes through CD27 in conjunction with
TCR, however, does not result in increased levels of IL-2, IL-4 or IL-10, suggesting another
mechanism of co-stimulation other than increasing phosphorylation of signalling pathways,
namely ZAP-70. CD27 cytoplasmic domain, like CD30 associates with TRAF2 and TRAF5
(Akiba H et al. 1997) which eventually lead to NFkB and JNK activation. This may suggests
that the mechanisms of co-stimulation that CD30 and CD27 use may be similar. CD27 also
associates with a pro-apoptotic molecule (Siva) (Prasad et al. 1997) and therefore has the
potential regulate cell death. Lowering the threshold of apoptosis may, therefore, be the
mechanism by which CD27 acts as a costimulatory molecule rather than increasing cytokine
production. CD27 has not been directly identified as a target for metalloproteases but
increased levels of soluble CD27 in biological fluids in patients suffering from a variety of
immunopathological diseases has been reported suggesting activated T cells may release a
soluble form of CD27 (Loenen et al. 1992).
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1.5 MECHANISMS AND REQUIREMENTS FOR CD4+ T CELL
ACTIVATION
Activation of T lymphocytes is essential for mounting an efficient immune response, and this
process requires at least two stimuli; the primary stimulus is controlled by the T cell antigen
receptor (TCR) interacting with an antigenic peptide bound to Major Histocompatibility
Complex class I (MHC class I) for CD8+ T cells or MHC class II (for CD4+ T cells) on the
surface of an antigen presenting cell (APC).
The secondary stimulus, or co-stimulation, can be delivered through a variety of receptor
ligand pairs of which the interaction of B7.1 (CD80)/B7.2 (CD86) molecules on the APC with
CD28 and CTLA-4 receptors on T lymphocytes is the most important. Engagement of B7
molecules with CD28 and/or CTLA-4 appears to be fundamental since in the absence of this
ligand interaction, TCR stimulation fails to induce a T cell response and leads to anergy or
AICD (Radvanyi et al. 1996).
CD28 gene deficient animals, however, are capable of eliciting normal immune response to
viral infections (Shahinian et al. 1993) and reject allogeneic skin grafts (Sperling et al. 1995).
Administration of CTLA-4-lg, which blocks CD80 and CD86 signalling by competitively
binding CD80 and CD86, to immunised animals induces a profound reduction in Thi
cytokine-producing cells. However, antigen-reactive T cells are still capable of expansion in
CTLA-4-lg treated animals, although the degree of expansion is reduced by 50% compared
with that in control Ig-treated animals (Judge et al. 1996). These data suggest the presence
of other co-stimuli which may also be vital in eliciting effective T lymphocyte activation.
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These different interactions initiate a series of signalling cascades which are transduced
from the cell membrane to the nucleus, initiating gene transcription and subsequently, T
lymphocyte activation.
1.5.1 TCR COMPLEX: STRUCTURE AND KINETICS
There are two major types of TCR found in T cells: a.p and y8. This thesis describes ap TCR
and signalling events derived from this TCR type.
The TCR is found as a complex consisting of the polymorphic TCR a and p subunits which
contain the antigen binding site, non-covalently associated with the invariant chains of the
CD3 complex y, 5, s and ££ homo-dimer chains (Weiss 1993). The CD3 chains represent
the signal transducing complex although they do not possess intrinsic enzymatic activity.
Instead, CD3 chains display, in their cytoplasmic tails, motifs called ITAMs (immunoglobulin
family tyrosine-based activation motifs) (Osman et al. 1996; Weiss and Littman 1994).
ITAMs are capable of being tyrosine phosphorylated and, as a consequence are capable of
recruiting protein tyrosine kinases (PTK) (see Figure 1.11 at the end of the signalling
section) which transduce signals to the T lymphocytes. Although the biochemical signalling
processes occurring after TCR:MHC complex interaction are well understood, there remain
unresolved questions about the initial triggering event (Lanzavecchia et al. 1999).
The initial requirement for T cell activation is generally accepted to involve TCR complex
(TCR:CD3) aggregation on the T cell surface (Boniface et al. 1998; Grakoui et al. 1999).
Recent evidence confirmed that aggregation of several TCRs on the T cell surface could
promote concentration of lipid and kinase rich 'rafts' or 'microdomains' (Viola et al. 1999).
The rafts contain key signalling components such as Src (Lck) and Syk (ZAP-70) tyrosine
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kinases, as well as adapter proteins (LAT and SLP-76) (Simons and Ikonen 1997; van
Leeuwen and Samelson 1999; Zhang et al. 1998b). Concentration of the signalling
components at the site of TCR engagement with MHC:peptide complex would thus promote
and enhance the signalling to the T lymphocyte. Disruption of the rafts leads to decreased
phosphorylation of CD3d; chain and PLCyl, and also attenuated Ca2+ mobilisation within the
lymphocyte (Montixi et al. 1998).
Despite the interaction between a T cell and an APC presenting relevant antigen lasting
several hours, the interaction between one TCR and one MHC:peptide complex has a half
life of 10 seconds (Davis et al. 1998). The long lasting contact between a T cell and an APC
is absolutely necessary for the sustained signalling which maintains gene transcription and
to promote cell cycle progression (Timmerman et al. 1996). Valitutti et al, showed that
approximately 100 MHC:peptide complexes were capable of sequentially triggering over
20000 TCRs on one T lymphocyte suggesting that the MHC:peptide complexes are capable
of engaging and triggering, but also dissociating from one TCR to become available for
another similar interaction (Valitutti et al. 1995).
Upon correct TCR/MHC:peptide complex engagement and subsequent dissociation, the
triggered TCR is internalised and degraded in an antigen dose dependent fashion (Viola and
Lanzavecchia 1996). High affinity mitogenic monoclonal antibodies to CD3 which induce
TCR mediated signalling events, are, therefore, much less effective at triggering TCR at low
concentrations since they display a stoichiometry of 1:1 and induce a single cycle of
activation rather than serial triggering events (Viola and Lanzavecchia 1996). T cell
activation using monoclonal anti-CD3 antibodies, therefore, although very efficient at
inducing activation and proliferation at high doses, does not mimic physiological activation
processes.
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1.6 TCR SIGNALLING PATHWAYS
TCR/CD3 complexes bind MHC molecules bearing relevant peptide. This process of
recognition induces raft or microdomain aggregation, thus bringing into close proximity
molecules necessary for signal transduction pathways. One of the first events to occur after
TCR/CD3 and MHC/peptide contact is activation of the membrane bound Src tyrosine
kinase p56lck (Chan and Shaw 1996).
1.6.1 SRC KINASES AND p56 Lck ACTIVATION
SH3 SH2 Kinase
J
Figure 1. 8: Diagram representing Lck (56kDa). The amino
terminal contains a myristilated Lck specific sequence which
enables the Src kinase to remain membrane bound. The
carboxy terminal sequence contains SH3, SH2 and the enzyme
domain of the kinase.
The importance of Lck (Figure 1.8) in T cell activation was highlighted by the finding that
mice deficient for Lck suffer from severe combined immune deficiency (SCID) (Molina et al.
1992). Another T cell Src tyrosine kinase, Fyn, closely related to but less well characterised
than Lck is not critical for T cell activation since Fyn deficient animals still produce normal
numbers of antigen responsive peripheral T cells (Stein et al. 1992).
Until very recently, Src family tyrosine kinases (including Lck) were thought to be negatively
regulated by phosphorylation of tyrosine 527, a critical C-terminal tyrosine residue
(Cartwright et al. 1987; Kmiecik and Shalloway 1987). Phosphorylation of Y-527 maintains
Lck in an inactive state whilst dephosphorylation activates the kinase. Dephosphorylation of
Lck is generally accepted to be regulated by the tyrosine phosphatase CD45 since there is
increased phosphorylation at the inhibitory site of Src kinases in CD45 deficient mice
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(McFarland et at. 1993; Sieh et at. 1993). Resting T cells, however, also express the
tyrosine phosphatase CD45, and Lck is predominantly found dephosphorylated, and,
therefore, in an active state (Ostergaard and Trowbridge 1990).
Very recent evidence suggests that Lck activity is also regulated by the transmembrane
costimulator molecule, CD28. The SH3 domain of Lck (Figure 1.8) was shown to bind the
proline rich region of CD28 cytoplasmic tail. Deletion of either Lck SH3 or mutation of the
proline rich region within the cytoplasmic CD28 tail abrogated Lck activity. The interaction of
Lck with the proline rich region of the CD28 cytoplasmic tail was found to enhance Lck
activation and thus, these data support an additional model of Lck activation (Holdorf et at.
1999).
Regulation of Lck activation solely by CD45 seems an unlikely situation since resting T cells
contain large amounts of dephosphorylated Lck isoforms, and yet the cells remain
quiescent. Involvement of CD28 is appealing since aggregation of the rafts or microdomains
to the contact surface of the T cell and APC, would bring both CD28 and activated Lck into
close proximity enabling interaction and activation of Lck.
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1.6.2 IMPORTANCE OF CD3C ITAM PHOSPHORYLATION
CD3i; homo-dimers contain 6 ITAM sequences and, soon after ligation of TCR with
MHC:peptide complex, these become phosphorylated by activated Lck (Cantrell 1996)
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Figure 1. 9: Diagram showing association of one CD3i;
transmembrane molecule with the TCR. Each CD3d;
molecule contains 3 ITAM sequences, each with 2 tyrosines
(represented by O0). One CD3^ molecule thus contains 6
possible phosphorylation sites.
There are many reports of varied ITAM phosphorylation patterns which depend on the
activation potential of the MHC:peptide complex (Kersh et al. 1998; Madrenas et at. 1995;
Sloan-Lancaster et al. 1994). Most of these studies used altered peptide ligands (APL) and
have reported that a strong agonist MHC:peptide complex, capable of eliciting elevated T
cell proliferation, induces elevated amounts of CD3t; tyrosine phosphorylation as compared
to weak agonist MHC:peptide complex which induces 5 fold less proliferation (Kersh et al.
1998).
The difference between strong and weak agonist peptide:MHC complexes lies in the pattern
of CD3(t; ITAM phosphorylation. Strong agonist peptides will promote phosphorylation of all
six tyrosine residues on a single CD3<!; molecule (A1->C2) whereas, weaker agonists
promote phosphorylation of only the first three tyrosine residues (A1->B1). These patterns
of phosphorylation give rise to phospho-isoforms with different molecular weights; p23 and p
-54-
Defective CD4* T Cell Activation in the Presence of a Metalloproteinase Inhibitor
21 respectively which can be visualised by electrophoresis and western blotting (Kersh et al.
1998).
1.6.3 RECRUITMENT AND ACTIVATION OF ZAP-70
NH2 - SH2 SH2 Kinase -COOH
Figure 1. 10: Diagram of ZAP-70. ZAP-70 contains two
amino SH2 domains and a carboxy terminal enzyme. One SH2
domain binds to one phospho-tyrosine on one ITAM from CD3i!;
ZAP-70 (zeta/t; associated protein of 70kDa (Figure 1.10)) is a member of the Syk tyrosine
kinase family which acts downstream of phosphorylation of ITAMs on CD3(^. Both tyrosine
residues within each ITAM (A, B or C) on CD3^ must be phosphorylated for ZAP-70 to
efficiently dock onto a CD3d; subunit (Figure 1.9). The efficient interaction between ZAP-70
and phospho-ITAM sequences subsequently influences the downstream TCR-mediated
effector functions (Chan et al. 1994a). ZAP-70 interacts with the phosphotyrosine residues
of the ITAMs through the two SH2 domains (Figure 1.10) and consequently, ZAP-70
becomes activated by phosphorylation of two tyrosine residues (Y-315 and Y-319). ZAP-70
activation process is mediated by activated Src tyrosine kinase Lck (Iwashima et al. 1994;
Weil etal. 1995)(Figure 1.11).
Mice lacking ZAP-70, similarly to the Lck deficient animals, demonstrate a SCID phenotype,
which illustrates the critical role ZAP-70 has in TCR mediated signalling (Chan et al. 1994b;
Roifman 1995).
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Upon activation, ZAP-70 phosphorylates LAT and SLP-76, adapter molecules which
transduce signals further.
1.6.4 ADAPTER MOLECULES
1.6.4.1 LAT (LINKER FOR ACTIVATION OF T CELLS)
LAT (previously known as pp36/38) is a transmembrane adapter glycoprotein expressed in
T cells which is readily phosphorylated by ZAP-70 and is found associated with CD4 in CD4+
T cells (Cantrell 1996) (Figure 1.11). Phosphorylated LAT recruits SH2 bearing signalling
molecules to the membrane, such as PLCyl and Grb2 (van Leeuwen and Samelson 1999).
From studies in Jurkat J.CAM2 cells deficient in LAT, it has become clear that the primary
function of LAT is to mediate the coupling of TCR and PLCy1-Ca2+ and Ras signalling
pathways (described later in this introduction) (Finco et at. 1998). Association of Grb2 to
phosphorylated LAT however provides a link to MAPK pathway through Sos/Ras activation.
1.6.4.2 SLP-76
SLP-76, is also an adapter protein expressed in T cells which binds LAT/Grb2 complex and
is then phosphorylated by activated ZAP-70 (Figure 1.11). SLP-76 contains three NH2
tyrosine phosphorylation sites which upon TCR signalling recruits guanine exchange factor
(GEF) Vav which induces an activation of NFATc and thus an increase in IL-2 gene
transcription (Bubeck Wardenburg et at. 1998). Studies in Jurkat cells deficient in SLP-76
demonstrated defects in activation of PLCyl, IP3 accumulation, and Ras activation.
The adapter proteins are therefore responsible for linking TCR mediated events to
appropriate signalling cascades.
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1.6.5 PHOSPHOLIPASE Cy1 (PLCyl) AND DOWNSTREAM EVENTS
After successful ZAP-70 docking and phosphorylation, the Syk kinase tyrosine
phosphorylates and activates LAT bound PLCy (Cantrell 1996).
Activated PLCy hydrolyses phosphatidylinositol 4,5-biphosphate (PiP2) and thereby
generates inositol polyphosphates (IP3) and diaglycerols (DAG), which allow TCR mediated
signalling to regulate both intracellular calcium levels and the serine/threonine kinase family
of protein kinase C isozymes (PKC) respectively ((Cantrell 1996) and Figure 1.11).
1.6.6 CALCIUM
The presence of elevated IP3 concentrations within the T lymphocyte evokes a rise in [Ca2+]j
within the cells. The first phase of the [Ca2+]i rise is generally thought to be mediated by IP3
binding to receptors in the endoplasmic reticulum (ER) membrane and opening Ca2+
channels that releases Ca2+ into the cytosol (Imboden and Stobo 1985). The second phase
is considerably less well understood and is initiated by the depletion of Ca2+ within the ER
stores. The second phase consists of prolonged influx of Ca2+ across the plasma
membrane through Calcium Release Activated Calcium channels (CRAC channels) leading
to the activation of the serine/threonine phosphatase calcineurin, via a calmodulin:Ca2+
intermediate. Dephosphorylation of inactive transcription factors by calcineurin promotes
their translocation across the nuclear membrane where they combine with nuclear elements
to help drive the expression specific genes (Figure 1.11). Some reports state that Ca2+
influx must be sustained for over 30 minutes to commit T cells to become activated and
express the IL-2 gene through NFATc activation (Crabtree and Clipstone 1994; Goldsmith
and Weiss 1988; Negulescu et al. 1994 and Figure 1.11).
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1.6.7 RAS ACTIVATION
Following TCR ligation, Ras is activated through GTP binding either through interaction with
Sos or direct effects from DAG. Ras activation leads to phosphorylation and activation of
the serine/threonine kinase Raf-1(Hallberg et al. 1994). Raf-1 is capable of phosphorylating
mitogen activated protein kinase kinase (MAPKK or MEK). ERK is the principal substrate
for MEK and upon activation phosphorylates transcription factors such as Fos and Jun
which then translocate to the nucleus. NFkB activation by ERK is thought to be mediated by
phosphorylation of the inhibitor of NFkB (IkB) which causes the dissociation of the two
molecules, releasing NFkB now free to translocate to the nucleus (Li and Sedivy 1993).
-58-
Defective CD4+ T Cell Activation in the Presence of a Metalloproteinase Inhibitor
Figure 1.11: Outline of TCR mediated signalling pathways.
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1.7 CD4+ T LYMPHOCYTE SUBSETS- T^ VS TH2
In 1986 Mosmann and colleagues identified two types of lymphokine patterns produced by
long-term cultured CD4+ T-helper (Th) clones that provide help for different arms of the
immune system and which have profound counter-regulatory effects on each other
(Mosmann et al. 1986). These two CD4+ T-helper types were named Th-i and Th2.
Th-i cells mainly secrete IL-2, IL-3, IFNy, TNFa and TNFp thus inducing an inflammatory
immune response. Th2 cells, however, secrete IL-4, IL-5, IL-6 and IL-13, which favour a
humoral response associated with allergies. Since then, much work has been focused on
defining the different factors which may determine either Th, or Th2 functional differentiation.
1.7.1 ANTIGEN DOSE
Firstly, antigen dose plays a pivotal role in determining the differentiation of precursor CD4+
Th cells into either type 1 or type 2 helper CD4+ T cells. The first reports of this observation
demonstrated that in vivo, low and high doses of antigen would promote humoral and cell
mediated responses respectively (Liew 1989). This field of research, however, has many
conflicting reports (Rogers and Croft 1999). One view which is generally accepted, is that
low doses of antigen lead to low numbers of MFIC molecules bearing relevant peptides on
APCs, resulting in low numbers of ligated TCRs and, consequently, limited phosphorylation
of intracellular kinases and reduced mobilisation of calcium in the T cells.
Some reports indicate that in vitro, a low degree of T cell activation induces IL-4 production
without IFNy production in resting human memory and effector Th cells (Secrist et al. 1995;
Carballido et al. 1997) and leads to the development of Th2-cell responses in naive Th cells
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from TCR-transgenic mice (Boutin et al. 1997). As many allergens enter the body at low
concentrations, this low-dose effect may contribute to the preferential development of Th2-
cell responses as found in allergy. Interestingly, on the basis of the reactivity of allergen-
specific Th-cell clones in vitro, the study of Carbadillio et al. (Carballido et al. 1997)
suggests that Th cells from patients with atopic allergy require higher doses of allergen to
produce IFNy than their counterparts from non-allergic subjects.
Other, more recent studies, however suggest that a low overall level of stimulation induces
short term effector T cells secreting IL-2 with little commitment to either Th! or Th2
differentiation, whereas, a moderate level of stimulation is necessary for T cell survival over
an extended time. T cell cultures containing enough peptide to generate long term survival
showed that at early time points, lower levels of stimulation could generate Th-, type
differentiation whereas at the same time points, high levels of peptide could favour the Th2
type differentiation. Over an extended period of time, however, the phenomenon was
reversed with low doses and high doses generating Th2 and Thi type T cells respectively
(Rogers and Croft 1999).
1.7.2 COSTIMULATION
Secondly, costimulation provided by the APC to the CD4+ Th cell has also been found to
influence the outcome of Thi versus Th2 differentiation. CD28 deficient mice have impaired
immunoglobulin production, but preserved cytotoxic T lymphocyte and delayed type
hypersensitivity responses (Shahinian et al. 1993). Mice transgenic for soluble CTLA-4-lg
molecule (Lane et al. 1994; Ronchese et al. 1994) have severe impairment in T-dependent
B-cell responses and germinal centre formation, whereas their T cells produce higher levels
of IFNy but lower levels of IL-4.
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In three in vivo models of Th2 development (anti-lgD antibody administration, infection with
Heligmosomoides polygyrus, and infection with Leishmania major) CTLA-4-lg treatment had
a profound effect in blocking the generation of IL-4 producing cells (Corry et al. 1994; Lu et
al. 1994; Lu et al. 1995). CTLA-4-lg administration to resistant C57BL/6 mice did not impair
their ability to resist infection with L. major (Corry et al. 1994), and CD28 deficient mice on a
resistant background have normal development of Thi responses and healing (Reiner and
Seder 1995). These results suggest that the initial interaction of CD28 (or possibly CTLA-4)
with its B7 ligand is probably required for priming Th2 responses but is non-essential for
some Th-i responses. The findings that CD86 becomes rapidly upregulated on dendritic cells
(Inaba et al. 1994) and that both B7 ligands can be induced quickly on a wide variety of
APCs bearing MHC class II (Hathcock et al. 1994) support their potential role at initiation of
any immune response.
Studies using selective blockade of CD80 or CD86 suggest unique roles for the B7 ligands in
preferential Th development (Kuchroo et al. 1995). Priming or restimulation of TCR
transgenic T cells leads to increased IL-4 production in the presence of anti-CD80 (blocking
CD80 mediated signalling), but increased IFNy production in the presence of anti-CD86
(blocking CD86 mediated signalling). When anti-CD80 was used in an experimental
autoimmune encephalomyelitis model, disease severity was reduced (and IL-4 production
was augmented), whereas the use of anti-CD86 increased disease severity (and augmented
IFNy production) (Kuchroo et al. 1995). A role for CD80 in Thi development is supported by
the finding that CD80 costimulation increases the number of IL-2 mRNA positive cells among
the Thi and Th0 clones but is less effective in increasing the number of Th2 cells that
produce IL-4 (Bucy et al. 1994). More recent studies, however, using CD80/CD86 gene
deficient animals suggest that these molecules contribute to the magnitude of T cell
activation, but do not appear to selectively regulate Thi versus Th2 differentiation
(Schweitzer et al. 1997).
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1.7.3 CYTOKINE ENVIRONMENT
Thirdly, the cytokine environment in which naive T cells encounter antigen influences the
differentiation of precursor CD4+ Th cells to adopt either a Th-i or a Th2 fate. The two main
cytokines which play a direct role on the CD4+ T cell are IL-4 and IL-12.
IL-12 is a heterodimeric cytokine produced primarily by phagocytic cells such as
macrophages and DCs but absent in B cells (Guery et al. 1997) although there are some
reports of non germinal centre B cells capable of IL-12 secretion (Schultze et at. 1999). Its
role in directing Thi development in several in vitro and in vivo systems is now well
established (Trinchieri and Scott 1994). Recent advances in IL-12 biology have elucidated
some of the mechanisms by which it acts in the initiation and maintenance of immune
responses in vivo. Some studies (Trinchieri and Scott 1994) highlight the potency of IL-12 in
selectively driving the differentiation of Th! development but the mechanism of action is less
clear: other studies, however, suggest that IL-12 can act directly on T cells to suppress IL-4,
whilst some imply that the effects of IL-12 are mediated through the induction of IFNy. The
ability of IL-12 to induce Thi responses in vivo was initially established in studies of mice
infected with L. major. Treatment of susceptible BALB/c mice with recombinant (r)IL-12 can
inhibit the usual Th2 response and promote the successful outgrowth of Th-i effector cells
(Heinzel et at. 1993; Sypek et al. 1993). The importance of endogenous IL-12, however, is
highlighted in murine models of candidiasis and toxoplasmosis, in which neutralisation of IL-
12 abrogated Th! development and impaired survival while promoting Th2-type responses
(Gazzinelli et al. 1994; Romani et al. 1994). Most studies support the notion that the primary
effect of IL-12 in inhibiting initiation of a Th2 response is indirect, through its induction of
IFNy, but that IL-12 is capable of suppressing IL-4 production directly in some CD4+
subpopulations.
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Sources of IL-4 which prime Th2 differentiation has been extensively reviewed (Coffman and
von der Weid 1997). In the murine L. major model, there is a burst in IL-4 transcription from
CD4+ cells four days after infection in both susceptible and resistant mice (Reiner et al.
1994). Similar findings were made in the schistosome egg granuloma and intestinal
helminth models (Svetic et al. 1993; Wynn et al. 1993). In adoptive transfer studies with IL-4
gene deficient mice, CD4+ rather than CD4" cells were the primary source of IL-4 for Th2
mediated responses (Schmitz et al. 1994). A potential source for early IL-4 production by a
CD4+ cell population includes NK1.1+ CD4+ cell which was the predominant source of IL-4 in
one model of in vivo T-cell activation (Yoshimoto and Paul 1994). A pre-activated T cell as
primary source of IL-4 is also supported by studies in which CD62L|0W cells were able to
produce the IL-4 that drove the CD62Lh'9h cells to become Th2-like (Gollob and Coffman
1994). Since recent evidence suggests low level of CD62L expression primarily distinguish
Th2 from TLh (CD62Lh'9h) cells (Wely et al. 1999), it is not surprising that CD62Ll0W cells are
capable of inducing IL-4 secretion of naive (CD62Lh'9h) CD4+ T cells.
Established Th-i and Th2 lines from TCR transgenic mice are long-lived and retain their
cytokine phenotype after being adoptively transferred into normal recipients (Swain 1994).
These cells may be an important source of primary cytokines during a chronic immune
response that educates newly activated naive, precursor Th cells during epitope spreading.
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MATERIALS AND METHODS
All buffers and reagent sourcing is indicated at the rear of this chapter in Section 2.5. All
reagents were purchased from Sigma unless otherwise stated in brackets after the reagent.
Buffers underlined are described in detail in Section 2.5.
2.1 CELL ISOLATIONS AND PURIFICATIONS
2.1.1 MURINE SPLEEN
Isolation of C57BL/6 spleens were used either for proliferation assays or further cell isolation.
Spleens were excised from 6-8 week old females, dissected into 2mm sized cubes and
placed in 5ml PBS. Tissues were ground between 2 frosted glass slides until a homogenous
cell suspension was obtained. Cell suspensions were passed through 70pm sterile gauzes
and were centrifuged at 100 x g for 7 minutes at room temperature. Cell pellets were
resuspended in 1ml ice cold Tris-NKiCI red blood cell (rbc) Ivsis buffer 71 ml rbc lysis buffer
per spleen) and left on ice for 5 minutes. Cell suspensions were washed three times in PBS
by centrifugation at 300 x g and counted using a haemacytometer chamber with 0.4% trypan
blue (Sigma) exclusion. Cells were resuspended at 106/ml in complete DMEM (Sigma) until
further use. Using this method typically isolated between 100-150x10® cells per spleen
depending on the age of the animal. Cells could be purified further using MACS isolation
methods described below.
2.1.2 HUMAN PBMC ISOLATION
Human peripheral blood mononuclear cells (PBMCs) were isolated by centrifugal separation
over Histopaque-1077 (Sigma). Briefly, blood was obtained from adult volunteers by
intravenous puncture into heparinised syringes (5000 units Heparin sodium salt (Sigma) /ml
of blood) . The blood was diluted in a 1:1 ratio with room temperature PBS, layered onto
15mls room temperature Histopaque-1077 (Sigma) in 50 ml conical centrifuge tubes
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(Falcon) and centrifuged at 800 x g for 20 minutes at room temperature. The mononuclear
cell layer was gently aspirated and washed 3 times with 3 volumes PBS by centrifugation at
600 x g for 15 minutes at room temperature. Cells were resuspended in complete RPMI-
1640 (Sigma) and counted using a haemacytometer chamber with 0.4% trypan blue (Sigma)
exclusion. PBMC numbers typically recovered using this method ranged from 1-2.5x106
cells/ml of blood.
Cells could be purified further using MACS isolation methods described below.
2.1.3 CELL PURIFICATIONS
CD3+, CD4+, CD8+, or CD90+ expressing cells were separated from whole spleen
suspensions or PBMCs (except CD90+) by positive selection to generate enriched cell
populations. This was performed using a magnetic cell separation method (MACS) (Miltenyi
Biotech, Surrey, U.K.) according to the manufacturer's instructions. Briefly, single cell
suspensions were generated as described above (for mouse spleen or human peripheral
blood) with the final resuspension at 107 cells per 90pl in MACS buffer (see section 2.5) prior
to a 6°C, 15 minute incubation with 10pl antibody coated microbeads (Miltenyi Biotech) per
107 cells. Excess microbeads were removed by washing once in 50 mis MACS buffer and
the cell pellet resuspended in 500pl MACS buffer. Labelled cells were allowed to pass
through a pre-rinsed (6mls MACS buffer) magnetised positive selection column (Myltenyi
Biotech) by gravity flow. The selection column was washed with 3 bed volumes of MACS
buffer (9mls total), removing unlabelled cells. The column was demagnetised and cells
bearing the antigen of interest (i.e. CD3, CD4, CD8 or CD90) were expelled from the column
in 5mls MACS buffer by inserting the column plunger. Mouse cells were washed in 50 mis
complete DMEM (Sigma), human cells were washed in 50mls complete RPMI-1640 (Sigma)
and counted using a haemacytometer with 0.4% trypan blue (Sigma) exclusion. Using this
method of purification typically generated >90% pure populations as assessed by flow
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cytometric analysis for T cell markers such as TCR or antigen used for separation (CD3,
CD4, CD8 or CD90).
2.2 IMMUNOLOGICAL ASSAYS
2.2.1 MITOGEN PROLIFERATION
Polyclonal mitogens used in this study were phorbol 12-myristate 13-acetate (PMA) (Sigma)
with lonomvcin (Sigma), Concanavalin A (Con A) (Sigma), Pokeweed mitogen (PWM)
(Sigma), E. coli lipopolysaccharide (LPS) (serotype 055:B5) (Sigma) and anti-p-chain laM
F(ab")2 (Jackson ImmunoResearch, USA).
Briefly, single cell suspensions were obtained as previously described for mouse spleen and
plated out at 2.5x105 cells/well in tissue culture treated 96 round bottom wells (Costar) in a
final volume of 200pl. Mitogens were added to the wells at pre-determined optimal
concentrations, diluted in complete DMEM (Sigma) (PMA and lonomycin- 0.1pg and
0.5pg/ml respectively, Con A - 2.5pg/ml, PWM - 1pg/ml, LPS - 5pg/ml, anti-p-chain IgM
F(ab')2 - 20pg/ml). BB-3103 inhibitor was added at a range of concentrations (0.02pM,
0.2pM, 2pM and 20pM) to appropriate wells before addition of mitogens. Samples were
incubated at 37°C in a humidified incubator with 5% C02 for 72 hours. Proliferation was
assessed by addition of excess (1pCi/well) tritiated thymidine diluted in PBS (3H-TdR-
Amersham Pharmacia Biotech, Amersham, U.K.) for the last 6 or 16 hours of culture or
overnight (as stated in the text). Plates were harvested onto glass fibre filtermats (Wallac,
Milton Keynes, U.K.) with an automated 96 well plate harvester (Tomtec, Harborview, USA),
dried and heat-sealed into plastic bags (Wallac, Milton Keynes, U.K.) with 10ml of
scintillation fluid (Wallac, Milton Keynes, U.K.). 3H-TdR incorporation was assessed using a
liquid scintillation counter Betaplate 1205 (Wallac, Milton Keynes, U.K.) and associated
software. Counts per minute (cpm) observed per sample were indicative of the extent of
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proliferation. All samples were tested in triplicate or sextuplet and each experiment repeated
three times unless otherwise stated in the Figure legends.
2.2.2 POLYCLONAL TCR STIMULATION USING PLATE BOUND AND
SOLUBLE ANTIBODIES
Stimulation of purified T cell populations was performed using immobilised monoclonal
antibodies against CD3s and soluble monoclonal antibodies directed against CD28
(Pharmingen, San Diego, CA, USA). Briefly, immobilisation of anti-CD3s monoclonal
antibodies (Pharmingen clone 2C11) onto plastic was performed by diluting the antibody to a
final concentration of 5pg/ml in PBS and dispensing 30pl of the diluted monoclonal per well
of a tissue culture treated flat bottom 96 well plate (Costar). The sealed plates were
incubated for 16 hours at 4°C. Wells were washed three times with ice cold PBS to remove
excess unbound antibody. BB-3103 inhibitor was added at a range of concentrations
(0.02pM, 0.2pM, 2pM and 20pM final) to appropriate wells before addition of cells. Purified
cells were plated out at 2.5x105 per well in complete DMEM (Sigma) for murine cells or
complete RPMI 1640 (Sigma) for human cells. Anti-CD28 (Pharmingen clone 37.51)
monoclonal antibodies were added to the wells at a final concentration of 5pg/ml diluted in
the appropriate cell culture medium in a final culture volume of 200pl. Addition of other
exogenous soluble monoclonal antibodies was performed prior to incubation at 37°C in a
humidified incubator with 5% C02 for 72 hours. Proliferation was assessed by incorporation
of tritiated thymidine for 6 or 16 hours (as described in the text) and assayed by scintillation
as described previously. All samples were tested in triplicate or sextuplet and each
experiment repeated three times unless otherwise stated in the Figure legends.
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2.2.3 CELL COUNTS
Cell counts from proliferation assays were performed on the days 1, 2 and 3 using
haemacytometers and 0.4% trypan blue (Sigma) exclusion. 5x105 cells were dispensed per
well of a tissue culture treated 96 well flat bottom plate in comlete DMEM (Sigma), previously
coated with excess anti-CD3 antibody (Pharmingen clone 2C11) as described above. 20pM
BB-3103 was added to appropriate wells and 5pg/ml anti-CD28 mAb (Pharmingen clone
37.51) was also added to the culture for a final volume of 200pl per well. Counts from each
sample were performed in triplicate. The experiments were repeated in triplicate.
2.2.4 APOPTOSIS ASSAY (ANNEXINV-FITC STAINING)
AnnexinV-FITC staining of CD4+ cells was performed using an apoptosis detection kit
following the manufacturer's instructions (BenderMed Systems, Vienna, Austria). Briefly,
5x10s proliferating cells (activated with anti-CD3 and anti CD28, as described in section
2.2.3) were centrifuged at 300 x g, 4°C and resuspended in 10Opil 1X calcium buffer provided
in the kit. 5ju.l AnnexinV-FITC conjugate was added to the resuspended cells and incubated
on ice for 30 minutes. Cells were washed once in 1ml 1X ice cold calcium buffer and
resuspended in 200pl 1X calcium buffer containing 5pl propidium iodide. Cells were
incubated on ice for a further 10 minutes prior to flow cytometric analysis using Becton
Dickinson FACSCalibur (BDIS, San Jose, CA, USA).
2.2.5 FLOW CYTOMETRY
All flow cytometry was performed on a Becton Dickinson FACSCalibur (BDIS, San Jose, CA,
USA) and experiments were repeated three times. Phenotypic analysis of murine cell
surface markers was accomplished using Pharmingen (Pharmingen, San Diego, CA, USA)
monoclonal antibodies recognising the following cell surface proteins (CD4, CD8a, CD25,
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CD27, CD30, CD40L, CD62L, CD69, CD95, CD95L, CD137). Appropriate isotype controls
were also purchased from Pharmingen. Briefly, cells of interest were washed in ice-cold
PBS and resuspended in FACS staining buffer at a final concentration of 106 cells per 10Opil.
1pg of relevant monoclonal antibody was added per 106 cells and incubated in the dark on
ice for 30 minutes. Samples were washed three times with 500pl ice-cold PBS and
resuspended in ice-cold FACS fixing solution. Fixed samples were kept at 4°C and analysed
as specified by Becton Dickinson.
2.2.6 ENZYME LINKED IMMUNOSORBANT ASSAYS (ELISAs)
Cytokine secretion was analysed by detecting soluble protein in aliquots of supernatants
collected from cell cultures at 48hrs. Similar methods were used for murine and human
cytokine detection. Reagents for cytokine detection and standards were purchased from
Pharmingen (San Diego, CA, USA). Briefly, anti-cytokine capture antibodies were diluted to
1pg/ml in ELISA binding buffer. 50pl of diluted capture antibody was added to the wells of
enhanced protein binding ELISA plates (Corning, NY, USA). The plates were sealed and
incubated overnight at 4°C. Excess capture antibody was removed, 200pl of ELISA blocking
buffer was added to each well and the plates incubated at 37°C for one hour. Wells were
washed 3 times with ELISA wash buffer and 10Opil of standards and samples were added to
the wells (diluted in ELISA wash buffer). Plates were sealed and incubated overnight at 4°C.
Wells were washed 4 times with 200pl ELISA wash buffer and 10Opil of 1gg/ml biotinylated
detection antibody diluted in ELISA wash buffer was added to each well. Plates were
incubated for one hour at room temperature after which wells were washed 5 times with
200pl ELISA wash buffer and 200pl of 1 in 2000 diluted (manufacturer's instructions)
Streptavidin-alkaline phosphatase conjugate (Amersham Life Sciences, Amersham, U.K.) in
ELISA wash buffer was added to the wells and incubated for 30 minutes at room
temperature. Wells were washed 7 times with ELISA wash buffer to remove excess alkaline
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phosphatase and 200j.il of ELISA substrate solution was added to wells. Plates were placed
in the dark for colour change to occur and assayed at 10 minute intervals on a Microplate
Reader 450 (BioRad Laboratories, Hemel Hempstead, U.K.) and associated software.
2.3 SIGNALLING
2.3.1 IMMUNOPRECIPITATION
In order to immunoprecipitate and detect proteins by western blotting, the activation method
of CD4+ cells was modified. Each sample required 107 purified cells which were stimulated
in larger bulk cultures. Briefly, per sample, 107 purified CD4+ T cells (resuspended in 1ml
complete DMEM (Sigma)) were added to one well of tissue culture treated 24 well plates
(Costar), previously coated with excess (20pig/ml) anti-CD3s monoclonal antibody for 16
hours, as previously described. Plates were very briefly centrifuged at room temperature
(100 x g for 15 seconds) to initiate contact between cells and immobilised monoclonal
antibodies. Time points started once the plates were removed from the centrifuge. At
appropriate time points, lysis of cells was performed by addition of 1ml 2 X Tris-based Ivsis
buffer to each sample followed by thorough pipetting to ensure complete lysis. Lysed
samples were transferred to fresh tubes and placed on ice for 30 minutes with vigorous
vortexing at regular intervals. Samples were clarified by centrifugation at 14000xg at 4°C.
Insoluble nuclei formed a pellet which was avoided as the supernatant was removed.
Agarose conjugated monoclonal antibodies directed against tyrosine phosphorylated
residues, PY-20 and PY-99 (Santa Cruz Biotechnology, Santa Cruz, USA- both antibodies
mouse lgG2b isotype) were added as supplied by the manufacturer (50pg antibody per 107
cells) to the clarified supernatants and gently mixed at 4°C overnight. Samples were washed
5 times with 1ml freshly prepared ice-cold 1 X Tris based lysis buffer with 4°C 1000xg
centrifugations. 50pl boiling Laemlli buffer (Sigma, Dorset, U.K) was added to each pellet
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and samples were boiled for 5 minutes prior to immunoblotting. Positive control samples
consisting of 5x106 unstimulated Jurkat cell pellets were lysed by addition of 20pl boiling
Laemlli buffer.
2.3.2 IMMUNOBLOTTING
8% mini SDS-poIv acrvlamide gel electrophesis (PAGE) gels were cast with 4% stacking
gels on BioRad mini Protean II rigs (BioRad). Samples were electrophoresed at 200 Volts
using SDS-Tris-Glvcine electrophoresis buffer for one hour beside pre-stained molecular
weight markers (Gibco BRL, Paisley, U.K.). Proteins were transferred to nitrocellulose
(Amersham Pharmacia Biotech, Amersham, U.K.) using methanol based transfer buffer at
400 milliAmps for 45 minutes. Non-specific protein binding sites on the nitrocellulose
membrane were blocked by incubation of the membranes in 50mls blocking buffer for one
hour at 37°C or overnight at 4°C. Membranes were washed 3 times in 50 ml nitrocellulose
wash buffer for 5 minutes. Appropriate primary antibodies were diluted in 20mls
nitrocellulose wash buffer and incubated for one hour at 37°C with constant shaking.
Antibodies used were mouse IgGi monoclonal anti-p56lck (Pharmingen, San Diego, USA),
mouse monoclonal IgG-i anti-CD3t; chain (Santa Cruz Biotechnology, Santa Cruz, USA) and
rabbit polyclonal IgG anti ZAP-70 (Santa Cruz Biotechnology, Santa Cruz, USA) which bind
proteins from both murine and human species. Membranes were washed 5 times with
50mls nitrocellulose wash buffer at room temperature. Detection horseradish peroxidase
(HRP) conjugated antibodies (Dako Corporation, Carpinteria, CA, USA; (a) HRP-Goat anti
mouse Ig, or (b) HRP-Goat anti rabbit Ig) were diluted 1 in 2000 (manufacturer's instructions)
in nitrocellulose wash buffer and incubated with the membranes for one hour at room
temperature with gentle shaking. Membranes were washed a further 5 times with 50mls
nitrocellulose wash buffer before 5 minute incubation with enhanced chemiluminescent
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(ECL) reagent (Amersham Pharmacia Biotech, Amersham, U.K.). Excess ECL reagent was
removed and the membrane placed under BioMax MS-1 X-ray sensitive film. Films were
processed through an X-ray developer (X-Ograph Imaging Systems, Wilts, U.K.) at various
exposure time points (1min, 3min, 5 min and 10 minutes). Optimal exposure time films were
photographed using a white trans-illuminator and gel documentation system (Ultra Violet
Products, Cambridge, U.K.).
2.3.3 CALCIUM DETECTION IN HUMAN CD4+ T CELLS
Calcium flux detection was performed using a modified method previously described
(O'Flaherty and Rossi 1993) which examined [Ca2+] in neutrophils. Briefly, single cell
suspension of human CD4+ T cells were isolated from PBMCs as previously described.
Purified CD4+ T cells were resuspended in Hanks Balanced Salt Solution without Ca2+ or
Mg2+ (Sigma) at a concentration of 107 cells/ml. 1pM Fura-2AM (Sigma) final concentration
was added to the cells and incubated, shaking in the dark at 37°C for 20 minutes. Cells
were washed 3 times with HBSS (Sigma), resuspended in 37°C HBSS (Sigma) and allowed
to rest for 10 minutes at 37°C to allow total de-esterification of Fura-2AM. Cells were
centrifuged gently and resuspended in PBS giving a cell concentration of 4x106/ml. 107 cells
(2.5mls) were placed in a 37°C heated, stirred cuvette fluorimeter (SPEX Fluoromax) with
dual wavelength excitation (340 and 380 nm), emission at 510nm. After a 2 minute warm-up
period in the heated chamber, stimulus in the form of monoclonal antibodies purchased from
Pharmingen (anti-CD3s (HIT3a) or anti-CD62L (Dreg 56)) was added to give final
concentrations as described in the figure legends. [Ca2+] variations were compiled over 10
minute periods and analysed using the following formula: Maximal (Rmax) and minimum
(Rmin) fluorescence were determined by addition of 50pM digitonin and 25mM EGTA to
samples respectively. [Ca2+] was calculated from the relationship:
[Ca2+]i=Kd-(R-RminMRmax-R).p
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where [Ca2+]i is the cytosolic calcium concentration, R is the ratio of fluorescence obtained at
340 and 380m, in the sample before calibration, and Rmax is the fluorescence ratio under
saturating [Ca2+],, Rmin is the fluorescence ratio in the absence of Ca2+, Kd is the dissociation
constant for Fura-2AM, taken as 224nm at 37°C and (3 is the fluorescence ratio at 340nm of
cells in the absence and presence of Ca2+.
2.4 CD4+T CELLS SUBSETS
2.4.1 HUMAN CD4+ T CELL CLONE PROLIFERATION
Proliferation of two human CD4+ T cell clones (HA1.7 and AC1.1) was accomplished by
purification of PBMCs from histocompatibie donors (HLA-DRB1*1101 for HA1.7 and HLA-
DQB1*0301 for AC1.1) as described previously. PBMCs were y-irradiated with 2000rad
using a 137Caesium source. Irradiated PBMCs were resuspended in complete RPMI 1640
and plated out in tissue culture treated 96 round bottom well plates (Costar) at 2.5x104
cells/well. 1pg/ml final concentration appropriate peptide (HA 306-318 for HA1.7 and Der p 2
16-31 for AC1.1 kindly donated by Dr A Verhoef, Imperial College, London U.K.) was added
to appropriate wells. Dilutions of BB-3103 (0.02, 0.2, 2 and 20pM) were added to
appropriate wells. CD4+ T cell clones were washed three times in PBS, resuspended in
complete RPMI 1640 and added to feeder cells at 2x104 cells/well in a final volume of 200pl.
Cells were incubated at 37°C in a humidified incubator 5% C02 for 3 days. 50pl aliquots of
supernatants were removed after 48hrs of culture for cytokine analysis. Proliferation was
assessed by incorporation of tritiated thymidine for 16 hrs by scintillation as described
previously. All samples were tested in triplicate.
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2.4.2 PROLIFERATION OF PBMCs FROM ATOPIC AND NON-ATOPIC
VOLUNTEERS
PBMCs isolated from atopic and non-atopic volunteers were plated out in tissue culture
treated round bottom 96 well plates (Costar) at 2.5x105 cells/well in complete RPMI 1640 in
a final volume of 200pl. Dilutions of BB-3103 were added to relevant wells. 10pg/ml
(previously determined optimal concentration) of Per p 1 (in house purification) was added to
appropriate wells. 50pl aliquots of supernatants were removed at 48 hrs. Plates were
incubated at 37°C in a humidified incubator with 5% C02 for 3 days. Proliferation was
assessed by incorporation of tritiated thymidine for 16 hrs as described before. Counts per
minute (cpm) observed per sample were indicative of the extent of proliferation. All samples
were tested in triplicate.
2.4.3 GENERATION OF MURINE Th! AND Th2 TYPE CELLS
Naive CD4+ T cells were enriched, resuspended in complete DMEM. plated out at 2.5x105
cells/well in tissue culture treated flat bottom 96 well plates (Costar) coated with immobilised
anti murine CD3e monoclonal antibody (Pharmingen clone 2C11) as previously described.
Anti-murine CD28 monoclonal antibody was added at a final concentration of 5pg/ml in
complete DMEM. BB-3103 titrations were added to the appropriate wells. To generate a
Tfq type environment, 20ng/ml recombinant murine IFNy (Serotech, Oxford, U.K.), 20ng/ml
recombinant murine IL-12 (p70) (Pharmingen, San Diego, CA, USA) and 20gg/ml purified
neutralising monoclonal anti IL-4 antibody (11B11 clone, in house purification) was added to
the cultures. For a Th2 type environment, 20ng/ml recombinant murine IL-4 (Serotech,
Oxford, U.K.) and 20pg/ml purified neutralising monoclonal anti IFNy antibody (HB170 clone,
in house purification) was added to the cultures for a final volume of 200pl/well. Plates were
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incubated at 37°C in a humidified incubator with 5% C02 for 3 days. Proliferation was
assessed by incorporation of tritiated thymidine for 6 or 16 hrs as described in the figure
legends. Counts per minute (cpm) observed per sample were indicative of the extent of
proliferation. All samples were tested in triplicate and experiments performed three times
unless otherwise stated in the text.
2.5 MATERIALS AND BUFFERS
Ail chemicals were purchased from Sigma (Dorset, U.K.) unless otherwise stated.
• Red Blood Cell Lysis Buffer (Tris-NFLCh
0.017M Tris Base (T-1503) in 0.83% NH4CI(A-5666), pH 7.65 (HCI). Kept at 4°C.
• Complete Murine DMEM culture media
500mls DMEM (D-5921) with 10% foetal calf serum (FCS) (F-9665), 5x10"5
M p-mercaptoethanol (M-7522), 100IU/ml penicillin/streptomycin (Gibco, Paisley, U.K.
15070-071), 2mM L-Glutamine (Gibco, Paisley, U.K., 25033-010). Kept at 4°C.
• Complete Human RPMI culture media
500mls RPMI 1640 (R-0883) with 5% human AB serum [heat inactivated] (H-1513),
100IU/ml penicillin/streptomycin (Gibco, Paisley, U.K. 15070-071), 2mM L-Glutamine (Gibco,
Paisley, U.K., 25033-010). Kept at 4°C.
. MACS Buffer
0.5% BSA (A-2153) in PBS"" (D-5652). Kept at 4°C.
• FACS Staining Buffer
10% normal mouse serum (Scottish Antibody Production Unit-SAPU, Scotland, U.K.-NMS) in
PBS"" (D-5652). Kept at 4°C.
• FACS Fixing Buffer
2% paraformaldehyde (P-6148) in PBS" (D-5652). Kept at 4°C.
• ELISA Binding Buffer
Carbonate-Bicarbonate buffer (C-3041). Made fresh.
• ELISA Blocking Buffer
PBS" (D-5652) containing 5% Casein (C-7078) and 0.1% Tween-20 (P-7949). Made fresh.
• ELISA Wash Buffer
PBS" (D-5652) containing 0.1% Tween-20 (P-7949). Kept at room temperature.
• ELISA Substrate Solution
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E.U.S.A. ethanolamine buffer (Don Whitley Scientific, Shipton, U.K. E-016) containing
1mg/ml pNPP (N-2770). Made fresh.
• 1 X Tris-Based Cell Lvsis Buffer
50mM Tris (T-1503) pH7.4, 150mM NaCi (S-7653), 2mM EDTA (E-1644) pH 8.0, 5mM NaFI
(S-7920), 5mM Na3V04 (S-6508), 1% NP-40/IGEPAL CA-630 (1-3021), anti-protease cocktail
(P-2714). Made fresh. (2X cones doubled)
• 8% SDS-PAGE Gel (200mls)
94.8mls dH20, 53.2mls 30% acrylamide/bis-acrylamide mix (A-3699), 50mls 1.5M Trizma
Base pH 8.8 (T-1503), 1ml 10% SDS (L-4509). Kept at 4°C. Polymerisation of 5mls gel
mixture catalysed by addition of 5pl TEMED (T-9281) and 50pl 10% APS (A-3678).
• 4% Stacking Gel (IQOmlsl
69.5% dH20, 17mls 30% acrylamide/bis-acrylamide mix (A-3699), 12.5mls 1.5M Trizma
Base pH 8.8 (T-1503), 0.5ml 10% SDS (L-4509). Kept at 4°C. Polymerisation of 5mls gel
mixture catalysed by addition of 5pl TEMED (T-9281) and 50gl 10% APS (A-3678).
• SDS-Tris Glycine Electrophoresis Buffer
25mM Trizma Base (T-1503), 250mM Glycine (G-7403), 0.1% SDS (L-4509). Kept at room
temperature.
• Methanol Based Transfer Buffer
39mM Glycine (G-7403), 48mM Trizma Base (T-1503), 0.037% SDS (L-4509), 20%
methanol (M-1770). Made fresh.
• Blocking Buffer
PBS" (D-5652) with 0.1% Tween-20 (P-7949) and 5% BSA (A-2153). Made fresh.
• Nitrocellulose Wash Buffer
PBS" (D-5652) with 0.1 % Tween-20 (P-7949). Kept at room temperature.
• Per p 1 purification
Der p 1 group 1 allergen from Dermatophagoides pteronysinnus was purified by
immunoaffinity chromatography as described before (Hoyne et al. 1993). Purity of protein
was assessed electrophoresis on an staining 8% SDS-PAGE gel stained with Coomassie
brilliant blue (B-5133) buffer and destain.
• Neutralising antibody purification
Neutralising antibodies to IFNy and IL-4 were purified as described before (Darby et al. 1993)
from B cell hybridoma supernatants (anti-IFNy, HB170 clone; anti-IL-4, 11B11 clone).
Purified antibodies were resuspended in PBS"(D-5652) and stored at 4°C.
• Preparation of mitogens
ConA (C-7275), PWM (L-9379) and LPS (L-2880) mitogens were resuspended at 1mg/ml in
PBS" and stored at -20°C. Anti-p chain IgM was resuspended in PBS" (D-5652) and stored
at 4°C. PMA (P-8139) was resuspended in ethanol (E-7023) at 0.1mg/ml and stored at -
20°C. lonomycin (I-0634) was resuspended at 0.5mg/ml in ethanol (E-7023) and stored at -
20°C.
• Preparation of BB-3103 fBB-2116)
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BB-3103 was provided in powder form and resuspended at a final concentration of 20mM in
DMSO (D-2650). The compound was stored at 4°C.
• Coomassie Stain (1L1
10% glacial acetic acid (A-6283), 40% methanol (M-1770) 1g Coomassie brilliant blue (B-
5133).
• Coomassie Destain
10% glacial acetic acid (A-6283), 40% methanol (M-1770).
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RESULTS AND DISCUSSIONS
All results are shown as means of three experiments unless otherwise stated in the text.
Statistics were calculated using means of repeated experiments against a one-way ANOVA
test. Significant p values are represented on graphs as follows p<0.05=*, p<0.01=** and
p<0.001=***. Data points labeled 'Control' signify samples not containing BB-3103.
CHAPTER 3
3.1 PMA/IONOMYCIN INDUCED PROLIFERATION IS
UNAFFECTED BY BB-3103
These experiments were designed to investigate if BB-3103 could affect the proliferation of T
and B lymphocytes from spleens of naive (unimmunised) C57BL/6 (H-2b) mice stimulated in
an antigen independent manner. PMA is a diaglycerol (DAG) analogue which constitutively
activates the mitogen activated protein kinase (MAPK) pathway (see section 1.6.5 and
Figure 1.11), whereas ionomycin is a calcium ionophore which opens calcium channels and
enables the influx of extracellular calcium ions into cells to activate calcineurin (see section
1.6.6 and Figure 1.11). Both pathways mentioned are required for full lymphocyte activation
and proliferation (Watts and DeBenedette 1999). Splenocytes were isolated from C57BL/6
mice and cultured for 3 days in the presence of 0.5j.ig/ml ionomycin and O.lpg/ml PMA.
Proliferation was determined by thymidine incorporation for 6 hrs (Figure 3.1)
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Figure 3. 1: C57BL/6 spleen
proliferation to PMA/iono in the
presence of BB-3103. Whole naive
C56BL/6 spleen isolated and cultured with
0.1 pig/ml PMA and 0.5pg/ml ionomycin for
3 days in the presence of BB-3103
concentrations indicated on x-axis.
Proliferation was determined by thymidine
incorporation for the last 6 hours of
culture. Graph represents mean
proliferation of 4 animals. Background
poliferation counts did not exceed 1000
cpm in all experiments.
BB-3103, over the concentrations tested, did not inhibit PMA/lonomycin induced splenocyte
proliferation. Since PMA and ionomycin bypass receptor mediated signalling, it appeared
BB-3103 did not directly interfere with intracellular signalling events. BB-3103 is incapable of
penetrating the cell and thus remains extracellular (Layton G., British Biotech, personal
communication).
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3.2 BB-3103 DOES NOT AFFECT B LYMPHOCYTE
PROLIFERATION
In order to investigate the effect of BB-3103 hydroxamate inhibitor on the activation and
subsequent proliferation of B lymphocytes, spleens from naive C57BL/6 mice were cultured
in the presence of the mitogen LPS (Figure 3.2), or activated by cross linking B cell receptor
(BCR) with the use of anti-p-chain of IgM F(ab')2 monoclonal antibody (Figure 3.3) in the
presence of various BB-3103 doses.













Figure 3. 2: C57BL/6 spleen
proliferation to LPS in the presence of
BB-3103. Spleen cells from naive
C57BL/6 mice cultured for 3 days in the
presence of 5pg/ml LPS and various
doses of BB-3103 as indicated on the x-
axis. Proliferation was determined by
thymidine incorporation for the last 6
hours of culture. Graph represents mean
of three animals. Background
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3.2.2 BB-3103 DOES NOT MODULATE BCR MEDIATED B CELL
PROLIFERATION
Figure 3. 3: Proliferation of B cells
in C57BL/6 spleen by cross linking
BCR in the presence of BB-3103.
Spleen cells from naive C57BL/6
mice cultured for 3 days in the
presence of 20pg/ml anti p-IgM
F(ab')2 and various doses of BB-
3103 as indicated on the x-axis.
Proliferation was determined by
thymidine incorporation for the last 6
hours of culture. Graph represents
means of three animals. Background
proliferation did not exceed 1000
cpm.
Although no flow cytometry was performed on resulting cultures to establish B cell
expansion, BB-3103 seemed to have no effect on cell activation and proliferation by different
activation mechanisms investigated, LPS-CD14/TLR4 dependent activation (Hoshino et al.
1999) and anti-p-IgM F(ab')2-BCR dependent activation (Maruyama et al. 1985). Neither of
these modes of cell activation were affected by the presence of metalloproteinase inhibitor
suggesting MP activity may not essential for B cell activation and proliferation.
SUMMARY
• BB-3103 does not modulate splenocyte proliferation induced by:
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Anti-p-chain IgM
3.3 MITOGEN DRIVEN T LYMPHOCYTE PROLIFERATION IS
DOWNREGULATED BY BB-3103
T lymphocytes can also be activated with mitogens. In these experiments, two mitogenic
plant lectins were investigated, Concanavalin A (ConA) (Figure 3.4) and pokeweed mitogen
(PWM)-(Figure 3.5). Lectin induced T cell stimulation is dependent on accessory cells which
provided the necessary co-stimulatory signals to complete T cell activation (Torbett and
Clark 1988). In these experiments, pre-determined optimal doses of each lectin were added
to naive spleen cell suspensions in the presence of BB-3103.










35000 Figure 3. 4: C57BL/6 spleen proliferation
to ConA in the presence of BB-3103.
Naive C56BL/6 spleen cells cultured with
2.5pg/ml ConA for 3 days in the presence
of BB-3103 concentrations as indicated on
the x-axis. Proliferation was determined by
thymidine incorporation for the last 6 hours
of culture. Graph represents means of
three animals. Background proliferation
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BB-3103 downregulated splenocyte proliferation induced by ConA.
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3.3.2 BB-3103 REDUCES PWM MEDIATED T CELL PROLIFERATION
Figure 3. 5: C57BL/6 spleen
proliferation to PWM in the presence of
BB-3103. Naive C56BL/6 spleen cells
cultured with 1pg/ml PWM for 3 days in
the presence of BB-3103 concentrations
as indicated on the x-axis. Proliferation
was determined by thymidine
incorporation for the last 6 hours of
culture. Graph represents means of three
animals. Background proliferation did not
exceed 1000 cpm.
It was observed that splenocyte proliferation induced with both plant lectin mitogens (ConA
and PWM) was markedly inhibited by BB-3103 as compared to controls. These results
suggested that the inhibition of metalloproteinase activity could downregulate T cell
proliferation, since ConA and PWM are both known T cell activatiors. No flow cytometric
analysis was performed on the resulting cultures however, therefore it can only be assumed
the proliferation see was due to T cell expansion.
SUMMARY
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3.4 T LYMPHOCYTE PROLIFERATION IS AFFECTED BY BB-
3103 IN THE ABSENCE OF ACCESSORY CELLS
The following series of experiments were designed to investigate the proliferation of various
subsets of T lymphocytes in the absence of accessory cells in order to assess whether the
inhibitory effect of BB-3103 was due to direct action on T lymphocytes or through
costimulation provided by accessory cells.
Thy1 antigen (CD90) is expressed on murine CD4+ and CD8+ T lymphocytes (Gunter et al.
1984) and can be used as a cell surface molecule to isolate both cell types from other
splenocytes using positive selection with magnetic associated cell separation columns
(MACS, Miltenyi Biotech). Furthermore, CD4 and CD8 cell surface antigens may also be
used to fractionate T cell populations (Schmitz et al. 1994) using the same positive selection
mechanism.
In order to investigate the proliferation of purified T cell subsets in the absence of accessory
cells, TCRs were cross-linked using immobilised anti-CD3s mAb and costimulation provided
by 5(ig/ml soluble anti-CD28 mAb. The actual amounts of anti-CD3s which immobilised to
the plate was not assayed, but presumed to be similar between each experiment.
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3.4.1 BB-3103 INHIBITS THE PROLIFERATION OF PURIFIED CD90+
CELLS
MACS enriched CD90+ cells were activated for 3 days using immobilised anti-CD3 mAb and
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Figure 3. 6: Proliferation of purified
CD90+ cells to anti-CD3 mAb & anti-
CD28 mAb in the presence of BB-3103.
Proliferation of CD90+ cells isolated from
naive C57BL/6 spleens and stimulated
for 3 days with immobilised anti-CD3
mAb and 5gg/ml soluble anti-CD28 mAb
in the presence of inhibitor as indicated
on the x-axis. Proliferation was
determined by thymidine incorporation for
the last 6 hours of culture. Graph
represents means of three animals.
Background proliferation did not exceed
5000 cpm.
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3.4.2 BB-3103 INHIBITS THE PROLIFERATION OF PURIFIED CD4+
CELLS
MACS enriched CD4+ T cells were activated for 3 days using immobilised anti-CD3 mAb and
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Figure 3. 7: Proliferation of purified
CD4+ cells to anti-CD3 mAb and anti-
CD28 mAb in the presence of BB-3103.
Proliferation of purified CD4+ cells isolated
from naive C57BL/6 spleens and
stimulated for 3 days with immobilised anti-
CD3 mAb and 5gg/ml soluble anti-CD28
mAb in the presence of inhibitor as
indicated on the x-axis. Proliferation was
determined by thymidine incorporation for
the last 6 hours of culture. Graph
represents means of three animals.
Background proliferation did not exceed
5000 cpm.
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3.4.3 BB-3103 INHIBITS THE PROLIFERATION OF PURIFIED CD8+
CELLS
The effect of BB-3103 on CD8+ T lymphocytes was similarly investigated. Figure 3.8
illustrates the decrease in proliferation of enriched CD8+ T cells activated with immobilised
anti-CD3 mAb and 5fig/ml soluble anti-CD28 mAb in the presence of various doses of BB-
3103.
Figure 3. 8: Proliferation of purified
CD8+ cells to anti-CD3 mAb and anti-
CD28 mAb in the presence of BB-
3103. Proliferation of CD8+ cells
purified from naive C57BL/6 spleens
and stimulated for 3 days with
immobilised anti-CD3 mAb and 5pg/mi
soluble anti-CD28 mAb in the presence
of BB-3103 inhibitor as indicated on the
x-axis. Proliferation was determined by
thymidine incorporation for the last 6
hours of culture. Graph represents
means of three animals. Background
proliferation did not exceed 5000 cpm.
Trestmert (pM B&3103)
MACS enrichment of spleen cells led to 96% purity for CD4+, 89% for CD8+ and 91% for
CD90+ cells populations. When these cells were stimulated in vitro with immobilised anti-
CD3 mAb and soluble anti-CD28 mAb , strong proliferation was observed. However,
consistent with the previous lymphocyte proliferation data observed using mitogenic lectins,
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• BB-3103 reduced proliferation of CD90+, CD4+ and CD8+ enriched lymphocytes by 58%,
50% and 64% respectively.
• Enriched T lymphocytes were used in these assays, therefore, these data suggest that
BB-3103 acted directly on T cells.
DISCUSSION (CHAPTER 3)
It has not been previously reported that inhibition of metalloproteinase activity is capable of
downregulating T lymphocyte proliferation.
The experiments described so far reveal that BB-3103 inhibits proliferation of enriched T
lymphocytes but does not affect the proliferation of splenocytes to LPS or B cells through B
cell receptor. These results are surprising, since, while this is the first demonstration that T
lymphocytes require metalloproteinase activity for normal proliferation to occur, the same
could not be demonstrated in B lymphocytes. The activation of B cells involved cross-linking
the surface IgM (BCR) with the use of anti-p IgM F(ab')2 fragments which induces signalling
events within the B cell similar to those observed in T lymphocytes (Harnett and Rigley
1992). This suggests that the mechanism by which metalloproteinase activity increases T
cell proliferation is either not present, not required, or is redundant in B cells.
T lymphocyte proliferation was still inhibited when activated as a highly enriched population
suggesting that the metalloproteinase responsible for T lymphocyte proliferation was not
secreted by accessory cells which were present in previous, mitogen induced proliferation
which investigated whole spleenocytes.
Activation of splenocytes, however, with PMA and lonomycin mitogens revealed that
proliferation was not inhibited. These data indicated that the metalloproteinase substrate
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responsible for fully activating T lymphocytes may act upstream of PLCy phosphorylation and
activation (see Figure 1.11). It is possible however, that the optimal mitogenic doses used in
these experiments could have clouded any other, downstream effects which could have
been modulated by BB-3103.
Another interesting observation is that stimulation of TCR with anti-CD3 mAb and anti-CD28
mAb activated different pathways to those activated through mitogenic lectins. The
pathways leading from TCR activation are well established (Cantrell 1996), whereas, the
mitogenic characteristic of lectins is poorly understood. Concanavalin A, for example, is
thought to induce Na+/H+ exchange in T lymphocytes (Grinstein et at. 1987) which
subsequently leads to IL-2 production. It is evident, however, that optimal T lymphocyte
proliferation, whether through TCR or mitogenic plant lectins, utilises metalloproteinase
activity, whereas, BCR or LPS mediated B cell activation is not dependent on
metalloproteinase activity.
The proliferation assays performed in this Chapter are, however, limitted in as far as kinetics
of BB-3103 effects are concerned. This issue is highlighted later in the thesis (Fig 4.1)
where cells treated with BB-3103 demonstrated a delayed proliferation profile rahter than a
complete inhibition. To address this issue, experiments investigating proliferation at various
time points (24, 48, 72, 92 and 120 hrs) should have been performed in order to establish
the kinetics of cell proliferation in the presence of BB-3103. The experiment shown in Fig 4.1
in fact suggests that cell treated with BB-3103 are not inhibited, but delayed in their
proliferation, thus suggesting that the results shown in this Chapter are only investigating a
small window of a kinetic response, not showing the real effects of BB-3103. Another issue
which should have been investigated is the effect of BB-3103 addition at different time points
using these stimulation methods, this would resolve whether BB-3103 could downregulate
thymidine incoporation when added after stimulation rather than at the same time. The
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experiments shown in Chapter 3 are also incomplete in as far as flow cytometry was never
performed on the samples prior to thymidine incorporation. It is impossible to asses which
cell types were thus affected by BB-3103 where splenocytes were stimulated with mitogenic
lectins (ConA and LPS). Although the general understanding is that LPS activates B cells,
this was not checked in these experiments and it can only thus be assumed that BB-3103
does not affect B cell proliferation. Similarly, Concanavalin A is a known T cell stimulator,
however, since flow cytometric analysis was not performed on cells stimulated with ConA,
the results can only be interpreted as BB-3103 affecting T cell proliferation. In experiments
where enriched populations of T cells were used, the thymidine incorporation could only
have been provided from the starting population and therefore are more indicative that BB-
3103 only affects T cells. There are also, however, some limitations to these experiments
since only optimal doses of immobilised anti CD3 and CD28 mAb were used. It was not
considered whether at sub-optimal or supra-optimal antibody doses, BB-3103 would have
the same effect. Similarly, varying the doses of lectins may have generated different
patterns of inhibition, if any. Another issue which was not investigated was the fact that BB-
3103 irreversibly binds in a 1:1 ratio with metalloproteases therefore it is conceivable that
over time, the actual concentration of BB-3103 within the culture was reducing over time. To
address this issue, proliferation experiments where adding a constant amount of BB-3103 on
a daily basis should have been performed. These are all issues which could have generated
a better understanding of BB-3103 kinetics and which cells were affected by BB-3103.
The percentage of proliferation inhibition generated from these experiments appears not to
be consistent throughout the thesis and this may be attributed to either a slow degradation of
BB-3103 through time and also a different batch of BB-3103 provided by British Biotech pic.
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CHAPTER 4
4. THE INHIBITION OF T LYMPHOCYTE PROLIFERATION IS
NOT DUE TO APOPTOSIS OR TOXICITY
The reduction in proliferation of T lymphocytes observed in the previous experiments was not
due to toxic effects of BB-3103. This is supported by the finding that PMA/lonomycin
stimulation of whole splenocytes was not affected by BB-3103 when used at the same
molarity as the TCR mediated proliferation experiments.
In order to assess apoptosis and/or toxicity of BB-3103 on T lymphocytes, cell counts were
performed during a 3 day immobilised anti-CD3 mAb and 5pg/ml soluble anti-CD28 mAb
proliferation assay (Figure 4.1). This was followed by FACS analysis looking for membrane
bound AnnexinV-FITC conjugate (Figure 4.2) which binds phospholipid phosphatidylserine
(PS). PS is translocated from the inner leaflet of the plasma membrane to the outer leaflet
during very early phases of apoptosis and can thus bind AnnexinV-FITC extracellularly and
can be used to detect early indications of programmed cell death by flow cytometry.
Propidium Iodide was used in conjunction with AnnexinV-FITC to detect membrane integrity
of the cells, thus distinguishing necrotic cells and late apoptosis.
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4.1 BB-3103 INHIBITS EARLY CD4+ T CELL EXPANSION
i nd bb3103 □ 20pm bb-3103 Figure 4. 1: BB-3103 affects cell
number in proliferation assays. Cell
counts of purified CD4+ T cells activated
using immobilised anti-CD3 mAb and
5pg/ml soluble anti-CD28 mAb in the
presence of 20pM BB-3103 over a period
of 3 days. The p symbols (*) represent
ANOVA statistics between the two
samples within each daily group. Each
sample was counted in triplicate. The




The cell number observed at each time point in the presence of BB-3103 was significantly
lower than in the absence of BB-3103. An interesting observation drawn from these
experiments is that the cell number in BB-3103 treated groups, although still lower than
control groups, started to increase on day 2. The major inhibition in proliferation was seen
on day 1 suggesting that BB-3103 affected one or more early events in the T cell activation
and clonal expansion and enhances the issue of kinetics of proliferation in the presence of
BB0-3103 (see Discussion Chapter 3).
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4.2 PRESENCE OF BB-3103 DOES NOT INCREASE
APOPTOSIS
Figure 4.2 shows that there is no increased apoptosis in BB-3103 treated groups. Cells in
the lower left quadrants do not stain for either Annexin-V or PI and are, therefore, considered
to be viable cells. Figure 4.2 panel A (positive control) demonstrates 42% of aged (16hrs in
culture) neutrophils are actively undergoing early apoptosis (lower right quadrant-LR).
These cells are staining positive for Annexin V-FITC indicating the cell membrane has lost
symmetry and PS has translocated to the outer leaflet of the plasma membrane.
The upper right quadrants (UR) select cells at advanced stages of apoptosis, since these
cells stain positive for Annexin-V and are also Propidium Iodide (PI) positive due to
increased plasma membrane permeability.
Events acquired in the upper left quandrants (UL), are cells which stain positive for PI, but
negative for AnnexinV-FITC due to the membranes having lost so much integrity they are no
longer capable of binding Annexin-V.
There were no significant differences between cells treated in the absence of BB-3103
(Figure 4.2 panel B) and in the presence of 20pM BB-3103 (Figure 4.2 panel C) in any of the
quadrants, suggesting the observed decrease in proliferation in the presence of BB-3103
was not due to increased apoptosis or necrosis.
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Figure 4. 2: BB-3103 does not increase Annexin-V-FITC staining on CD4+ T cells.
FACS analyses of CD4+ T cells treated with BB-3103 do not show increased apoptosis.
Panel A shows purified human neutrophils aged overnight at 37°C (+ve control). Panel B
shows purified murine CD4+ T cells activated for 2 days in the absence of BB-3103 with
immobilised anti-CD3 mAb and 5pg/ml soluble anti-CD28 mAb . Panel C shows similarly
activated CD4+ T cells for 2 days in the presence of 20pM BB-3103. Values in boxes (lower
right quandrant, or LR) are the values of positively stained Annexin-V cells undergoing early
apoptosis. Cells in upper right quadrant (UR values) represent cells positively staining
AnnexinV and PI denoting cells in a late stage of apoptosis.
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SUMMARY
• BB-3103 does not induce apoptosis or necrosis in proliferating CD4+ T cells
• BB-3103 prevents increase in numbers of CD4+ T cells early in proliferation assays.
4.3 BB-3103 DOES NOT AFFECT IL-2 DEPENDENT AND
INDEPENDENT TRANSFORMED T CELL LINES
The effect of BB-3103 inhibitor was assessed on two transformed T cell lines Jurkat E6.1,
EL4 and the IL-2 dependent cell line, HT-2. Jurkat T cell line clone E6-1 was derived from
an acute human T cell leukemia and consists of CD4+ T cells (Weiss et al. 1984). EL4 was
established from a murine lymphoma (Shevach et at. 1972) and HT-2 is a murine T helper
cell line which was originally established by limiting dilution in the presence of IL-2, and is
highly dependent on IL-2 for proliferation (Woods et al. 1987). HT-2 cells are capable of
growing in the presence of IL-2 alone without the requirement for TCR engagement or co-
stimulatory signals. EL-4 and Jurkat cells proliferate continuously in vitro without the
requirement of any stimulus. As shown in Figures 4.3 and 4.4, BB-3103 did not affect the
proliferation of these cells even at the highest dose used of 20pM. Similarly, BB-3103 did
not affect the proliferative response of HT-2 cells when cultured in the presence of various
doses of IL-2. It would, therefore, appear that the IL-2 signalling pathway is not dependent
on active metalloproteinases and the transformed status of Jurkat E6.1 and EL4 bypasses
any requirement for metalloproteinase activity.
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Figure 4. 3: Proliferation of EL4 and Jurkat E6.1 in the
presence of 20pM BB-3103. Graph representing proliferation
of transformed T cell lines in the presence or absence of 20pM
BB-3103. Cells were cultured in the presence of 20pM BB-
3103 without stimulus for 24hours. Thymidine incorporation
was determined for the last 6 hours of culture. Graph
represents mean of three experiments.
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Figure 4. 4: Proliferation of HT-2 cells in the presence of
BB-3103. HT-2 cells were grown in different concentrations of
IL-2 as indicated in the legend. Titration of BB-3103 into each
sample revealed that HT-2 cells were not affected by BB-3103.
Thymidine incorporation was determined for the last 6 hours of
culture. Graph represents mean of three experiments.
Background proliferation (no IL-2) did not exceed 500cpm.
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SUMMARY
• BB-3103 does not inhibit:
• Proliferation of transformed T cell lines
• IL-2 mediated proliferation of HT-2 cells.
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4.4 IC50 VALUES FOR BB-3103 IN T CELL PROLIFERATION
The inhibitory efficiency of pharmaceutical compounds is measured in IC50 values, which are
the concentrations of compounds at which the activity of what the compound is being tested
against, is reduced by half regardless of cytotoxicity, in cellular systems. For these
experiments purified CD4+ T cells were isolated from C57BL/6 spleens and activated using
immobilised anti-CD3 mAb and soluble anti-CD28 (5pg/ml) mAb for 3 days in the presence
of a much broader titration of inhibitor. The concentrations ranged from 2x10"5 to 2x103pM
BB-3103 (Figure 4.5 below)
Figure 4. 5: IC50 curve for BB-3103 in
CD4+ T cells. Graphic representing the
inhibition of CD4+ T cell proliferation in
the presence of a large concentration
range of BB-3103. The IC50 values range
from 0.0002pM to 2pM BB-3103. Graph
represents mean of experiments
performed on two animals. Thymidine
incorporation was determined for the last
16 hours of culture Background
proliferation did not exceed 10000 cpm.
Establishing the exact IC50 value for BB-3103 on T cell proliferation was extremely difficult
since the inhibitory curve was bimodal and the 50% inhibition value lay on a plateau which
encompassed 5 concentration values of BB-3103 (2x10"4 to 2pM BB-3103). The presence of
the plateau seen in the inhibition curve indicated that BB-3103 was capable of inhibiting
CD4+ T cell proliferation by half and the higher concentrations used (above 20(iM) were
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more than likely toxic due to elevated vehicle concentrations (DMSO) although this should
have been investigated by titrating equivalent DMSO concentrations to proliferating CD4+ T
cells.
SUMMARY
• IC50 values for BB-3103 are broad and span concentrations from 2x10"4 to 2pM.
DISCUSSION (CHAPTER 4)
In the presence of BB-3103, T lymphocyte proliferation was inhibited. The experiments in
this chapter were designed to determine whether the reduction in proliferation was due to cell
apoptosis or necrosis. Assessing cell number by simply counting viable cells, revealed that
20pM BB-3103 was capable of inhibiting early cell division, since T lymphocyte division
occurs every 6-8hrs (Cantrell 1996). Cell proliferation, however, recovered at later stages (3
days) but was still significantly lower than CD4+ T cells activated in the absence of BB-3103.
These data suggested that the presence of BB-3103 either inhibited early events in
activation of all T lymphocytes or that BB-3103 was incapable of inhibiting the proliferation of
a minor population which, over time, expanded sufficiently to generate 30% less proliferation
as compared to no inhibitor controls. As discussed at the end of Chapter 3, this
'recuperation' sheds some light onto the issue of kinetics studies to be performed. The data
in Fig 4.1 highly suggests that had the experiment been taken further, the cell treated with
BB-3103 may have demonstrated a delayed proliferation curve rather than an inhibition
altogether.
AnnexinV binding to T lymphocytes did not increase in the presence of 20pM BB-3103,
excluding the possibility of reduced counts being attributed to increased apoptosis. The
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presence of PI in the assay investigated possible necrotic effects of BB-3103 but showed no
increase in staining in the presence of BB-3103.
The concentration of inhibitor used in these apoptosis assays, 20pM, fell outwith the IC50
range but still demonstrated no necrotic or apoptosis inducing properties on activated CD4+
T cells. Investigating the IC50 values of BB-3103 on CD4+ T lymphocyte proliferation
demonstrated a sudden reduction in proliferation between 200 and 2000pM concentrations.
This may have been due to cytotoxic effect of DMSO which exceeded 0.05% at those
concentrations. Exceeding 0.05% DMSO in the absence of BB-3103 downregulated T cell
proliferation (results not shown and Dr R Rintoul, personal communication). To complete
this experiment, a second titration of vehicle only (in this case, DMSO) should have been
performed in order to establish whether the toxicity could be attributed to DMSO or whether
this was entirely a BB-3103 cytotoxicity effect. The thymidine incoporation in these assays is
noticeably higher than in other experiments and this cannot be attributed to any known factor
other than a 16hr thymidine incorporation uptake period.
Two transformed T cell lines, Jurkats and EL-4, were grown in the presence of BB-3103 and
revealed no change in cell expansion, suggesting that only TOR driven proliferation of naive
CD4+ T cells was capable of being inhibited, and the mechanism by which BB-3103 could
inhibit proliferation was redundant or not present in transformed T cells.
BB-3103 did not affect the IL-2 driven proliferation response in HT-2 cells. These data
strongly suggested that BB-3103 could not interfere with the IL-2 JAK/STAT signalling
pathway (Beadling et al. 1994), although HT-2 cells were originally isolated and grown under
highly selective and abnormal circumstances (Woods et al. 1987).
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Taken together, the data presented so far, support the idea that, in the presence of BB-3103,
T cells cannot be activated maximally because of absent metalloproteolytic activity. Also,
since BB-3103 did not affect the IL-2 driven proliferation of HT2 cells, the observed decrease
in CD4+ T cell proliferation could be due to decreased IL-2 production in the presence of
inhibitor.
-102-
Defective CD4+ T Cell Activation in the Presence of a Metalloproteinase Inhibitor
CHAPTER 5
5.1 BB-3103 REDUCES IL-2 SECRETION IN ACTIVATED
CD4+ T CELLS
Since proliferation of activated CD4+ T cells was reduced in the presence of BB-3103, the
cytokine secretion patterns were analysed. CD4+ T cells purified from spleens of
unimmunised animals were activated with immobilised anti-CD3 mAb and 5pg/ml soluble
anti-CD28 mAb for 48hrs in the presence or absence of BB-3103 as indicated on the x-axis
(Figure 5.1).
-IL-2 —■—IL-5 —A—IL-4 -X— IFNg
X X *
Control 0.02 0.2 2
Treatment (pM BB-3103)
20
Figure 5. 1: Cytokine secretion of
activated CD4+ T cells in the presence
of BB-3103: Graph representing IL-2, IL-
5, IL-4 and IFNy concentrations in
supernatants of activated CD4+ T cells at
48hrs. IL-2 concentration was reduced by
approximately 25% in the presence of
BB-3103, whereas other cytokines
analysed showed no variation in the
presence of inhibitor. Graph represents
mean of two animals. IL-5
concentrations fell beneath detection
range and therefore may not accurately
represent actual IL-5 concentrations in
the culture medium.
IL-2 secretion was reduced by 25% in the presence of inhibitor suggesting that this decrease
may be one factor in the observed decrease in CD4+ T cell proliferation.
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5.2 PHENOTYPIC ANALYSIS OF CD4+ T CELLS IN THE
PRESENCE OF BB-3103
Since BB-3103 inhibited CD4+ T cell proliferation it was of interest to investigate the effect of
BB-3103 on surface markers of CD4+ T cells. Flow cytometric analysis was performed on
purified, activated cells (immobilised anti-CD3 mAb and 5pg/ml soluble anti-CD28 mAb) in
the presence or absence of 20pM BB-3103 for the following cell surface proteins:- CD25,
CD69, CD40L, Fas, FasL, CD62L, CD27, CD30, 4-1BB/CD137 (Table 5.1 below). The
mean fluorescence intensity values (MFI) indicated in Table 5.1 are not representative of
poisson distribution, and represents total fluorescence of cell populations which may contain
2 or more fluorescence intensities (see Fig. 5.2 for expample). The use of MFI in this thesis
is used as a mean of interpreting general effects by BB-3103 rather than describing poisson
distribution of staining patterns.
day 0 day 1 day 2 day 3
WT control 20uM BB control 20uM BB control 20uM BB
CD25 6.08 142.41 113.4 113.33 185.3 238.82 186.24
CD69 10.76 1163 1033.87 1144.29 1083.51 913 915
CD40L 8.45 8.58 11.11 10.93 17.91 21.43 33.15
Fas 97.59 162 144 265.2 238.62 327.08 364.51
FasL 9.29 17.74 17.28 15.47 13.95 17.31 18.93
CD62L 90.02 39.34 261.15 50.58 235.13 47.92 173.69
CD27 291.18 155.84 375.38 324.89 534.12 326.05 664.62
CD30 11.24 29.27 36.59 47.04 42.93 77 98.84
4-1BB 8.41 42.59 37.56 57.06 71.52 134.74 118.5
Table 5. 1: Summary of the phenotypic data acquired by flow
cytometery on purified CD4+ T cells activated with immobilised anti-
CD3 mAb and 5pg/ml soluble anti-CD28 mAb in the presence or
absence of 20pM BB-3103. The numbers indicate mean fluorescent
intensity values found for each marker (MFI). Results show that
CD27 and CD62L expressions are highly upregulated in the
presence of BB-3103. Results for shaded cell surface proteins are
discussed in more detail later in the text. Values indicated in the
table are representative of triplicates. See Figs 5.2-5.5 for histogram
profiles.
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5.2.1 BB-3103 AFFECTS CD27 EXPRESSION ON CD4+ T CELLS
Of the markers tested, significant inhibition of activation induced downregulation was
observed for CD27 (Table 5.1 and Figure 5.2 below)
io' i<r io° i<r itr 10' i<r ioJ nr icr 101 i<r 10'
FL2-CD27 FL2-CD27 FL2-CD27
Figure 5. 2: BB-3103 affects CD27 expression on CD4+ T cells. Analysis of
CD27 expression on naive C57BL/6 enriched CD4+ T cells activated with
immobilised anti-CD3 mAb and soluble anti-CD28 mAb over a period of 3
days in the presence or absence of BB-3103. Panels represent: a)freshly
purified CD4+ T cells, b)activated CD4+ T cells for 24hrs, c)activated CD4+ T
cells for 48hrs, d) activated CD4+ T cells for 72hrs, e)activated CD4+ T cells for
24hrs+20pM BB-3103, f) activated CD4+ T cells for 48hrs+20pM BB-3103, g)
activated CD4+ T cells for 72hrs+20pM BB-3103. Dotted lines represent
isotype controls, filled profiles represent positively stained cell counts. MFI
values for CD27 expression are indicated top right in each panel. The
histograms shown are from one experiment and are representative of three
animals.
From the results presented above, CD27 was expressed at high levels on the surface of
resting naive CD4+ T cells, supporting published data (Hintzen et at. 1993). CD27 was,
however, downregulated following activation at 24hrs but by day 3, a population of CD27hl
CD4+ T cells was observed. Presence of BB-3103 during the activation process inhibited
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early CD27 downregulation events and maintained high CD27 expression throughout the 3
days. Thus, it appeared that CD27 may be shed by a metalloproteinase enzyme which
could have been inhibited by the presence of hydroxamate containing pseudopeptide, BB-
3103, although the shedding process was never examined by soluble CD27 ELISA of culture
supernatants.
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5.2.2 CD62L EXPRESSION ON CD4+ T CELLS IS MAINTAINED IN THE
PRESENCE OF BB-3103
It has also been reported that CD62L is shed from the surface of a variety of immune cells
upon activation (Kuhns et at. 1995; Matsumoto et at. 1998). The addition of BB-3103 to
activated CD4+ T cells inhibited CD62L downregulation throughout the 3 days of the assay
(Figure 5.3).
Figure 5. 3: BB-3103 affects CD62L expression on wild type (WT) CD4+ T cells.
Analysis of CD62L expression on naive C57BL/6 enriched CD4+ T cells activated with
immobilised anti-CD3 mAb and soluble anti-CD28 mAb over a period of 3 days in the
presence or absence of BB-3103. Panels represent: a)freshly purified CD4+ T cells,
b)activated CD4+ T cells for 24hrs, c)activated CD4+ T cells for 48hrs, d) activated CD4+ T
cells for 72hrs, e)activated CD4+ T cells for 24hrs+20pM BB-3103, f)activated CD4+ T
cells for 48hrs+20pM BB-3103, g) activated CD4+ T cells for 72hrs+20pM BB-3103.
Dotted lines represent isotype controls, filled profiles represent positively stained cell
counts expressing CD62L. MFI values for CD62L expression are indicated top right in
each panel. The histograms shown are from one experiment and are representative of
three animals.
CD62L was downregulated from the surface of the CD4+ T cells upon activation (Figure 5.3).
The presence of BB-3103 during the activation process inhibited downregulation, suggesting
the process may have been mediated by a metalloproteinase. The decrease in CD62L
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expression in BB-3103 treated groups over time may have been due to decrease in molarity
of free inhibitor in the culture medium since one molecule of pseudopeptide irreversibly binds
and inhibits one molecule of metalloproteinase.
SUMMARY
• CD27 may have been downregulated by metalloproteinase activity upon CD4+ T cell
activation since this process was inhibited by BB-3103. CD27 was subsequently
upregulated in both BB-3103 and control samples.
• CD62L was downregulated upon activation possibly by metalloproteinase activity since
this process was inhibited by BB-3103.
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5.2.3 BB-3103 DOES NOT AFFECT CD25 AND CD69 EXPRESSION ON
CD4+ T CELLS
Other proteins investigated included CD25 and CD69, which are both upregulated on the
surface of the CD4+ T cell upon activation through TOR (Cantrell 1996). BB-3103 treated
CD4+ T cells upregulated the low affinity IL-2 receptor a chain, CD25, to comparable levels
as the no inhibitor controls (Figure 5.4).
10u 10' 10' 103 10^ 10 101 10 103 10^ 10 101 102 103 lO4
FL2-CD25 FL2-CD25 FL2-CD25
10" 10' 10' 10J 10^ ■:
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FL2-CD25 FL2-CD25 FL2-CD25
Figure 5. 4: BB-3103 does not affect CD25 expression on WT CD4+ T cells.
Analysis of CD25 expression on naive C57BL/6 enriched CD4+ T cells activated with
immobilised anti-CD3 mAb and soluble anti-CD28 mAb over a period of 3 days in the
presence or absence of BB-3103. Panels represent: a)freshly purified CD4+ T cells,
b)activated CD4+ T cells for 24hrs, c)activated CD4+ T cells for 48hrs, d)activated
CD4+ T cells for 72hrs, e)activated CD4+ T cells for 24hrs+20pM BB-3103, f)activated
CD4+ T cells for 48hrs+20pM BB-3103, g)activated CD4+ T cells for 72hrs+20pM BB-
3103. Dotted lines represent isotype controls, filled profiles represent positively
stained cell counts expressing CD25. MFI values for CD25 expression are indicated
top right in each panel. The histograms shown are from one experiment and are
representative of three animals.
Resting CD4+ T cells expressed very low levels of CD25 while it was considerably
upregulated upon activation (Figure 5.4). There seemed to be, however, no distinguishable
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difference of CD25 expression between BB-3103 treated and control groups. The inhibition
of proliferation discussed earlier in this chapter was, therefore, not due to dysregulation of
CD25 expression, but possibly due to reduced IL-2 secretion.
Another activation marker, CD69 which is rapidly upregulated on CD4+ T cells upon
activation was also investigated. The results of CD69 upregulation in the presence or
absence of BB-3103 are shown in Figure 5.5 below.
FL2-CD69 FL2-CD69 FL2-CD69
Figure 5. 5: BB-3103 does not affect CD69 expression on WT CD4+ T cells. Analysis of
CD69 expression on naive C57BL/6 enriched CD4+ T cells activated with immobilised anti-
CD3 mAb and soluble anti-CD28 mAb over a period of 3 days in the presence or absence of
BB-3103. Panels represent: a)freshly purified CD4+ T cells, b)activated CD4+ T cells for
24hrs, c)activated CD4+ T cells for 48hrs, d)activated CD4+ T cells for 72hrs, e)activated
CD4+ T cells for 24hrs+20pM BB-3103, f)activated CD4+ T cells for 48hrs+20pM BB-3103,
g)activated CD4+ T cells for 72hrs+20pM BB-3103. Dotted lines represent isotype controls,
blue-filled profiles represent positively stained cell counts expressing CD69. MFI values for
CD69 expression are indicated top right in each panel. The histograms shown are from one
experiment and are representative of three animals.
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Similarly to CD25 expression, CD69 was also upregulated in activated CD4+ T cells in the
presence of BB-3103 despite the proliferation being markedly reduced in the presence of the
inhibitor (see Chapter 3).
5.2.4 BB-2116 AFFECTS TNFa AND TNFRII RELEASE FROM HUMAN
PBMCs*
BB-2116 is another hydroxamate inhibitor which issimilar to BB-3103 in that it is broad range
and inhibits PWM induced proliferation of human PBMCs to similar extents (GT Layton,
personal communication). TNFa and TNFRII are both prime targets for metalloproteinase
activity and, therefore, it was investigated whether inhibition of TNFa and TNFRII release
was the cause of reduced T cell proliferation. Figure 5.6 below shows results of ELISAs
performed for soluble forms of TNFa and TNFRII. Activation mediated release of TNF and
TNFRII from PBMCs seemed to be inhibited in the presence of BB-2116.
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Figure 5. 6: BB-2116 affects TNFa and TNFRII release from human PBMCs. TNFa and
TNFRII release was measured from activated human PBMCs (2.5pg/ml PWM for 48hrs) in
the presence of BB-2116. BB-2116 inhibited the release of both TNFa and TNFRII upon
PBMC activation.
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These experiments were performed by S.J. Harris and I.G Hemingway at British Biotech
Pic.
5.2.4.1 EXOGENOUS TNFct DOES NOT RECONSTITUTE PBMC PROLIFERATION*
Since the hydroxamate inhibitor was capable of inhibiting the release of TNFa and TNFRII,
the effect of adding soluble TNFa to PWM treated PBMCs in the presence of BB-2116 was
investigated. This would determine whether a lack of soluble TNFa within the culture
medium could be responsible for downregulating the proliferative response of human T cells
to PWM. Human PBMCs were treated with 2.5pg/ml PWM and 10pM BB-2116 in the
presence of 100ng/ml recombinant human TNFa (Figure 5.7).
Figure 5. 7: Inhibition of proliferation
is not due to inhibition of TNFa
release. Proliferation of human PBMCs
in the presence of 2.5pg/ml PWM
(control) and 10pM BB-2116 (BB-2116)
and 100ng/ml recombinant human TNFa
(BB-2116 plus TNF). Addition of BB-
2116 inhibited PBMC proliferation as
expected and the addition of recombinant
TNFa did not restore the proliferation
response seen in the absence of BB-
2116. No details are known about length
of thymidine uptake in this experiment.
The results of these experiments confirm that BB-2116 is capable of inhibiting T cell
proliferation to PMW and that addition of recombinant TNFa to the culture did not restore
proliferation of PBMCs. These findings hint that the inhibition of soluble TNFa production
through metalloproteinase activity may not be responsible for the decrease in proliferation
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properties to membrane bound TNFa, but rather acts as a competitor to membrane bound
TNFRII.
*These experiments were performed by S.J. FHarris and I.G Hemingway at British Biotech
Pic.
SUMMARY
• CD25 and CD69 expression was upregulated on both BB-3103 and control samples.
DISCUSSION (CHAPTER 5)
Analysis of cytokine secretion showed that IL-2 production was decreased in the presence of
BB-3103, whereas IL-4, IL-5 and IFNy secretion was unaffected. The observed decrease in
IL-2 secretion was the first indication which could clarify the decrease in proliferation of CD4+
T cells in the presence of BB-3103 since IL-2 secretion is directly proportional to the amount
of proliferation of activated CD4+ T cells (Jain et al. 1995). This observation would have
been extended by addition of exogenous IL-2 to BB-3103 treated T cells, but unfortunately,
these experiments were not performed.
Phenotypic analysis revealed that several cell surface molecules were differently regulated in
the presence of BB-3103, notably CD27 and CD62L. Both of these proteins were
downregulated from the surface of the CD4+ T cells in the absence of BB-3103. In the
presence of the inhibitor, however, expression of these markers was maintained on the
surface suggesting that they may have been shed upon activation, and the enzyme
mediating the shedding process was a metalloproteinase. This is the first report that CD27
expression could be regulated by (a) metalloproteinase(s).
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CD27 was an appealing candidate to investigate since it is a member of metalloproteinase-
sensitive TNFR family and is capable of influencing the activation state of the CD4+ T cell.
Cross-linking CD27 on the surface of activated CD4+ T cells enhances proliferation and
increases TNFa release from the cell without affecting IL-2, IL-4 and IL-10 secretion (Flintzen
et at. 1995; Lens et at. 1998; Watts and DeBenedette 1999). Moreover, upon activation, the
TNF-family ligand for CD27 (CD70) is transiently expressed on the surface of activated CD4+
T cells and thus provides a T-T cell signalling mechanism which enhances proliferation of the
CD27 bearing cell (Hintzen et at. 1995). Inhibition of CD27 shedding with the use of BB-
3103 could therefore be seen to modify the proliferative state of enriched, activated CD4+ T
cell, although maintaining CD27 on the surface of these cells might have been expected to
enhance the proliferative response due to prolonged interactions with CD70. Furthermore,
since CD27 signalling does not affect the expression of IL-2 (Watts and DeBenedette 1999),
and since IL-2 secretion was reduced in the presence of BB-3103, it seemed unlikely that
maintaining CD27 on the cell surface could be responsible for inhibiting CD4+ T cell
proliferation. To verify that CD27 was actually shed from the surface of the lymphocytes, an
ELISA assay should have been performed to ensure that soluble CD27 was present in the
culture medium and that this concentration of sCD27 was downregulated in the presence of
BB-3103.
CD62L was also inhibited from being downregulated upon activation in the presence of BB-
3103, this observation had already been reported with other inhibitors of metalloproteinases
(Feehan et at. 1996; Preece et at. 1996; Walcheck et at. 1996). Upon activation, CD4+ T
cells shed CD62L which was inhibited in the presence of BB-3103. CD62L has been
implicated in signalling events in neutrophils upon ligation with natural or synthetic ligands
(Palecanda et at. 1992) and thus capable of increasing cytosolic calcium flux and activate
MAPK signalling cascade (Brenner et at. 1996; Laudanna et at. 1994; Waddell et at. 1995;
Brenner et at. 1997). CD62L has also been found associated with p56lck, CD3 complex and
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calmodulin (Brenner et al. 1996; Murakawa et at. 1992) and inhibition of shedding of CD62L
could potentially modify the activation state of these molecules although this has never been
demonstrated to date. Similarly to CD27 generation of a soluble form of CD62L should have
been investigated by performing ELISAs with the culture supernatant. If CD62L was indeed
shed, we would expect the soluble form of CD62L to be reduced in the presence of BB-3103.
Activation of CD4+ T cells in the presence of BB-3103 significantly decreased proliferation
but had no effect on cell surface markers which are upregulated upon activation of T
lymphocytes such as CD25 (IL-2 receptor a chain) and CD69 (activation inducer molecule
(AIM)). CD25 expression has been demonstrated to be maintained on the surface of T
lymphocytes by activated STAT5 (A and B) although initial expression of CD25 is regulated
by TCR activation (Nakajima et al. 1997). Maintenance of CD25 expression on T
lymphocytes thus works in a cyclic pattern whereby ligation of IL-2 to IL2R initiates STAT5
activation which in turn induces expression of IL2R. Taken together these data suggest that
presence of BB-3103 in proliferation assays cannot affect STAT5 A/B activation. The
starting population of cells which was used in all these experiments demonstrated a small
percentage of cells expressing CD25 and CD69. This could be attributed to either, infections
in the animals used, thus generating a small population of activated T cells, or activation of
cells by the method used for preparation of enriched CD4+ T cell populations which could
non-specifically activate CD4+ T cells.
Expression of CD69 is regulated by activated Ras (D'Ambrosio et al. 1994). Ras plays an
integral role in TCR mediated signalling (Cantrell 1996; Hallberg et al. 1994) and Figure
1.11) and upon activation, induces CD69 expression. In the presence of BB-3103, however,
CD69 expression was not downregulated which therefore suggests that Ras activation may
not directly be modified in the presence of BB-3103.
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Metalloproteinase mediated shedding of TNFa and TNFRII have also been reported (Black
et al. 1997) and shown in this thesis to be inhibited by BB-2116. Since TNFRII mediated
signalling is involved in anti-apoptotic pathways ((Rothe et al. 1995) and Figure 1.6), it would
have been expected that maintaining the receptor on the surface of lymphocytes upon
activation in the presence of inhibitor, would enhance lymphocyte survival and therefore
either increase proliferation counts or have no effect. This was not the case, however,
suggesting that inhibition of TNFRII shedding was not responsible for downregulating
proliferation. The effect of inhibiting TNFa shedding was also investigated by reconstituting
proliferation assays with recombinant soluble TNFa, but, showed no variance between
inhibitor with or without exogenous TNFa. These data loosely indicated that inhibition of
TNFa shedding may not have been the causative factor in inhibition of proliferation in the
presence of BB-3103. Unfortunately, modulation of TNFR1 shedding in the presence of
inhibitor was not investigated but since signalling through TNFR1 induces apoptotic events
(Figure 1.6 and (Wallach et al. 1998) but since no increase in apoptosis was observed by
AnnexinV binding, it is unlikely that modulation of TNFa/TNFR1 signalling was responsible
for inhibition of CD4+ T cell proliferation. These experiments, performed at British Biotech,
are, however, incomplete and do not answer the question addressed by this thesis. Firstly,
BB-2116 is a different inhibitor to BB-3103 and although they are both broad range
hydroxamate inhibitors, they cannot be compared. The other issue involves the use of
species. These experiments were performed on human peripheral blood lymphocytes and
therefore do not necessarily correlate to the immune response which may be observed in
mouse cells. To address these issues, similar experiments should be performed on PWM
activated mouse splenocytes with BB-3103 and to confirm inhibition of shedding, flow
cytometry should be performed on the cells to determine whether TNFa and TNFRII
expression on the splenocytes is maintained. The results shown in Figure 5.7, although
suggesting that inhibition of TNFa shedding may not play a role in cell proliferation in the
presence of a hydroxamate inhibitor, should have included controls showing cells activated
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by PWM in the pesence of TNFa as well as cells in the presence of TNFa alone, to
determine their effect in the absence of inhibitor. No data was provided showing background
proliferation of cells in the absence of PWM or TNFa and therefore we cannot determine
whether the proliferation caused was not due to contamination or another problem. In these
experiments, 100ng/ml of recombinant TNFa was used which is a very high concentration in
terms of TNF related molecules. Further experiments showing a dose response curve to
TNFa and TNFa in the presence of BB-3103 would have been more informative.
The results shown in Fig 5.7 are presented as percentage of inhibition which does not
provide enough information as to the state of the cells in the assay. Presenting the data in
cpm of tritiated thymidine incorporation would have been more appropriate.
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CHAPTER 6
6.1 PROLIFERATION OF CD4+ T CELLS FROM CD62L GENE
DEFICIENT ANIMALS IS NOT INHIBITED BY BB-3103
The effect of BB-3103 was investigated on the proliferation of enriched CD4+ T cells isolated
from CD62L gene deficient (C57BL/6) mice. This was performed determine whether the
inhibition of CD62L shedding was responsible of downregulating CD4+ T cell proliferation.
CD4+ T cells were isolated from naive (unimmunised) wild type (WT) spleens and naive
CD62L gene deficient (CD62L KO) spleens. The purified cells were activated using
immobilised anti-CD3 mAb and 5pg/ml soluble anti-CD28 mAb, over a period of 3 days as
previously described for WT CD4+ T cells. The proliferative response obtained from WT and
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samples to respective control groups.
Figure 6. 1: CD4+ T cell
proliferation from WT and
CD62L KO animals in the
presence of BB-3103. Graph
representing immobilised anti-
CD3 mAb and soluble anti-CD28
mAb induced proliferation of
purified CD4+ T cells from WT or
CD62L deficient animals in the
presence of BB-3103.
Proliferation was assessed by
thymidine incoporation for the last
16hrs of culture. The WT CD4+ T
cell proliferation was inhibited by
BB-3103 (■) as previously
observed, whereas the CD62L
gene deficient CD4+ T cells were
not affected by BB-3103 (O).
Graph represents mean of four
animals. Background proliferation
did not exceed 5000cpm. p
values compare BB-3103 treated
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The CD62L deficient CD4+ T cells failed to proliferate to the same extent as the WT CD4+ T
cells in the control samples. It also appeared that the CD62L deficient CD4+ T cells were not
affected by BB-3103. Furthermore, proliferation of WT CD4+ T cells in the presence of BB-
3103 was reduced to that of the CD62L deficient groups. This latter finding is highly
suggestive that CD62L on CD4+ T cells plays a critical role in promoting proliferation.
SUMMARY
• T cell proliferation in CD62L deficient animals was
• downregulated compared to wild type CD4+ T cells
• not inhibited by BB-3103
6.2 CYTOKINE SECRETION FROM CD62L KO CD4+ T
CELLS IS NOT AFFECTED BY BB-3103
Cytokine secretion by purified, activated CD4+ T cells isolated from CD62L deficient animals
was measured at 48hrs and showed no variation in the presence of BB-3103 (Figure 6.2).
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Figure 6. 2: Cytokine secretion of
activated CD62L KO CD4+ T cells in the
presence of BB-3103: Graph
representing IL-2, IL-5, IL-4 and IFNy
concentrations in supernatants of activated
CD62L KO CD4+ T cells as detected by
ELISA. All cytokines tested showed no
variation in the presence of inhibitor.
Graph represents mean of two animals.
IL-5 concentrations fell beneath detection
level and may not represent actual IL-5
concentrations in culture supernatants.
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6.3 PHENOTYPIC ANALYSIS OF CD62L DEFICIENT CD4+ T
CELLS
CD62L deficient CD4+ T cells failed to proliferate to the same extent as WT cells regardless
of the presence of BB-3103, therefore, the expression of activation antigens on the CD62L
deficient CD4+ T cells was analysed. The histogram in Figure 6.3a verifies that CD62L is
absent from the surface of the cell as described previously (Arbones et at. 1994). MFI
values do not necessarily represent a poisson distribution staining pattern as canbe seen in
Fig 6.3b, where 2 peaks are evident.
Figure 6. 3: CD62L expression on CD62L gene deficient
CD4+ T cells. (a)Analysis of CD62L expression on purified
CD62L deficient CD4+ T cells as compared to CD62L
expression on wild type CD4+ T cells (b).. The MFI value for
CD62L staining is shown in the top right hand corner of the
panel and is comparable to the isotype control staining pattern
(MFI isotype=3.91)
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6.3.1 PHENOTYPIC ANALYSIS OF CD62L KO CD4+ T CELLS IN THE
PRESENCE OF BB-3103
Analysis of cell surface proteins expressed on activated CD62L KO CD4+ T cells in the
presence or absence of BB-3103 are summarised below in Table 6.1. As in Table 5.1, use
of MFI values is not representative of poisson distribution, but represents total fluorescence
of cell populations which may contain 2 or more fluorescence intensities (see Fig. 6.4 for
expample). The use of MFI in this thesis is used as a mean of interpreting general effects by
BB-3103 rather than describing a poisson distribution of staining.
day 0 day 1 day 2 day 3
ko ko ko ko
control 20p.M BB control 20|iM BB control 20(rM BB
CD25 5.38 104.13 106.19 123.68 109.62 139.6 141.24
CD69 7.81 785.8 883.1 1202.35 1180 1005.46 884.52
CD40L 6.24 9.8 16.1 13.79 18.96 23.4 32.01
Fas 84.75 123.53 121.6 236.2 218.72 379.36 328.49
FasL 5.17 10.31 9.88 10.15 10.04 12.24 16.09
CD62L 3.71 9.1 10.41 9.52 10.18 12.37 11.98
CD27 362.24 181.88 393.42 312.17 539.52 330.39 608.3
CD30 11.68 11.17 20.89 30.39 28.59 69.63 54.95
4-1BB 9.42 34.05 29.5 43.56 50.46 70.9 69.88
Table 6. 1: Summary of the phenotypic data acquired by flow
cytometry on purified CD62L KO CD4+ T cells activated with
immobilised anti-CD3 mAb and 5pg/ml soluble anti-CD28 mAb in the
presence or absence of 20pM BB-3103. The numbers indicate MFI
values found for each marker. Results show that CD27 expression is
highly upregulated in the presence of BB-3103. Shaded markers are
shown in more detail later in the text. Values indicated in the table are
representative of triplicates.
-121-
Defective CD4* T Cell Activation in the Presence of a Metalloproteinase Inhibitor
6.3.1 BB-3103 DOES NOT MODULATE CD25 EXPRESSION ON CD62L
KO CD4+ T CELLS
The expression pattern of CD25 on CD62L deficient CD4+ T cells in the presence of BB-
3103 is presented in Figure 6.4.
10' 1<T 10° 1CT 1CT 10' 10 10° 1CT 10u 101 1CT 10'
FL2-CD25 FL2-CD25 FL2-CD25
Figure 6. 4: BB-3103 does not affect CD25 expression on CD62L KO CD4+ T cells.
Analysis of CD25 expression on nai've CD62L deficient enriched CD4+ T cells activated
with immobilised anti-CD3 mAb and soluble anti-CD28 mAb over a period of 3 days in the
presence or absence of BB-3103. Panels represent: a)freshly purified CD4+ T cells,
b)activated CD4+ T cells for 24hrs, c)activated CD4+ T cells for 48hrs, d)activated CD4+ T
cells for 72hrs, e)activated CD4+ T cells for 24hrs+20pM BB-3103, f)activated CD4+ T
cells for 48hrs+20pM BB-3103, g)activated CD4+ T cells for 72hrs+20pM BB-3103.
Dotted lines represent isotype controls, filled profiles represent positively stained cell
counts expressing CD25. MFI values for CD25 expression are indicated top right in each
panel. The histograms shown are from one experiment and are representative of 3
different animals.
Expression of CD25 on CD62L deficient CD4+ T cells was not modified in the presence of
BB-3103 (Figure 6.4). It would therefore appear that the reduced proliferation displayed by
CD62L deficient CD4+ T cells in the absence of BB-3103 is not due to diminished expression
of CD25 upon activation.
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6.3.2 BB-3103 DOES NOT REDUCE CD69 EXPRESSION ON CD62L KO
CD4+T CELLS
CD69 expression was also investigated on the surface of activated CD62L deficient CD4+ T
cells and was upregulated regardless of the presence of BB-3103 (Figure 6.5).
10" 10' 10' 103 1011
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Figure 6. 5: BB-3103 does not affect CD69 expression on CD62L deficient CD4+ T cells.
Analysis of CD69 expression on naive CD62L deficient enriched CD4+ T cells activated with
immobilised anti-CD3 mAb and soluble anti-CD28 mAb over a period of 3 days in the
presence or absence of BB-3103. Panels represent: a)freshly purified CD4+ T cells,
b)activated CD4+ T cells for 24hrs, c)activated CD4+ T cells for 48hrs, d)activated CD4+ T
cells for 72hrs, e)activated CD4+ T cells for 24hrs+20pM BB-3103, f)activated CD4+ T cells
for 48hrs+20pM BB-3103, g)activated CD4+ T cells for 72hrs+20pM BB-3103. Dotted lines
represent isotype controls, filled profiles represent positively stained cell counts expressing
CD69. MFI values for CD69 expression are indicated top right in each panel. The
histograms shown are from one experiment and are representative of 3 different animals.
Despite the reduced proliferation of CD62L deficient CD4+ T cells, both activation markers
tested (CD25 and CD69) were upregulated indicating that the CD4+ T cells were being
activated.
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SUMMARY
• CD25 and CD69 expression on CD62L KO CD4+ T cells was comparable to WT cells
and was not modulated by BB-3103.
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6.3.3 BB-3103 AFFECTS CD27 EXPRESSION ON CD62L KO CD4+ T
CELLS
Since the expression of CD27 was modified in the presence of BB-3103 in WT CD4+ T cells,
the analysis was extended to CD4+ T cells from CD62L deficient mice in the presence of BB-
3103. The expression pattern observed was similar to that seen in WT CD4+ T cells in the
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Figure 6. 6: BB-3103 affects CD27 expression on CD62L deficient CD4+ T cells.
Analysis of CD27 expression on naive CD62L deficient enriched CD4+ T cells activated
with immobilised anti-CD3 mAb and soluble anti-CD28 mAb over a period of 3 days in
the presence or absence of BB-3103. Panels represent: a)freshly purified CD4+ T cells,
b)activated CD4+ T cells for 24hrs, c)activated CD4+ T cells for 48hrs, d)activated CD4+
T cells for 72hrs, e)activated CD4+ T cells for 24hrs+20pM BB-3103, f)activated CD4+ T
cells for 48hrs+20|iM BB-3103, g)activated CD4+ T cells for 72hrs+20pM BB-3103.
Dotted lines represent isotype controls, filled profiles represent positively stained cell
counts expressing CD27. MFI values for CD27 expression are indicated top right in
each panel. The histograms shown are from one experiment and are representative of
3 different animals.
CD27 expression was high on CD62L deficient CD4+ T cells and upon activation, was
downregulated by metalloproteinase activity, since on the BB-3103 treated samples, the
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expression of CD27 was maintained at high levels, and showed similar patterns of
expression as on the WT CD4+ T cells (compare Figure 6.6 with Figure 5.2).
6.4 SOLUBLE ANTI-CD27 mAb INCREASES
PROLIFERATION IN WT AND CD62L DEFICIENT CD4+ T
CELLS
Although the evidence so far strongly suggested CD62L on CD4+ T cells was a primary
target for BB-3103 and that this led to reduced proliferation, the effect of activating the CD27
pathway in conjunction with TCR mediated signalling was investigated. Proliferation of WT
CD4+ T cells purified from a naive spleen was increased in the presence of various doses of
agonist anti-CD27 mAb (Figure 6.7).
Figure 6. 7: Soluble anti-CD27 mAb
increases proliferation of WT CD4+ T cells.
Purified wild type CD4+ T cells stimulated with
immobilised anti-CD3 mAb and 5gg/ml soluble
anti-CD28 mAb in the presence of varying
concentrations of soluble agonist anti-CD27
mAb. Results indicated an increase in
proliferation when CD27 is cross-linked on the T
cell surface (-30% increase). Interestingly,
higher doses of soluble anti-CD27 mAb
(25pg/ml) were not as effective in increasing the
proliferative state of the T cells as compared to
lower doses (12.5 and 6.35pg/ml). Graph
represents mean of three animals. Proliferation
was assessed by thymidine incorporation for the
last 16hrs of culture. Background proliferation
did not exceed 5000cpm.
250000
3, 200000
Control 6.25 12.5 25
Concentration of soluble aC027(pg/rr1)
As previously reported (Gravestein et al. 1995; van Lier et al. 1987) activation of the CD27
pathway in conjunction with TCR mediated signalling enhances proliferation in CD4+ T cells.
Similar results were obtained from binding CD27 on the surface of CD62L deficient CD4+ T
cells (Figure 6.8).
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did not exceed 5000 cpm.
Figure 6. 8: Soluble anti-CD27 mAb
increases proliferation of CD62L
deficient CD4+ T cells. Purified CD62L
deficient CD4+ T cells activated with
immobilised anti-CD3 mAb and 5pg/ml
soluble anti-CD28 mAb in the presence of
varying concentrations of soluble agonist
anti-CD27 mAb. Results indicated an
increase in proliferation of CD62L
deficient CD4+ T cells when CD27 was
cross-linked on the T cell surface (-17%
increase). Similarly to WT CD4+ T cells,
higher doses of anti-CD27 mAb (25pg/ml)
were not as effective in increasing the
proliferative state of the T cells as
compared to lower doses (12.5 and
6.35pg/ml). Proliferation was assessed by
thymidine incorporation for the last 16hrs
of culture. Graph represents mean of
three animals. Background proliferation
SUMMARY
• Cross-linking CD27 with monoclonal antibodies increases proliferation of WT and CD62L
KO CD4+ T cells
6.5 BB-3103 INHIBITS ANTI-CD27 MEDIATED
PROLIFERATION INCREASE IN WT CD4+ T CELLS
Since addition of soluble agonist anti-CD27 mAb to cultures increased both WT and CD62L
deficient CD4+ T cell proliferation, the effect of inhibition of CD27 shedding by addition of BB-
3103 to similar proliferation conditions was determined.
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Proliferation of purified WT CD4+ T cells with 6.25|ag/ml soluble agonist anti-CD27 mAb in
conjunction with a BB-3103 titration was measured. This concentration of anti-CD27 mAb
was selected as this was the dose which caused WT CD4+ T cells to proliferate maximally
(see Figure 6.9).
Figure 6. 9: Proliferation of WT CD4+ T
cells in the presence of soluble anti-CD27
mAb and BB-3103. Graph showing that
addition of BB-3103 to proliferation assays in
the presence of 6.25pg/ml anti-CD27 mAb
was still capable of decreasing wild type
CD4+ T cell proliferation. 'No CD27' bar
indicates WT CD4+ T cell proliferation using
immobilised anti-CD3 mAb and 5pg/ml
soluble anti-CD28 mAb only. 'Control' bar
represents WT CD4+ T cells activated with
anti-CD3 mAb and anti-CD28 mAb in
conjunction with 6.25pg/ml anti-CD27 mAb.
The molarity values indicate the
concentration of BB-3103 in samples
containing immobilised anti-CD3 mAb and
no cd27 control o.o2 o.2 2 20 soluble anti-CD28 mAb and soluble anti-
Treatment (j_jvi BB-3103) CD27 mAb- P values shown are relevant
only to the 'Control' results which contain
6.25pg/ml soluble anti-CD27 mAb and no BB-3103. Proliferation was assessed by
thymidine incorporation for the last 16hrs of culture. Graph represents mean of three
animals. Background proliferation did not exceed 10000 cpm.
Results demonstrate that the increase in proliferation of WT CD4+ T cells is due to the
presence of anti-CD27 mAb. Titration of BB-3103 into these assays, however, demonstrated
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6.6 BB-3103 DOES NOT INHIBIT ANTI-CD27 mAb
MEDIATED PROLIFERATION INCREASE IN CD62L KO
CD4+ T CELLS
A similar experiment was applied to CD62L deficient CD4+ T cells and revealed that titration
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Figure 6. 10: Proliferation of CD62L KO
CD4+ T cells in the presence of soluble
anti-CD27 mAb and BB-3103. Graph
showing that addition of BB-3103 to
proliferation assays (anti-CD3/anti-CD28
mAbs) in the presence of 6.25pg/ml soluble
anti-CD27 mAb was incapable of
decreasing CD4+ T cell proliferation
isolated from CD62L deficient animals. 'No
CD27' bar indicates CD62L deficient CD4+
T cell proliferation using immobilised anti-
CD3 mAb and soluble anti-CD28 mAbs
only. 'Control' bar represents CD62L
deficient CD4+ T cells activated with anti-
CD3 mAb and anti-CD28 mAbs in
conjunction with 6.25pg/ml anti-CD27 mAb.
The molarity values indicate the
concentration of BB-3103 in samples
containing anti-CD3/anti-CD28 mAbs and anti-CD27 mAb. p values shown are relevant only
to the control results which contain anti-CD27 mAb and no BB-3103. Proliferation was
assessed by thymidine incorporation for the last 16hrs of culture. Graph represents mean of






Soluble agonist anti-CD27 mAb increased the proliferation of CD62L deficient CD4+ T cells
(Figure 6.8). However, addition of BB-3103 did not reduce proliferation as seen in the WT
CD4+ T cells (Figure 6.9). This finding again strongly suggests that maintaining CD27 on the
surface of CD4+ T cells upon activation or addition of an agonist mAb, and BB-3103 plays no
role in reducing the subsequent proliferation of the cells.
-129-
Defective CD4+ t Cell Activation in the Presence of a Metalloproteinase Inhibitor
SUMMARY
• BB-3103 reduced WT CD4+ T cell proliferation even in the presence of anti CD27 mAb,
but had no effect on CD62L deficient CD4+ T cells
DISCUSSION (CHAPTER 6)
When added to proliferation assays with cells purified from CD62L deficient animals, BB-
3103 did not reduce proliferation. This was evidence that presence of CD62L on the surface
of CD4+ T cells can regulate the amount of proliferation and that inhibition of CD62L
shedding (in the presence of the inhibitor with BB-3103), reduces proliferation to similar
levels observed in CD62L KO. Evidence that CD62L KO CD4+ T cells do not proliferate to
the same extent in the absence of BB-3103 suggest that the association of CD62L with
CD3complex and p56lck (Brenner et at. 1996; Murakawa et at. 1992) is an important
determinant in regulating the amount of activation and subsequent proliferation.
Investigation of cytokine secretion from CD62L deficient CD4+ T cells in the presence or
absence of BB-3103 showed no variation in IL-4, IL-5 and IFNy secretion as determined in
the wild type CD4+ T cells. IL-2 secretion which was affected in the presence of BB-3103 in
wild type CD4+ T cells was not affected in CD62L deficient CD4+ T cells despite the presence
of BB-3103. The inability of BB-3103 to modulate IL-2 secretion in the CD62L deficient cells
could correspond to the proliferative response since the proliferation of CD62L KO CD4+ T
cells were not affected by BB-3103.
The values shown in Table 6.1, are, like Table 5.1, not representative of a poisson
distribution of staining, and in some instances shows the mean fluorescence of two or more
distinct populations expressing various amounts of protein. Therefore, the MFI values
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should not be interpreted as anything else but indicative of a trend rather than a staining
pattern.
Similarly to wild type CD4+ T cells, the expression of activation markers such as CD25 and
CD69 were not modulated in the presence of BB-3103, again, suggesting that the
JAK3/STAT5 A/B pathway was not affected (for expression and maintenance of CD25 at the
cell surface (Nakajima et al. 1997)) and that normal activation of Ras was occurring for the
expression of CD69 (D'Ambrosio et al. 1994). Similarly to CD62L+ cells, the starting
population always demonstrated a small percentage of CD25 expressing cells. This
population cannot be attributed to anything else than an infection in the animals used fror
these experiments or a non-specific activation process occuring during the enrichement of
lymphocytes prior to activation.
Expression of CD27 on the CD62L deficient cells was modified in a similar fashion to that
observed in the wild type CD4+ T cells in the presence of BB-3103 (CD27 shedding was
inhibited) despite the observation that CD62L deficient cells were not affected by BB-3103.
Cross-linking CD27 on the surface of the T cells in conjunction with TCR mediated activation
(wild type and CD62L KO CD4+ T cells) increased the proliferation as described before (Lens
et al. 1998; Watts, DeBenedette 1999; Hintzen et al. 1995) but in the presence of BB-3103
wild type CD4+ T cell proliferation was still inhibited whilst CD62L deficient cells remained
unaffected. These data were further evidence of the non-involvement of CD27 signalling
pathway in proliferation reduction in the presence of BB-3103.
Ligating CD27 with monoclonal antibodies may have had the same effect as ligating with
CD70 which is also transiently expressed on activated T cells (Hintzen et al. 1995). Wild
type CD4+ T cells were still inhibited in the presence of BB-3103 when the CD27 pathway
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was engaged which suggests that modulation of the interaction of CD27 with CD70 was not
the causative factor in reducing T cell proliferation.
The following experiments were designed to further investigate the role of CD62L on T
lymphocytes.
CHAPTER 7
7.1 AGONIST ANTI-CD62L mAb INCREASES
PROLIFERATION IN WT CD4+ T CELLS
Since CD62L deficient CD4+ T cells were not modulated by BB-3103, the role of CD62L on
WT CD4+ T cells was examined. This question was addressed by activating WT CD4+ T
cells using immobilised anti-CD3 mAb and 5pg/ml soluble anti-CD28 mAb in the presence of
varying concentration of soluble anti-CD62L mAb (Figure 7.1).
Figure 7. 1: Proliferation of WT CD4+ T
cells in the presence of plate bound
anti-CD3 mAb and soluble anti-CD28
mAb with soluble anti-CD62L mAb.
Graphical representation of proliferating
CD4+ T cells with immobilised anti-CD3
mAb and 5pg/ml soluble anti-CD28 mAb in
the presence of variou s doses of soluble
anti-CD62L mAb. A linear correlation
between concentration of soluble anti-
CD62L mAb and increase in proliferation
was observed, with the highest three doses
used (25, 12.5 and 6.25pg/ml) being
statistically relevant. Proliferation was
assayed on day 3 by thymidine
incorporation for the last 16hrs of culture.
Graph represents means of three animals.
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The results demonstrate that adding agonist anti-CD62L mAb to WT CD4+ T cells in
conjunction with TCR mediated signalling increases the proliferation of the CD4+ T cells,
supporting data obtained by other groups (Murakawa et al. 1992).
SUMMARY
• Addition of soluble anti-CD62L monoclonal antibody increased proliferation of CD4+ T
cells by 30% at highest concentration used of 25pg/ml.
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7.2 BB-3103 HAS NO EFFECT ON WT CD4+ T CELL
PROLIFERATION WHEN CD62L IS PROVIDED WITH A
LIGAND
The next experiments were designed to assess the effect of cross-linking CD62L on the
surface of the CD4+ T cell in conjunction with TCR mediated signalling whilst inhibiting
shedding of CD62L with the presence of BB-3103. The addition of BB-3103 to T cells which
were activated through TCR in the presence of soluble 12.5 pg/ml anti-CD62L mAb,


















Figure 7. 2: BB-3103 has no effect on
WT CD4+ T cell proliferation when
CD62L is provided with a ligand.
Proliferation of CD4+ T cells in the
presence of immobilised anti-CD3 mAb
and 5pg/ml soluble anti-CD28 mAb with
12.5pg/ml soluble anti-CD62L mAb.
Proliferation of CD4+ T cells in the
absence of anti-CD62L mAb is the
control bar. The increase in proliferation
seen upon addition of anti-CD62L mAb
was maintained in the presence of BB-
3103 despite the inhibition of shedding.
Proliferation assayed on day 3 by
thymidine incorporation. Graph
represents mean of four animals.
Background proliferation did not exceed
5000 cpm.
These results demonstrate that it was possible to protect the proliferation of WT CD4+ T cells
from the inhibitory effect of BB-3103 if CD62L was provided with a ligand.
SUMMARY
• BB-3103 has no inhibitory effect on CD4+ T cell proliferation if CD62L is provided with a
ligand (in this case anti-CD62L mAb).
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DISCUSSION (CHAPTER 7)
As previously described in other studies, ligation of CD62L on T-lymphocytes with the use of
monoclonal antibodies increased proliferation of T cells in a dose dependent manner
(Murakawa et al. 1992). Similarly, investigation of the effect of cross-linking CD62L in the
absence of TCR mediated activation revealed that CD62L was shed (Kahn et al. 1998) and
that this process was inhibited by BB-3103.
Two processes of CD62L shedding were apparent, TCR mediated shedding and CD62L
cross-linking shedding which were both inhibited by BB-3103 suggesting that the enzymes
responsible for both events were one or more metalloproteinase.
To investigate the role of CD62L cross-linking further, BB-3103 was added to proliferation
assays which contained soluble anti-CD62L antibodies. Unexpectedly, it emerged that
cross-linking CD62L on the surface of the T lymphocytes and inhibiting the expected
shedding event by addition of BB-3103, protected CD4+ T cell proliferation from the inhibitory
effects of BB-3103.
Although the latter results are intriguing, they do not explain the observations made in the
proliferation assays shown earlier in the chapter 3 since CD62L was never ligated. Ligands
for CD62L are expressed by endothelial cells and high endothelial venules. The ligands
include Glycam-1 Madcam-1, CD34 and various other highly glycosylated molecules
(T. Tedder web site http://www.ncbi.nlm.nih.gov/PROW/cd/cd62l.htm).
The data presented above demonstrate that cross-linking CD62L also plays an important
role in augmenting signal transduction to the lymphocyte, and, once cross-linked, inhibition of
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ligand induced CD62L shedding cannot modify the outcome of the increased signal
transduction.
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CHAPTER 8
8.1 THE EFFECT OF BB-3103 ON TYROSINE
PHOSPHORYLATION OF SIGNALLING MOLECULES
8.1.1 p56 Lck PHOSPHORYLATION IS NOT AFFECTED BY BB-3103
Since BB-3103 inhibited CD4+ T cell proliferation through mechanisms other than cytotoxicity
or apoptosis, BB-3103 was investigated for its ability to alter TCR mediated signalling
pathways induced by ligation with anti-CD3s monoclonal antibodies which would eventually
lead to IL-2 production.
A primary event upon TCR stimulation is activation (dephosphorylation) of p56lck Src tyrosine
kinase (Cartwright et al. 1987; Kmiecik and Shalloway 1987). The following experiments
were designed to investigate the phosphorylation state of p56lck upon anti-CD3e monoclonal
antibody stimulation in the presence or absence of BB-3103 on WT and CD62L deficient
CD4+ T cells. Purified CD4+ T cells were plated onto immobilised anti CD3s (20pg/ml) for
one minute (5x106 cells/sample). Cells were lysed in Tris based NP-40 lysis buffer. Lysates
were immunoprecipitated with murine monoclonal anti-phosphotyrosine antibody, PY-99.
Immunoprecipitations were loaded onto 8% SDS-PAGE gel, transferred to nitrocellulose and
probed with rabbit anti-p56lck mAb. Detection antibody was goat anti-rabbit HRP conjugated
mAb. The p56lck immuno-blot and densitometry are shown in Figure 8.1.
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Figure 8. 1: p56Lck phosphorylation is not affected by BB-
3103. (A)p56 immunoblot of WT and CD62L deficient CD4+ T
cells activated with 20pg/ml immobilised anti-CD3 mAb and BB-
3103 for 1 minute. Lane 1-Jurkat whole cell lysate +ve control.
Lane 2, WT no treatment control. Lane 3 WT 1 min anti-CD3
mAb. Lane 4 WT 1 min anti-CD3 mAb + 20pM BB-3103. Lane
5 CD62L deficient CD4+ T cells no treatment control. Lane 6
CD62L deficient CD4+ T ceils 1 min anti-CD3 mAb. Lane 7
CD62L deficient CD4+ T cells 1 min anti-CD3 mAb + 20pM BB-
3103. (B) Results of densitometry performed on Lck blot using
Grablt/GelBase software (UVP, Cambridge, U.K.).
Although strong signals for phosphorylated p56Lck were detected in all lanes, no differences
were observed between samples tested. Furthermore, there was no detectable difference
between resting cells and cells activated with immobilised anti-CD3 mAb for 1 minute.
Soluble monoclonal anti-CD28 mAb was not added to the system since early time points
were being examined and evidence showed CD28 signalling helps maintain long term
phosphorylation of signal transducing molecules (Lu et al. 1994). Recent evidence,
however, showed secondary regulatory pathways in the activation of p56lck is determined by
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factors other than phosphorylation, namely CD28 regulation of p56lck (Holdorf et al. 1999).
Also, it is possible that the immunoblotting procedure may not have been sensitive enough to
detect minor changes in phosphorylation patterns of p56lck. Jurkat cells were not activated
with anti-human CD3^ mAb since this would lead to apoptosis (Ruiz-Ruiz et al. 1995; Zhu
and Anasetti 1995). PY-99 and rabbit anti p56lck antibodies are species cross reactive, thus
reacting with human Jurkat cells as well as murine CD4+ T cells.
SUMMARY
• BB-3103 had no detectable effect on Lck tyrosine phosphorylation.
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8.1.2 ITAM PHOSPHORYLATION ON CD3C IS MODIFIED BY BB-3103
ITAM phosphorylation patterns on CD3^ subunit of the TCR complex determines the
activation state of the CD4+ T cell and subsequently the fate of the T cell (Kersh et at. 1998;
Madrenas et at. 1995; Sloan-Lancaster et at. 1994). The experiment below describes the
detection of modified ITAM phosphorylation pattern of CD3^ in the presence of BB-3103 in
purified WT and CD62L deficient CD4+ T cells. The lysates were immunoprecipitated as
before (see p56Lck) but immunoblotted with anti-CD3i; mAb (NH2-specificity mouse and
human reactive) and results are shown in Figure 8.2.
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Figure 8. 2: ITAM phosphorylation on CD3^ is modified by
BB-3103.(A) CD3^ immunoblot of WT and CD62L deficient
CD4+ T cells activated with 20pg/ml immobilised anti-CD3 mAb
and BB-3103. Lane 1-Jurkat whole cell lysate +ve control.
Lane 2, WT no treatment control. Lane 3 WT 1 min anti-CD3
mAb. Lane 4 WT 1 min Anti-CD3 mAb+ 20pM BB-3103. Lane
5 CD62L deficient no treatment control. Lane 6 CD62L
deficient 1 min anti-CD3 mAb. Lane 7 CD62L deficient 1 min
anti-CD3 mAb+ 20pM BB-3103. Equal loading of protein was
assessed by density of PY99 light chain (LC) at 25kDa. (B)
Results of densitometry performed on CD3(^ blot using
Grablt/GelBase software (UVP, Cambridge, U.K.).
The Jurkat positive control contains only one phospho-isoform of CD3^ - p23 (Figure 8.2).
The WT control, however, contains both phospho-isoforms (p21, p23) of CD3t; suggesting a
state of slight activation perhaps due to cell isolation and centrifugations. After one minute of
exposure to immobilised anti-CD3 mAb, WT CD4+ T cells upregulated both the p21 and p23
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CD3^ phospho-isoforms. In the presence of BB-3103, however, only p21 was visibly
upregulated suggesting a variation in CD3^ phosphorylation and, thus, an altered activation
state as compared to no inhibitor control. The CD62L deficient CD4+ T cells, on the other
hand, did not upregulate any phospho-isoforms of CD3^ upon stimulation and this pattern
was not altered in the presence of BB-3103. These results suggest that inhibition of T cell
proliferation by BB-3103 correlates with a change in CD3<; chain phosphorylation, and this
effect was not observed in the CD62L deficient mice.
SUMMARY
• Presence of BB-3103 seemed to reduced production of p23 isoform of CD3^ in WT
CD4+ T cells, whereas it had no significant effect on CD62L deficient CD4+ T cells.
These data however, cannot accurately be quantified using this method of detection (see
discussion).
• CD62L deficient T cells did not upregulate either phospho-isoforms in the time points
investigated. These data however, cannot accurately be quantified using this method of
detection (see discussion).
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8.1.3 ZAP-70 PHOSPHORYLATION IS REDUCED BY BB-3103
ZAP-70 (C, associated protein 70kDa) is the downstream transducer molecule from CD3
phosphorylation which associates with phosphorylated ITAMs on the C, subunit of CD3 (Chan
et at. 1994b). Upon docking with correctly phosphorylated ITAM sequences, ZAP-70
undergoes activation by phosphorylation of Tyrosine residues mediated by Lck (Iwashima et
at. 1994; Weil et at. 1995). The next experiments were designed to investigate the effect of
BB-3103 on the phosphorylation state of ZAP-70 after stimulation with immobilised anti CD3s
monoclonal antibody. Figure 8.3 shows the ZAP-70 immunoblot performed on WT CD4+ T
cells in the presence of BB-3103. Samples were treated as described in the legend and
immunoprecipitated with mouse monoclonal anti-phospho-Tyrosine (PY-20),
electrophoresed through 12% SDS-PAGE and transferred to nitrocellulose. Blots were
probed with rabbit monoclonal anti-ZAP-70 antibody and goat anti-rabbit HRP conjugated
mAb used as detection antibody.
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Figure 8. 3: ZAP-70 phosphorylation is modified by BB-
3103. ZAP-70 immunoblot of WT CD4+ T cells activated with
20pg/ml immobilised anti-CD3 mAb in the presence or absence
of BB-3103. Lane 1, Jurkat whole cell lysate (+ve control). Lane
2, freshly purified CD4+ T cells. Lane 3, 1 minute activation
control. Lane 4, 1 minute activation + 20pM BB-3103. Lane 5, 5
minute activation control. Lane 6, 5 minute activation +20pM
BB-3103.
ZAP-70 phosphorylation was inhibited in the presence of BB-3103 (Figure 8.3). These
results demonstrate that treatment of WT CD4+ T cells with BB-3103 can directly affect
intracellular signalling by altering tyrosine phosphorylation of key signalling molecules such
as CD3C and ZAP-70. The consequence of these altered signalling patterns is potentially
the causative factor in decreasing T cell activation and subsequent IL-2 dependent
proliferation.
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SUMMARY
• Presence of BB-3103 upon activation of CD4+ T cells reduced ZAP-70 phosphorylation.
These data however, cannot accurately be quantified using this method of detection (see
discussion)
8.2 CALCIUM FLUX IN T CELLS IS MODIFIED BY BB-3103
The signalling pathways which lead to T cell activation and subsequent proliferation depend
on MAPK pathways as well as calcineurin activation. Calcineurin is a calcium dependent
signal transducing molecule which complements the MAPK signalling cascade (Cantrell
1996) (Figure 1.11). The two pathways are independent but both are required to complete T
cell activation and subsequent proliferation (Radvanyi et at. 1996).
8.2.1 BB-3103 AFFECTS HUMAN CD4+ T CELL PROLIFERATION
The model used for calcium flux in this project used Fura-2AM loaded human CD4+ T cells in
a stirred cell suspension system, enabling results to represent the flux of 10x106 cells per
sample. Human CD4+ T cells were used for these experiments due to the availability of anti-
CD3 monoclonal antibodies capable of activating T cells in soluble form (i.e. HIT3a and
OKT3 mAb). No soluble, mitogenic mAbs against murine CD3 were available at the time of
the experiments. The effect of BB-3103 on human CD3+ T cell proliferation isolated from
peripheral blood by MACS, was similar to the effect seen on murine CD4+ T cells (Figure
8.4).
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Figure 8. 4: Proliferation of human
CD3+ cells is inhibited by BB-3103.
Graph showing the effect of BB-3103 on
proliferating human CD3+ T cells using
immobilised anti-CD3 mAb and 5pg/ml
soluble anti-CD28 mAb for 3 days.
Graph represents mean of three
experiments performed on 3 separate
individuals. Proliferation was assessed
by thymidine incorporation for the last
6hrs in culture Background proliferation
did not exceed 5000 cpm.
Human T cell proliferation was also inhibited in the presence of BB-3103 suggesting the
mechanism of murine CD4+ T cell inhibition may be similar in human T cells (compare
Figures 3.7 and 8.4).
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8.2.2 BB-3103 INCREASES TCR MEDIATED [Ca2+]i FLUX
The effect of incubating human CD4+ T ceils with 20pM BB-3103 prior to addition of HIT3a
mAb (Figure 8.5).
(7 0 )H IT3 a (4 0 )B B (7 0 )H IT 3 a (70 )B B
tim e (s e cs )
Figure 8. 5: BB-3103 increases TCR mediated [Ca2+]j flux. Graph representing
/ calcium flux in human CD4+ T cells resuspended in Ca2+ containing medium in the
presence or absence of 20pM BB-3103. Thick line shows calcium flux in cells
treated with 20pM BB-3103 only at 70 seconds. Medium thick line depicts the
calcium flux of cells treated with 10pg/ml HIT3a at 70 seconds. Thin line shows
calcium flux in T cells pre-incubated with 20pM BB-3103 (added at 40secs) and
activated with 10pg/ml HIT3a mAb at 70 seconds. Graph shows results from one
experiment representative of three experiments performed on cells isolated from 3
individuals.
The highest dose of BB-3103 (20pM) used had no effect on calcium flux in the human CD4+
T cells when added alone (Figure 8.5). Interestingly, the pre-incubation of T cells with 20pM
BB-3103 prior to HIT3a addition induced a more rapid and augmented calcium flux within the
CD4+ T cells compared to the flux observed in HIT3a only samples. The increase in Ca2+
concentration was maintained for 10 minutes and was constantly higher in the BB-3103
treated groups.
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8.2.3 BB-3103 INCREASES CD62L MEDIATED [Ca2+]i FLUX
The following experiments investigated the role of cross-linking CD62L in inducing calcium




Figure 8. 6: BB-3103 increases CD62L mediated [Ca2+]( flux. Graph
representing the calcium flux within human CD4+ T cells treated with 10pig/ml anti-
CD62L mAb in the presence or the absence of BB-3103. Thick line represents
control cells treated with 20pM BB-3103 at 70 seconds. Medium thick line
represents cells treated with 10pg/ml anti-CD62L mAb at 70 seconds thus inducing
the shedding from the surface of the cell. Thin line represents data observed from
cells treated with 20pM BB-3103 (40 seconds) prior to addition of 10pg/ml anti-
CD62L (70 seconds). Graph shows results from one experiment representative of
three consecutive experiments performed on cells isolated from 3 individuals.
Antibody mediated cross-linking CD62L on the surface of a CD4+ T cell induced a calcium
flux. The increase in calcium concentration in the cells however, is greater in the presence
of inhibitor suggesting that maintaining the cross-linked CD62L on the surface of the cell
could enhance the calcium signalling pathway.
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SUMMARY
• The addition of BB-3103:
• on human CD4+ T cells activation induced a rapid and augmented calcium flux and
• upon cross-linking CD62L with monoclonal antibody induces an increase in calcium
flux independently from any TCR mediated signalling.
DISCUSSION (CHAPTER 8)
For phosphorylation experiments in this chapter, Western blots were developed using
enahanced chemiluminescence (ECL) and developed using light sensitive X-Ray film. It
should be noted that quantitative analysis of films developed in this fashion is highly
inaccurate due to the limitations of the X-Ray film. The films used in these experiments have
a finite detection level with a plateau, beyond which detection is highly inaccurate. In order
to validate phosphorylation quantitatively, the Western blots should have been developed
using phospho-imaging apparatus which does not plateau and therefore, poses no risk in
quantitating over-exposed films. The densitometry shown in this chapter, therefore, should
not be over-interpreted as these epxeriments should be repeated using a phospho-imager.
This section described that BB-3103 was capable of modifying signalling pathways upon
activation of T cells through the TCR. As described in Figure 1.11 one of the first events
upon TCR engagement, is the activation of the Src tyrosine kinase Lck (Cantrell 1996). The
method used in this study may not have been sensitive enough to detect changes in Lck
activation status. Also, the signalling experiments were performed in the absence of soluble
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anti-CD28 mAb, but since recent evidence describes CD28 involvement in regulation of Lck
(Holdorf et at. 1999), the experiments could be repeated in the presence of anti-CD28 mAb.
Following Lck activation, CD3t; ITAM phosphorylation occurs (Cantrell 1996) and generates
two CD3C phospho-isoforms, pp21 and pp23. Activation of wild type CD4+ T cells with
immobilised anti-CD3e monoclonal antibodies appeared to upregulate both isoforms as
previously described (Kersh et at. 1998). In the presence of BB-3103 however, the
upregulation of pp23 semmed to be reduced suggesting the possible generation of different
phosphorylation patterns. CD62L deficient CD4+ T cells did not seem to upregulate either
phospho-isoforms at the time points investigated and there seemed to be no variation in
phosphorylation was observed in the presence of BB-3103. This would suggest that CD62L
may modulate CD3i; phosphorylation and that inhibition of CD62L shedding by BB-3103
could possibly downregulate the capability of CD62L to aid CD3£; signalling.
Following phosphorylation of CD3<!; ITAM sequences, Syk tyrosine kinase ZAP-70 docks to
the phospho ITAMs and becomes tyrosine phosphorylated itself by Lck (Cantrell 1996).
Activation of ZAP-70 was also investigated and suggested that CD4+ T cells in the presence
of BB-3103, significantly less ZAP-70 was found in the activated form using standard ECL
detection methods. These results, and suggestions of modified CD3t; phosphorylation,
suggest that ZAP-70 may not subsequently be activated.
Since CD62L has been immunoprecipitated with several different signalling molecules (CD3
complex (Murakawa et at. 1992), Lck (Brenner et at. 1996) and Calmodulin (CaM) (Kahn ef
at. 1998), it is possible that shedding of CD62L enhances activation of Lck by a dissociation
mechanism, thus leading to reduced or retarded release of Lck when shedding of CD62L is
inhibited. Downregulation of ZAP-70 activation would subsequently lead to reduced IL-2
secretion which was observed in proliferation assays in the presence of BB-3103.
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CD69 expression, however, was reported to be regulated by Ras activation (D'Ambrosio et
at. 1994), which is an integral part of the TCR activation pathway (Figure 1.11). Based on
the results of signalling observations reported in this thesis, CD69 expression should be
downregulated, however, this is not the case and may suggest that CD69 expression may be
regulated through another pathway or that the Ras activation in the presence of BB-3103 is
sufficient for the upregulation of CD69.
Calcium studies revealed that in the presence of BB-3103, a rapid and elevated flux in
calcium ions was observed. In the absence of BB-3103, however, a 40 second delay was
observed between activation through the TCR and the detection of a reduced calcium flux,
presumably due to the step-wise activation of molecules (ZAP-70, LAT etc.), eventually
leading to the increase in calcium mobilisation. When pre-incubated with BB-3103, T cells
demonstrated very little delay between TCR activation and calcium mobilisation (15
seconds). This observation may be linked to the association of calmodulin with the
cytoplasmic tail of CD62L (Kahn et at. 1998), where upon TCR activation, intracellular serine
phosphorylation of the CD62L cytoplasmic tail initiates dissociation of calmodulin and
subsequent shedding of CD62L. Inhibiting CD62L shedding may either enhance activation
induced serine phosphorylation, thereby, leading to more calmodulin dissociation, or cause
CD62L to maintain a conformational structure which promotes activation of calmodulin.
In separate observations, it was established that the mechanism by which the calcium flux
was increased upon TCR activation may have been due to CD62L being maintained on the
surface of the cell since cross-linking CD62L with monoclonal antibodies demonstrated an
increased calcium flux in the presence of BB-3103.
Figure 8.7 hypothesises a possible mechanism by which inhibition of CD62L shedding could
downregulate tyrosine phosphorylation whilst upregulating calcium mobilisation.
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IL-2 Production ► Proliferation
Figure 8. 7: Diagrammatic representation of possible involvement of CD62L in the
regulation of T cell activation. Upon normal activation, Lck is activated through CD45
phosphatase and the release from CD62L cytoplasmic tail leading to CD3d; ITAM
phosphorylation. ZAP-70 becomes activated and through several signalling pathways, leads
to IL-2 production. In the presence of BB-3103, however, it is possible to speculate that Lck
activation is decreased since CD62L is not shed (O) and does not release Lck, this event
leads to modified or reduced ITAM phosphorylation (0) which subsequently leads to
decreased IL-2 production. Inhibition of CD62L shedding may induce enhanced calmodulin
release by unknown mechanisms (©) which could lead to a more rapid and elevated calcium
flux. CaM=Calmodulin.
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CHAPTER 9
9.1 BB-3103 DIFFERENTIALLY AFFECTS HUMAN Th, AND
Th2 CD4+ T CELL SUBSETS
Upon activation, naive CD4+ T cells adopt an effector phenotype and can differentiate into
various T helper subsets called Th0, Th-i or Th2 (Mosmann et al. 1986; Romagnani 1994).
This functional categorisation is based on the cytokines that the T cells secrete and is
determined by various factors described in the introduction of this thesis (Section 1.7). The
results presented here demonstrate that CD62L plays a critical role in regulating T ceil
activation. Recent reports state that CD62L expression, originally thought to be maintained
on naive CD4+ T cells only, is in fact maintained on Th-i cells (Wely et al. 1999). The next set
of experiments, therefore, were designed to investigate any potential differential effects of
BB-3103 on the two CD4+ T helper subsets, Th! and Th2.
Human subjects were chosen according to their atopic status to provide Th! and Th2 CD4+
responses. Six patients with acute atopic dermatitis were provided by Dr Bernadette DaSilva
from the Dermatology Dept (Royal Infirmary of Edinburgh) for the CD4+ Th2 type T cell
response. Atopic patients were selected according to positive tests for skin test reaction
against house dust mite allergens and high serum IgE antibody titres (results not shown).
Six non-atopic volunteers with no history of allergy or asthma were selected for the Th! type
CD4+ T cell response. Non atopic volunteers showed normal serum IgE antibody titres
(results not shown).
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9.1.1 CYTOKINE SECRETION FROM PROLIFERATING ATOPIC AND
CONTROL PBMCS TO HOUSE DUST MITE AEROALLERGEN Der
P 1
Experiments were designed to establish the cytokine secretion pattern of human T ceils to
the common aeroallergen derived from house dust mite Dermatophagoides pteronysinnus,
Der p 1. Whole PBMCs from 2 atopic and 2 non-atopic patients were isolated and cultured
for 48hrs in the presence of 10pg/ml Der p 1. Supernatants were collected at 48hrs and
concentrations of IFNy, IL-2, IL-4, IL-5 and IL-12 determined (Figure 9.1). No IL-12 was
detected (results not shown) and the concentrations of IL-5 may be misleading since they
are at the mimits of detection for this assay.




Der p 1. Cytokine
secretion at 48hrs from
atopic and non-atopic
PBMCs stimulated with
lOgg/ml Der p 1. IL-5
lower detection limit was
50ng/ml therefore, the
non-atopic values may not
accurately depict actual
concentrations of IL-5 in
culture supernatant.
Cytokine secretion reveals that proliferating T cells from atopic PBMCs secrete a Th2 like
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secrete a cytokine profile caracterising a Th1 type response (high IL-2 and IFNy with low IL-4
and IL-5) (Figure 9.1).
9.1.2 NON-ATOPIC PBMC PROLIFERATION TO Der p 1 IN THE
PRESENCE OF BB-3103
Whole PBMC populations from atopic and non atopic patients were used in proliferation
assays. To investigate the effect of BB-3103 further, the inhibitor was added at various
times (t=0hrs, t=24hrs and t=48hrs) post antigen stimulation. A summary of the CD4+ T cell
proliferation profile of these two patient groups in the presence of BB-3103 is presented in
Figures 9.2 and 9.3. The raw data for all the patients are presented in the appendix at the
end of this thesis.
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timeFChrs -i-tims=24hrs -A-tirre=4filTS
No inhibitor 0.02 0.2 2 20
Treatment (pMBB-3103)
Figure 9. 2: Non-atopic PBMC
proliferation to Der p 1 in the presence
of BB-3103. Graph representing a
summary of the CD4+ T cell proliferation
of PBMCs isolated from six non-atopic
patients (Th-, response) to 10gg/ml Der p
1 in the presence of BB-3103. Data
presented as percentage of control
proliferation to normalise all patients.
The effect of BB-3103 on cells isolated from non-atopic patients reveals some striking
findings. When the inhibitor was added at t=0hrs, the expected decrease in proliferation was
observed, however, when the inhibitor was added at later time points (t=24 and t=48hrs) the
proliferation was markedly increased.
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Proliferation of cells isolated from atopic patients, as expected, was reduced by the addition
of BB-3103 inhibitor at the initiation of the culture (time=0hrs) (Figure 9.3). In contrast to the
non-atopic patients, addition of BB-3103 at later time points also decreased CD4+ T cell
proliferation, although to a lesser extent than that observed at t=0hrs.
Figure 9. 3: Atopic PBMC proliferation
to Der p 1 in the presence of BB-3103.
Graph representing a summary of the
CD4+ T cell proliferation of PBMCs from six
atopic patients to 10pg/ml Der p1 in the
presence of BB-3103. Data presented as
percentage of control proliferation to
normalise all patients.
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SUMMARY
• Proliferation of human PBMCs to 10pg/ml Der p 1 isolated from atopic and non-atopic
patients revealed Th2 and Th-i type cytokine profiles respectively.
• Addition of BB-3103 to proliferation assays at the initiation of the cultures (t=0hrs)
inhibited both atopic and non-atopic proliferative responses but at later time points (24
and 48hrs) enhanced Tfn proliferation whereas Th2 type responses were still inhibited.
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9.1.4 MODIFIED CYTOKINE SECRETION FROM PBMCs IN THE
PRESENCE OF BB-3103
The results represented in the two previous graphs demonstrate a differential effect of BB-
3103 on proliferation of PBMCs isolated from atopic and non-atopic patients. These
experiments were extended to investigate if the cytokine response profiles of the mixed
populations isolated from atopic and non-atopic patients were differentially regulated by the
addition of BB-3103. The cytokines analysed included IFNy, IL-2, IL-4, IL-5 and IL-12 and
were performed on the supernatants of bulk cultures from PBMCs isolated from two atopic
and two non-atopic patients in the presence of 20pM BB-3103 only at 48 hrs. No IL-12 was
detected in any supernatants (results not shown) and the concentrations of IL-5 may not
accurately represent actual concentrations in culture supernatant since they lie at the lower
limit of detection for this assay. The findings are represented in Figure 9.4.
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Figure 9. 4: Modified cytokine secretion from PBMCs in the presence of BB-3103.
Cytokine secretion at 48 hrs from 2 atopic and 2 non-atopic PBMCs activated with
10pg/ml Der p 1 in the presence or absence of 20pM BB-3103 as shown on the x-axis.
Panel (a) IL-2 concentrations, panel (b) IFNy secretion, panel (c) IL-4 secretion, panel (d)
IL-5 secretion. Lane 1, Atopic control; Lane 2, atopic with 20pM BB-3103 at Ohrs; Lane 3,
atopic with 20pM BB-3103 at 24hrs; Lane 4, Non-atopic control; Lane 5, non-atopic with
20pM BB-3103 at Ohrs; Lane 6, non-atopic with 20pM BB-3103 at 24hrs. Lower detection
limits of IL-5 ELISA was 50 ng/ml, therefore IL-5 concentration in non-atopics may nor
accurately represent the actual concentration of IL-5 present in the culture supernatant.
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The levels of IL-2, predominantly secreted by Th-i type T cells (Casolaro et al. 1995), in the
control samples (i.e. in the absence BB-3103) was lower in atopic as compared to T cells
from non-atopic individuals. Addition of BB-3103 at later time points to samples from atopic
patients decreased the levels of IL-2 secretion. Addition of BB-3103 to T cell cultures from
non-atopic individuals at 0 hours also decreased IL-2 concentration but surprisingly, had no
effect on IL-2 production when added at an even later time point (24hrs). This finding
parallels the proliferation results observed on the non-atopic PBMCs since the expansion of
these cells was not inhibited by the presence of BB-3103 at later time points (24hrs and
48hrs).
IFNy, a cytokine secreted by Tfn and Th0 cells (Oriss et al. 1997), was present at low levels
in atopic controls and high levels in non-atopic controls, and showed a modest increase in
atopic samples in the presence of BB-3103. This observation suggested that Th2 CD4+ T
cells secreted higher levels of IFNy in the presence of BB-3103. Addition of BB-3103 to non-
atopic samples at time Ohrs, decreased the secretion of IFNy whereas BB-3103 had no
effect on IFNy levels when added at later time points.
IL-4, a cytokine secreted by Th2 cells (Walker et al. 1992), on the other hand, was
decreased in both atopic and non-atopic groups in the presence of BB-3103, regardless of
time of addition to the samples. IL-4 is a strong Th2 CD4+ T cell promoter and the presence
of BB-3103 which downregulated the secretion pattern of IL-4 could therefore inhibit the
promotion of Th2 CD4+ T cell activation and differentiation.
IL-5, also a Th2 cytokine (Lee et al. 1998) was present in higher concentrations in the atopic
controls compared to non-atopic samples. The presence of BB-3103 in atopic samples,
downregulated the secretion of IL-5 and had no effect on IL-5 secretion in non-atopic
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samples. Again, the data suggested that BB-3103 was downregulating Th2 type cytokine
secretion.
SUMMARY
• BB-3103 decreased levels of IL-2 in supernatants of T cells isolated from non-atopic
individuals when added at Ohrs but had no effect when added at 24hrs
• BB-3103 increased levels of IFNy in atopic supernatants when added at 0 and 24hrs but
only decreased IFNy levels in T cells from non-atopic patients when added at Ohrs
• IL-4 levels were markedly reduced in supernatants of T cells from atopic patients when
BB-3103 was added at 0 and 24hrs.
• IL-5 levels were slightly decreased in the presence of BB-3103 at 0 hrs in the
supernatants of T cells from atopic individuals.
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9.2 BB-3103 DIFFERENTIALLY AFFECTS HUMAN TH0 AND
TH2 CLONES
To confirm the results observed in the PBMCs from atopic and non-atopic patients, the effect
of BB-3103 on established polarised human CD4+ T cell clones was analysed. The clones
investigated were HA1.7 and AC1.1. HA1.7 is a Th0 clone specific for peptide 306-318 from
influenza virus haemagglutinin (HA) (Eckels et al. 1984; Lamb et al. 1982). AC1.1 is a Th2
CD4+ T cell clone specific for peptide (28-40) in Dermatophagoides pteronyssinus group 2
allergen, Der p 2 (Verhoef et al. 1993).
T cell clones were stimulated with irradiated histocompatible APC (PBMCs) and the optimal
peptide concentration (1.0pg/ml) for 3 days in the presence or absence of BB-3103. The
results are shown in Figure 9.5.
Proliferation of Th0 CD4+ T cell clone










0 0.02 0.2 2 20
Treatment (pM BB-3103)
Proliferation of Th2 CD4+ T cell clone
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Figure 9. 5: BB-3103 differentially affects human Th0 and
Th2 clones. Proliferation of Th0 and Th2 clones (HA1.7 and
AC1.1 respectively) in the presence of BB-3103. BB-3103
increases the proliferation of HA1.7 T cells, but decreases the
proliferation of Th2 cells. Experiment performed once. Oneway
ANOVA statistics preformed on individual triplicate samples
within the same experiment.
The results from these preliminary experiments (Figure 9.5) further support the evidence for
differential effects of BB-3103 on different T helper subsets. BB-3103, when added at later
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time points enhanced the proliferation of the Th0 clone but had the opposite effect on Th2
type CD4+ T cells. One noticeable difference, however, was the lack of inhibition of
proliferation altogether in HA1.7 (Th0) when the inhibitor BB-3103 was added at time Ohrs.
SUMMARY
• BB-3103 reduced proliferation of Th2 CD4+ human T cell clone AC1.1 although to a
lesser extent than polyclonal CD4+ T cells.
• BB-3103 increased proliferation of human CD4+ Th0 T cell clone HA1.7 with no inhibition
of proliferation observed when added at Ohrs.
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9.2.1 BB-3103 INDUCES IFNy PRODUCTION IN Th2 CD4+ CLONES
Cytokine secretion from the Th0 and Th2 cell clones was subsequently investigated and











□ HA1.7 ■ AC1.1
IFNg
Figure 9. 6: Cytokine profile from
AC1.1 and HA1.7 proliferations in the
absence of BB-3103. Graphical
representation of cytokine concentrations
in supernatants from proliferation assays
performed on HA1.7 and AC1.1 T cell
clones in the absence of BB-3103.
HA1.7, a Th0 clone, secreted IFNy, IL-5
and IL-4 cytokines, whereas AC1.1, a Th2
clone, secreted IL-5 and IL-4, but no
IFNy.
Figure 9.6 shows the typical cytokine profile observed in HA1.7 and AC1.1 and these results
verify the classification of these cells as Th0-like (FIA1.7) and Th2-like (AC1.1). Cytokine
secretion of HA1.7 and AC1.1 in the presence of BB-3103 was investigated (Figure 9.7).
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Figure 9. 7: BB-3103 induces IFNy production in a human
CD4+ Th2 clone. Graphical representation of cytokines
secreted from human CD4+ T cell clones HA1.7 (Th0) and
AC1.1 (Th2) in the presence of BB-3103 added at various time
points. Cytokines detected by sandwich ELISA. (a) IFNy in
HA1.7, (b) IFNy in AC1.1, (c) IL-5 in HA1.7, (d) IL-5 in AC1.1,
(e) IL-4 in HA1.7 and (f) IL-4 in AC1.1.
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IFNy secretion was not affected by BB-3103 in HA1.7 ceils whereas, surprisingly, AC1.1
cells upon addition of BB-3103 started secreting IFNy, suggesting a switch from Th2 to either
Th0 or Th-i type (Figure 9.7). IL-5 levels in both cell types were moderately decreased in the
presence of BB-3103, consistent with the data obtained from the human PBMCs. IL-4 levels
were strongly decreased in HA1.7 but unaffected in AC1.1 samples, which contradicts the
data observed in the human PBMCs.
SUMMARY
• BB-3103 failed to alter Th0 secretion of IFNy but increased IFNy secretion in cloned Th2
CD4+ T ceils when added at either 0 or 24hrs.
• BB-3103 moderately decreased IL-5 secretion in both Th0 or Th2 cell clones.
• BB-3103 reduced IL-4 production in Th0 CD4+ T cell clone HA1.7 when added at either 0
or 24hrs, but had no effect on IL-4 production from AC1.1 cells.
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9.3 BB-3103 AFFECTS MURINE POLARISED CD4+ T CELLS
9.3.1 INDUCTION OF Thi AND Th2 TYPE ENVIRONMENT
Since the effector functions of different subsets of human T helper CD4+ cells were
modulated by BB-3103, it was relevant to examine whether or not exogenous cytokine
addition to activated murine naive wild type CD4+ T cells could modify the pattern of
responses in the presence of BB-3103. CD4+ T cells were isolated from unimmunised
C57BL/6 spleens by MACS purification and stimulated in the presence of neutralising mAb
and exogenous cytokines. To induce CD4+ T cells to adopt a Th-i phenotype, 20(.ig/ml
neutralising anti-IL-4 mAb (11B11 clone) as well as 20ng/ml recombinant murine 1L-12 and
20ng/ml recombinant murine IFNy, was added to the cultures at the time of stimulus with
immobilised anti-CD3 mAb and 5pg/ml anti-CD28 mAb. For a Th2 type phenotype, 20pg/ml
neutralising IFNy mAb (HB170 clone) and 20ng/ml recombinant murine IL-4 was added to the
cultures at the time of stimulus with 5(ig/ml anti-CD3 mAb and 5pg/ml anti-CD28 mAb. In
Figure 9.8, the cytokine profile 48hrs-post stimulus of CD4+ T cells in the presence or
absence of exogenous additions (see above) is presented.
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Figure 9. 8: Induction of a Tfn or Th2 type environment.
Graph representing cytokine profile in purified CD4+ T cell
stimulation in the presence of exogenous neutralising
antibodies and recombinant cytokines. Control, no addition of
exogenous cytokines. Th1-20pg/ml anti-IL-4 mAb, 20ng/ml
rmlL-12, 20ng/ml rmlFNy. Th2- 20pg/ml anti-IFNy mAb, 20ng/ml
rmlL-4. Graph represents one ELISA on pooled supernatants
from 2 consecutive experiments.
The cytokine environment in which the CD4+ T cells are expanded is illustrated in Figure 9.8.
Neutralising IFNy and IL-4 was successful in creating Th2 and Tfn environments,
respectively. Since IL-5 was the only cytokine unmodified by addition of recombinant IL-5 or
neutralising with anti-IL-5 antibodies, IL-5 is the only cytokine tested in these experiments
which sugests that the protocol used was succesful in generating ThH and Th2 cells.
SUMMARY
• Addition of exogenous cytokines and neutralising antibodies to generate specific
cytokine environments was successful in downregulating IL-5 for Thn and upregulating
IL-5 for Th2 cells.
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9.3.2 PROLIFERATION OF MURINE Thi AND Th2 CD4+CELLS
In the next experiments, BB-3103 was added to both the Thi and Th2 environments, and
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Figure 9. 9: Proliferation of murine Th1 and Th2 type CD4+ T
cells. Graph representing the proliferation of purified naive WT
CD4+ T cells isolated from C57BL/6 spleens to immobilised anti-
CD3 mAb and 5pg/ml soluble anti-CD28 mAb in the presence
of either (a) Tl^ cytokines or (b) Th2 cytokines and BB-3103.
Addition of BB-3103 at time=0hrs inhibited proliferation of both
Th-i and Th2 as seen before from the human PBMC data,
whereas later addition (t=24hrs) induced an increase in
proliferation of Thi cells but not Th2 cells. Results represent the
means of three animals. Background proliferation did not
exceed 10000 cpm.
These observations demonstrate the importance of the local cytokine environment in
determining the outcome of the proliferation of T cells in the presence of BB-3103 and
supports the human PBMC proliferation to Der p 1 reported in sections 9.1.2 and 9.1.3. The
level of proliferation in the controls of Thrlike cultures was higher in all experiments as
compared to the controls of Th2 cells at equivalent cell numbers (89680cpm for Thq and
68547cpm for Th2 cultures).
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ELISAs were not performed on the experiments described above since addition of
neutralising mAb and exogenous cytokines would not indicate any modification in cytokine
secretion from the CD4+ T cells in the presence of BB-3103.
SUMMARY
• BB-3103 inhibited proliferation of both Tl^ and Th2 CD4+ T cells when added at Ohrs.
• Thi type cells were unaffected by addition of BB-3103 at 24hrs, whereas Th2 type cells
were still inhibited by BB-3103 addition at 24hrs.
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9.4 EXPRESSION OF CD62L IS MAINTAINED ON Th1 TYPE
CD4+ CELLS
The results obtained from the analysis of CD62L deficient CD4+ T cells suggested that the
presence of CD62L on the cell surface was responsible for the decrease in proliferation by
BB-3103. In addition, since Thn and Th2 are differently affected by BB-3103, CD62L
expression was investigated on T cells stimulated either in a Th-i or Th2 cytokine
environment.
CD4+ T cells were isolated from the spleens of unimmunised C57BL/6 mice and stimulated
with immobilised anti-CD3 mAb and 5pg/ml soluble anti-CD28 mAb in the appropriate
cytokine/antibody environment to induce Th-|/Th2 polarity as described before. Cell surface
expression of CD62L was then determined on the CD4+ T cells 12hours after stimulation by
flow cytometry (Figure 9.10).
T
FL1 cd4 FL2 cd62L
Figure 9. 10: CD62L expression is maintained on CD4+
T cells. FACS profiles showing expression of CD62L on
purified CD4+ T cells stimulated for 12hours in the presence of
(a) 20pg/ml anti-IL-4 mAb, 20ng/ml IFNy and 20ng/ml IL-12 for
Th-i cells, and (b) 20|ig/ml anti-IFNy mAb and 20ng/ml IL-4 for
Th2 cells. Mean fluorescent intensities are represented in the
top right corner of the histograms. Experiment performed only
once.
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CD62L dowregulation from activated CD4+ T cells is differentially regulated between Th^ and
Th2 type CD4+ T cells in the absence of any metalloproteinase inhibitor (Figure 9.10). Since
the presence of CD62L on the CD4+ T cell plays an important regulatory role in determining
the activation state, the results suggest that BB-3103 has selected effects on Th-i and Th2
due to the differential CD62L expression patterns.
SUMMARY
• Thi type cells maintain CD62L expression on the surface upon activation, whereas Th2
type cells shed CD62L.
DISCUSSION (CHAPTER 9)
PBMCs isolated from atopic and non-atopic patients revealed Th2 and Th-i type cytokine
secretion as expected (Mosmann et al. 1986), but the phenotype of the resulting cells from
these proliferation assays was not investigated. In order to establish what cell types
proliferated after addition of Der p 1, flow cytometric analysis for T cell markers should have
been performed to establish that T cells were indeed the cell type to be affected by BB-3103.
The cells which proliferated from these assays could have been NK cells or y5 T cells. If
interpreted as ap TCR T cells proliferating, it could be assumed that, in proliferation assays,
BB-3103 enhanced Thrtype proliferation when added at 24hrs, whereas, Th2-type
proliferation was still inhibited at similar time points.
However, in proliferation assays investigating the effect of BB-3103 on the proliferation of
human Th0 and Th2 clones, showed a Th0 clone to be different since no inhibition occurred
when BB-3103 was added at Ohrs which was not observed before. HA1.7 and AC1.1 were
the only clones investigated, however, and may not have represented the expected
functional heterogeneity. These experiments were only performed once.
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Investigating differential effects of BB-3103 on Th-i and Th2 proliferation was further
investigated by generating murine Th-, and Th2 CD4+ T cell types by addition of exogenous
cytokine/neutralising antibody cocktails. In order to establish whether the correct cytokine
profile had been generated, however, intracellular staining for cytokines should have been
performed rather than ELISAs which were influenced by the exogenous recombinant
cytokines added and the neutralising antibodies also present. From Figure 9.8, we can only
assume that the cells generated under this protocol are Th1 and Th2 because of the IL-5
secretion pattern. Proliferation assays on these cells revealed that both Th! and Th2 cells
were inhibited when BB-3103 was added at early time points, but, like the non atopic human
PBMC data, Th! cell proliferation was unaltered when BB-3103 was added at later time
points.
Cytokine analysis of human Th! /Th2-type CD4+ T cells in the presence of BB-3103
demonstrated a decrease in IL-2 secretion by Thi cells but no variation in IL-2 secretion in
Th2 cell types. Addition of BB-3103 at later time points increased IL-2 production in Th! cell
types but still had no effect in Th2 cell types. The IL-2 data obtained from Thi CD4+ T cells
correlates with the proliferation data. Cytokines other than IL-2, were also modulated in
culture supernatants from atopic and non-atopic individuals, namely IFNy, IL-4 and IL-5. The
response observed from in human PBMCs, however, is not restricted to the oversimplified
'polarised Thi and Th2' paradigm, but rather a whole range of responses (Adorini et al. 1996)
which could themselves be differentially modulated by BB-3103 and therefore give rise to
complex cytokine pattern secretions.
Identification of cytokines secreted by human CD4+ T cell clones HA1.7 and AC1.1,
revealed, as before very little modulation in pattern of secretion in the presence of BB-3103.
These results however, should not be over interpreted as the clones were fed with irradiated
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PBMC which may secrete vast amounts of cytokines following irradiation and/or could utilise
cytokines secreted by the clones. Thios raises important issues which were not considered
during the experiments as the donors which were used to feed te clones were not assed for
their atopy, which could strongly influence the outcome of cytokines secreted, not only by the
T cells themselves but also by the irradiated PBMCs used as feeders. Taking this into
account it appeared that AC1.1, the Th2 type clone secreted IFNy in increasing amounts
correlating to BB-3103 concentration. This is the first identification that CD4+ Th2 type cells
could secrete IFNy in the presence of a metalloproteinase inhibitor and could explain the
proliferation decrease observed in the presence of BB-3103 since IFNy inhibits Th2 type
proliferation (Oriss et at. 1997).
in order to explain how BB-3103 could differently affect Tfp and Th2 type cells, it was
postulated that CD62L could be differentially expressed between those two cell types. This
was investigated in murine CD4+ T cells skewed with exogenous cytokines and neutralising
antibodies and revealed that Th-, cells could maintain CD62L expression whilst Th2 cells lost
CD62L upon activation. This was also recently demonstrated (Wely et at. 1999) and from
this study, it emerged that the presence of IL-12 was responsible for upregulating CD62L
message in Th! cell types, although metalloproteinase activity was not investigated.
No IL-12 was detectable in the proliferation assays from human PBMCs, although the assay
used in this assay may not have been sensitive enough. CD62L expression on human Th-i
and Th2 cells and human Th0 and Th2 clones, unfortunately, was not investigated. There
are, however to date, no reports suggesting that lymphocytes isolated from either atopic or
non-atopic patients differentially express CD62L.
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Since CD62L expression is maintained on activated CD4+ Thi cells, it would have been
expected that inhibition of CD62L shedding (since CD62L is still present on the surface of
the cell) would further inhibit cell proliferation by reducing IL-2 production.
To address this aspect further, however, it would have been interesting to investigate
whether Tfn and Th2 cells are capable of re-expressing CD62L at different rates which would
explain the differential expression at the cell surface. Alternatively, the upregulation of
CD62L on Th-i cells may be due to a combination of both mRNA upregulation (driven by IL-
12 signalling (Wely 1999) and loss of metalloproteolytic activity, whereas Th2 cells may
maintain or increase metalloproteolytic activity.
In order for BB-3103 to interfere with proliferation when added at later time points (24 or
48hrs) to proliferation assays, the inhibitor would be expected to interfere with the IL-2
signalling pathway since T lymphocytes express IL-2 within a few hours of TCR mediated
activation (Cantrell 1996). Studies with HT-2 cells, however, revealed that BB-3103 does not
inhibit IL-2 driven signalling. These findings suggest there may be other unidentified
metalloproteinase-sensitive molecules which are differentially expressed on Th-i and Th2 type
cells.
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CONCLUSIONS
The results shown in this thesis indicated that metalloproteinase inhibitors could, potentially,
be useful in controlling or redressing deleterious Tfq vs. Th2 immune imbalances found in
diseased states such as allergic asthma. Much more investigation, however, should be
devoted into assessing the phenotypic and signalling differences between Tfp and Th2 cells
in the presence of the inhibitor, since, the discrepancies in proliferation observed between
the two groups in this study may not solely be due to differential CD62L expression but also
to other metalloproteinase-sensitive cell surface molecules which may differentially
expressed by these two cell types.
The majority of the work described in this thesis suggests that metalloproteinase activity is
required for optimal activation of CD4+ T lymphocytes. The observed decrease in
proliferation at certain time points of activated CD4+ T cells in the presence of a
metalloproteinase inhibitor, BB-3103, was determined to be due to the inhibition of CD62L
shedding, since the proliferation kinetics of CD62L gene deficient CD4+ T lymphocytes was
unaffected by BB-3103. The results also indicate that CD62L is involved in regulation of
signalling components upon CD4+ T cell activation, suggesting association of CD62L with
signal transduction molecules involved in CD4+ T cell activation and subsequent IL-2
production. CD62L has previously been investigated as an important molecule involved in
signal transduction in neutrophils. These results, however, are the first reports that CD62L is
implicated in regulating T cell activation processes.
The presence of CD62L at the cell surface of naive CD4+ T cells was originally thought only
to mediate tethering of CD62L bearing cells to endothelial cells. It is now interesting,
however, to consider that CD62L on CD4+ T lymphocytes may play a more important role, in
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regulating the activation state of the ceil through tyrosine kinases and calcium ions which
lead to the expression of IL-2. Studies investigating the physical association of CD62L in
naive CD4+ T cells to intracellular signalling components involved in TCR mediated
activation would have enabled further understanding of the role of CD62L in signal
transduction. Since the general understanding in CD4+ T cell activation is now thought to
involve conglomeration of lipid rich rafts containing transmembrane molecules and signal
transducing proteins, it may be possible that CD62L is an integral member of the rafts which
could regulate the amount of activation the CD4+ T cell undergoes.
-178-
Defective CD4* T Cell Activation in the Presence of a Metalloproteinase Inhibitor
APPENDIX
The following pages show the raw data obtained from PBMCs isolated from atopic and non-
atopic individuals and stimulated with the aeroallergen Der p 1 isolated from





Raw proliferation data for non-atopic 1
















-NA1 Ohrs 23333 20999 17499 10499 5833
-NA1 24hrs 23333 30332 35699 21699 13766





Raw proliferation data for non-atopic 2







































Raw proliferation data for non-atopic 3


















NA 3 Ohrs 16352 14144 11773 6377 5232
- NA 3 24hrs 16352 25018 26163 17987 10465





Raw proliferation data for non-atopic 4
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Raw proliferation for non-atopic 5






















NA5 Ohrs 18985 16327 12340 7783 5125
- NA5 24hrs 18985 29996 28857 19364 12530





Raw proliferation data for NA 6








































































































-♦—A 2 Ohrs 18876 14723 12646 13024 9060
-A 2 24hrs 18876 17365 16233 15667 12269
A 2 48hrs 18876 17365 16422 16044 11891
T reatment
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-♦— A 3 Ohrs 17933 13862 11656 12015 9145
-A3 24hrs 17933 15243 14167 14346 12965
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-♦—A 6 Ohrs 22731 17275 16275 15911 12729
-A 6 24hrs 22731 20230 18980 20003 15911
A 6 48hrs 22731 20912 19321 18866 15457
T reatment
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